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ISUMMARY OF THESIS
LACTOSE SENSTIVITY AND INFLAMMATORY BOWEL DISEASE
Controversy still exists as to the incidence, role and impact of lactose sensitivity
in inflammatory bowel disease. The thesis shows that there is a higher than
previously reported incidence of lactose sensitivity determined by a combination
of genotype, breath test and symptoms after a lactose challenge. Lactose
sensitivity in patients with inflammatory bowel disease who are in remission is
70%. There was no difference compared to healthy volunteers in terms of lactase
genotyping; however there was a significantly greater prevalence of positive
breath test and symptoms after lactose challenge. This suggests that lactose
sensitivity in inflammatory bowel disease is related to the disease itself or a
consequence of it and not due to a genetic predisposition. A significant proportion
of inflammatory bowel disease patients [16%] are methane producers which
warrants further investigation. A pilot study of reduced lactose intake in patients
with Crohn’s disease and lactose sensitivity, who were in remission, showed a
promising improvement in symptoms reported and quality of life scores.
The Real-Time Polymerase Chain Reaction is simple and quick compared
to Restrictive Fragment Length Polymorphism for assessing the lactase genotype.
The Quintron MicroLyzer to assess breath samples after lactose challenge is
preferred to the hand held Micro H2 meter. This detects methane in addition to
hydrogen and without this a number of cases of lactose sensitivity would be
II
missed. It may be possible to predict a negative breath test with the absence of any
GI symptoms after a breath test and vice-versa a positive breath test is very likely
if multiple GI symptoms are reported. The ‘hidden’ lactose in drugs used to treat
inflammatory bowel disease and co-existing conditions should be considered as it
is present in many drugs and can make a significant contribution to the amount of
lactose ingested; lactose free alternatives are widely available.
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1CHAPTER 1
INFLAMMATORY BOWEL DISEASE AND LACTOSE
SENSITIVITY – REVIEW OF LITERATURE
2The literature review will focus on three areas - inflammatory bowel disease [its
epidemiology, pathogenesis, clinical features and treatment], lactose sensitivity
[its definition, epidemiology, clinical features, diagnostic tests and treatment] and
finally the clinical significance of lactose sensitivity in inflammatory bowel
disease.
1.1: INFLAMMATORY BOWEL DISEASE
Inflammatory bowel disease [IBD] is a chronic relapsing and remitting
inflammatory condition of the gastro-intestinal [GI] tract. The exact cause is not
known but it is likely to arise from a combination of genetic and environmental
factors. It is a common cause of morbidity and currently there is no cure. Crohn’s
Disease [CD] and Ulcerative Colitis [UC] are the two most common forms of IBD
that are seen in clinical practice. They are diagnosed using clinical, endoscopic,
radiological and histological criteria; no single finding from these is absolutely
diagnostic of UC or CD.
UC was first described by the British physician Sir Samuel Wilks in 1859
(1) and CD is named after the American physician Burril B. Crohn who described
the disease in 1932 (2). UC is characterised by a continuous inflammation of the
colonic mucosa without granulomas on biopsy. It affects the rectum and then
extends proximally along the colon to a variable extent. On the other hand CD is
characterised by patchy, transmural inﬂammation, which may affect any part of
the GI tract from mouth to anus (3, 4). The presentation of colitis [UC or CD] is
characterised by frequency of bowel motions which are usually loose and can be
bloody or associated with mucus. The CD affecting other areas of the bowel can
often present insidiously with features such as abdominal pain and weight loss
3with or without diarrhoea (5). CD may also present with fistulae and/or peri-anal
disease.
1.1.1: EPIDEMIOLOGY OF IBD
IBD is primarily a disease of the western world and has a particularly high
incidence in North America and Europe. In the UK the reported prevalence of
IBD is 400 per 100,000 people [UC: 243/100,000 & CD: 145/100,000] (6). The
last published data from the city of Cardiff, UK where my research is based
showed the incidence of CD (7) was 6.6 and UC (8) 6.4 per 100,000 people for
the decade up to 2005. Gender distribution in IBD is dependent on the disease
subtype. In CD, there is a greater prevalence of females ranging from a published
ratio of 1.1 to 1.6 (7, 9, 10), whilst in UC population-based studies have shown no
signiﬁcant differences between the sexes (9).
1.1.2: PATHOGENESIS OF IBD
The pathogenesis of IBD is unknown but is believed to arise as a result of the
interplay between genetic and environmental factors.
1.1.2.1: FAMILY GENETICS
Epidemiological studies have shown a familial tendency for both types of IBD.
Patients with CD have an affected first degree relative in 2.2-16.2% of cases and
with either form of IBD in 5.2-22.5% of cases (11, 12). Patients with UC have an
affected first degree relative in 5.7-15.5% of cases and with either type of IBD in
6.6-15.8% of cases (12-15). Twin studies (16-19) also demonstrate a greater
genetic influence for CD compared with UC. The combined results from studies
4show a concordance rate for monozygotic twins of 36% for CD and 16% for UC;
for dizygotic twins it is 4% for both diseases (16-19).
1.1.2.2: IBD GENETICS
The complementary strategies of genome-wide linkage scanning and candidate
gene analysis have uncovered a number of genetic loci associated with IBD
susceptibility. A recent publication cited 99 IBD susceptibility loci/genes: 71
associated with CD, 47 with UC, and 28 with both CD and UC (20). These loci
are depicted by lead gene name attaining genome-wide signiﬁcance and are shown
in Table 1.1 (20). CD is associated with nucleotide binding oligomerisation
domain 2 [NOD2]/caspase recruitment domain 15 [CARD15] gene mutations on
chromosome 16 (21, 22). The protein encoded by this gene is an intracellular
receptor involved in the immune response against pathogens. It detects the N
acetyl muramic acid moiety of muramyl dipeptide in bacterial cell walls (23). This
recognition event triggers an inflammatory response by activation of Nuclear
Factor Kappa-Light Chain Enhancer of activated B cells [NF-kB]. The relative
risk of developing CD is 2.4 in a simple heterozygote and 17.1 in homozygotes
(24). The presence of this mutation is also a risk factor for the development of
ileal disease, increased disease severity, increased risk of surgery, diagnosis at a
younger age and it also confers a greater risk for development of stricturing and
penetrating disease (24-26). In contrast, the allele frequency of NOD2/CARD 15
variants has been similar in UC patients and healthy controls (27) except for one
study that has shown that it may interact with the IBD 5 locus to increase the risk
of UC (28).
5Table 1.1: Inﬂammatory bowel disease susceptibility loci [adapted from Lees CW
et al] (20). The loci depicted by lead gene name attaining genome-wide
signiﬁcance are shown for CD, UC and both UC & CD.
CD Both UC
Th17 IL23R*,
AK2*,STAT3*J,
TYK2, IL12B*
HLA DRB*103
Epithelial
barrier
ECM1, HNF4A,
CDH1, LAMB1,
GNA12
Cellular innate
immunity
NOD2, ATG16, IRGM,
LRRK2
Immune
mediated
PTPN22, CCR6,
IL2RA, IL18RAP,
IL27, ERAP2, ITLN1,
CCL2/CCL7,TNFSF11,
BACH2, TAGAP,
VAMP3
MST1*, IL10*,
CARD9*, REL*,
PRDM1*,TFSF15*,
ICOSLG*, IL1R2*,
YDJC, SMAD3,
PTPN2
IL26/IFNγ,
IL8RA/IL8RB,
IL2/IL21, IL7R,
TNFRSF9,
TNFRSF14, IRF5,
LSP1, FCGR2A
Others DENNDIB, DNMT3A,
GCKR, THADA,
SP140, PRDX5,
ZPF36L1, ZMIZI,
MUCI/SCAMP3,
CPEB4, FADS1, 5q31
NKX2-3*, CREM*,
C11Orf30*,
ORMDL3*, RTEL1*,
PTGER4*, KIF21B*,
CDKAL1, ZNF365
OTUD3/PLAG2G2E,
DAP, PIM3, CAPN10
The human leukocyte antigen [HLA] complex on chromosome 6 encompasses
genes which have an immuno-regulatory role. The HLA-DRB1*0103 allele (29)
has been implicated in the pathogenesis of UC. The association is particularly
6strong in patients with extensive disease and in those fail to respond to medical
therapy needing surgery (30). In addition, the HLA-DRB1*1502 allele is also
positively associated with the presence of UC whilst there is a negative
association with HLA-DRB1*04 (29, 30). The most consistently reported
association of CD is with the HLA-DRB1*07 (29). This is associated with ileal
disease and is only present in the absence of NOD2/CARD15 variant (31, 32).
HLA-DRB3*0301 and HLA-DRB1*04 [if possessing NOD2/CARD15 variants]
are positively associated with CD (31, 32). The HLA-DRB1*0103 is strongly
associated with CD of the colon (31, 32). The HLA-DRB1*1501 allele is
negatively associated with CD and appears to confer protection against the
condition (29).
1.1.2.3: ENVIRONMENTAL FACTORS
Epidemiological studies have strongly suggested environmental factors in the
pathogenesis of IBD.
1.1.2.3.1: SMOKING
The prevalence of UC in smokers is reduced when compared with lifelong non-
smokers and ex-smokers (33). The pooled odds ratio has been shown to be 0.41
for current smokers compared with lifelong non-smokers, 1.64 for ex-smokers
compared to non-smokers and 2.9 for lifelong non-smokers compared to those
who had ever smoked (33). There is a particularly high incidence in the onset of
UC in people who have recently quit smoking (34). The relationship between
smoking and CD is the opposite to that observed in UC (35) - smokers run a
higher risk of developing the disease than ex-smokers (36). Smoking adversely
7affects the clinical course of CD (37), it increases disease activity, promotes
formation of fistulas, accelerating the need for surgery (36) and increasing the risk
of recurrence after operations (38).
1.1.2.3.2: GUT FLORA
Humans maintain homeostasis with luminal bacteria until extrinsic factors such as
diet, infection etc alter this balance. It is postulated that this alteration may lead to
the development of IBD in susceptible individuals. A variety of microbial agents
have been thought to have a role in the pathogenesis of IBD, but there is no
convincing evidence to support any specific one. It has been proposed that the
exposure to infectious diseases during the early years of life could decrease the
incidence of IBD (39). Increased levels of antibodies directed against intestinal
bacteria have been observed in IBD. In addition patients with CD may show
clinical response to antibiotics and also faecal diversion has been shown to benefit
some patients with peri-anal disease (40). The disease activity increases rapidly
following reconnection of bowel loops after resection or after reperfusion with
faecal material (41). Animal models of IBD require the presence of intestinal flora
for the condition to manifest (42, 43) and inflammation is attenuated in germ free
mice (44). It has also been possible to transfer colitis between animals via T cells
that are reactive to enteric bacteria (45). In summary, the current consensus of
opinion is that IBD appears to occur when there is a loss of regulation in the
immune response to the normal commensal microbial antigens in a genetically
susceptible host (46). The genetic basis of this disease is centred on factors that
regulate the components of innate and adaptive immune responses. The
composition of the bacteria in the bowel and the barrier function of the mucosal
8epithelial cells are regulated by these immune responses. A variety of
environmental factors affect genetic susceptibility and they act by regulating the
immune response of the host, epithelial barrier activity and the type and function
of the commensal bacteria. A model proposed by Blumberg for pathogenesis of
IBD is summarised in the figure 1.2 (47). In this model IBD is apparently
determined by the genetically defined, innate immune responsiveness of the
intestinal tissue to components of the commensal bacteria. When this response is
initiated, it is characterised by an exaggerated adaptive immune response by the
production of immunoglobulin G antibodies that drive inflammation by T and B
lymphocyte cells as shown in Figure 1.2 (47). Under the influence of factors
derived from innate immune cells, the T cells which include T-helper 1 [TH1],
TH2 or TH17 cells secrete cytokines such as interferon, tumour necrosis factor,
interleukin [IL] IL 4, 5, 6, 13, 17 & 22 which cause the inflammation (47). These
inflammatory factors result in tissue injury and the clinical symptoms of IBD. The
T-regulatory cells secrete immunosuppressive cytokines such IL10, IL 35 and
tumour growth factor- ß (47) which help to overcome the inflammatory response
to achieve remission in IBD (47).
9Figure 1.2: A Proposed Model for the Pathogenesis of Inflammatory Bowel Disease. Adapted from Blumberg 2009 (47).
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1.1.2.3.3: DIET
Increased incidences of IBD in countries like Korea and Japan during the 1990’s
and the evidence from migration studies, may implicate westernised diet as an
underlying cause (48-50). As a result a variety of different food groups have been
studied. A positive association has been demonstrated for consumption of refined
sugar, protein and fat consumption with both forms of IBD (48, 51-53), in
addition fast foods, margarine and cola drinks have also been implicated as risk
factors (53, 54). Also, an inverse association has been shown for the ingestion of
both fruit and vegetables with IBD indicating that these could have protective
effect in its development (51, 55). Antibodies to bakers yeast have been reported
as being common in patients with CD but not in UC (56, 57). Studies have shown
conflicting results for any association between IBD and the ingestion of coffee
(54, 58), alcohol (58, 59) and cornflakes (60, 61). Curry contains curcumin which
has antioxidant and anti-inflammatory properties which could potentially be one
of the factors for the lower incidence of IBD in South Asians (62). IBD has also
been proposed to be a secondary phenomenon to an allergic inflammatory
response to food antigens. Patients with CD have a stronger response to food
antigens than healthy controls (63). It has also been shown that food additives can
mediate immune reactions (64) and so some authors have proposed that they are a
cause of IBD, one study showed a diet lacking these reduced disease activity (65).
1.1.2.3.4: OTHER POTENTIAL ENVIRONMENTAL TRIGGERS
The current consensus is that environmental factors such as oral contraceptives
(66), early weaning and childhood vaccination (67, 68) do not play any significant
role in IBD pathogenesis. The development of IBD has been reported to occur
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more frequently after gastrointestinal infections caused by contaminated food or
water (69, 70). Appendicectomy may protect against the subsequent development
of UC, whilst it may increase the risk of CD (71).
1.1.3: CLINICAL FEATURES
IBD primarily presents in late adolescence and early adulthood, although the
diagnosis may be made at any age (72). The cardinal symptom of ulcerative colitis
is bloody diarrhoea but patients may also complain of colicky abdominal pain,
urgency, tenesmus and nocturnal defecation. The onset of UC is usually insidious
and symptoms are often present for weeks. The clinical course is marked by
exacerbation and remission with about 50% of patients experiencing a relapse in
any year. Although the disease usually presents with intermittent episodes, it can
present as a severe attack in about 15% with systemic symptoms which include
weight loss, fever, tachycardia, nausea and vomiting (73). Crohn’s disease
patients have a wide range of symptoms and presentations. They include chronic
diarrhoea, abdominal pain and/or weight loss, malaise, anorexia, and fever.
Sometimes non-specific symptoms mimicking irritable bowel syndrome [IBS] and
unexplained anaemia can be the only presentation (74). CD may also cause
intestinal obstruction due to strictures, and peri-anal fistulas or abscesses. In 10%
of patients these are present at the time of diagnosis or may be the only presenting
complaint (75). 10% of patients with IBD present with extra-intestinal
manifestations, which include an axial or peripheral arthropathy, episcleritis and
erythema nodosum - these can precede intestinal symptoms (76).The clinical
course of both these diseases is characterised by exacerbations and remission.
Crohn’s disease tends to cause greater disability than ulcerative colitis with only
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75% of patients fully capable of work in the year after diagnosis and 15% of
patients unable to work after 5-10 years of disease (77).
1.1.4: INVESTIGATIONS
The current national and international guidelines (4, 78 & 79) recommend that a
full history should include enquiry about the onset and presentation of symptoms,
together with travel, food intolerances, medications, and a prior history of
appendicectomy. In addition information about smoking, family history, and
recent infectious gastroenteritis (78, 79) should also be obtained. Clinical
examination should include pulse rate, blood pressure, temperature, abdominal
examination and digital rectal examination. The perineum and oral cavity should
also be inspected together with the measurement of weight (78, 79). Laboratory
tests should include full blood count, urea and electrolytes, liver function tests and
erythrocyte sedimentation rate or C reactive protein, ferritin, vitamin B12 and
folate. In both new presentations and in those who have a ‘flare up’ stool cultures
should be sent – apart from bacteria that commonly cause gastroenteritis, the
presence of clostridium difficile and cytomegalovirus should be assessed.
Abdominal radiography is often very helpful. It can exclude small bowel
or colonic dilatation, show proximal constipation, calcified calculi, sacro-ilitis or
an impression of mass (4). It can be particularly helpful in suggesting disease
extent in active UC. In suspected UC or CD, the preferred procedure to establish
the diagnosis and extent of disease is ileo-colonoscopy with segmental biopsies
including the rectum. CT/MRI/Ultrasound has no role in the diagnosis of UC but
they may aid in the assessment/ management of complications in CD where they
can detect intestinal/extra-intestinal involvement and penetrating lesions (79).
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1.1.5: DIAGNOSIS
A gold standard for the diagnosis of UC or CD is not available. It should be
established by a combination of medical history, clinical evaluation and typical
endoscopic and histological findings. Where there is doubt about the diagnosis,
repeat endoscopic and histological confirmation is necessary after an interval (79).
1.1.6: PATHOLOGICAL FEATURES
A histological diagnosis of established UC is based upon the combination of:
basal plasmacytosis, heavy and diffuse increase of inflammatory cells in the
lamina propria and widespread mucosal or crypt architectural distortion. Mucosal
atrophy and a villous or irregular mucosal surface appear in the later stages of the
disease. General or widespread crypt epithelial neutrophilia [cryptitis and crypt
abscesses] favours ulcerative colitis (79). In CD there is a focal [discontinuous]
chronic [lymphocytes and plasma cells] pattern of inflammation, focal crypt
irregularity [discontinuous crypt distortion] and granulomas [not related to crypt
injury] (78).
1.1.7: TREATMENT
Currently there is no cure for inflammatory bowel disease. Medical and surgical
treatments are used to reduce symptoms, maintain remission, decrease disease-
related complications and improve the quality of life. Guidelines have been
recently published by the British Society of Gastroenterology and European
Crohn’s and Colitis Organisation on the management of these conditions (4, 80).
Drug treatment is normally the primary treatment option before surgery is
considered. Medical treatments aim to induce remission when the condition
14
becomes more active and also maintain the patient in remission thereby
preventing relapses. Commonly used medical therapy includes anti-inflammatory
therapy [e.g., 5-Amino-Salicylates or Corticosteroids] and immuno-modulatory
treatment [e.g., Azathioprine, 6 Mercapto-purine, Methotrexate or anti-TNF drugs
like Infliximab or Adalumimab]. These can cause significant side-effects and are
tolerated to a variable degree.
Surgery is performed when medical therapy fails or is not tolerated and
when complications develop. Indications for surgery in UC include a poor
response to intensive medical therapy, presence of colonic dysplasia or carcinoma
and poorly controlled disease (4, 81). Indications for surgery in CD again include
a sub-optimal response to medical therapy, obstructive symptoms, abdominal
abscesses, strictures and the presence of dysplasia or carcinoma (4, 80). If surgery
is necessary for ileo-colonic disease or localised small or large bowel disease then
resecting only the affected part is preferable (4, 80). For strictures in CD,
stricturoplasty is a safe and more effective alternative to resection.
It is therefore apparent from this review that IBD is a common problem that
causes significant morbidity. We are not aware of its exact pathogenesis but it
appears to arise, be affected by a combination of genetic predisposition and
environmental triggers such as intestinal microbes, diet and smoking. Our current
treatments are suboptimal as they cannot provide a cure or indeed reliably control
the symptoms of all the patients who suffer from IBD.
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1.2: LACTOSE SENSITIVITY
Lactose sensitivity describes the symptoms and/or the abnormal investigations
that some people have after the ingestion of the sugar lactose. It is due to
hypolactasia i.e. reduced levels of the enzyme lactase in the intestinal wall.
Specific focus will be given to how it is diagnosed, its clinical significance and
relationship with gastro-intestinal disorders.
1.2.1: TERMINOLOGY
HYPOLACTASIA, LACTASE NON-PERSISTENCE OR LACTASE
INSUFFICIENCY
These refer to a very low activity of lactase in the small bowel mucosa. It can be
primary [genetic] or secondary. The ‘primary’ form is an autosomal recessive
condition resulting from the physiological decline in activity of the lactase
enzyme in intestinal cells after weaning (82). The exact mechanism and the
reasons behind this change are not understood yet. It is thought that the lactose
content of food falls rapidly after weaning, and so the activity of lactase becomes
less important to life. The ‘secondary’ form is the most frequent cause of
insufficient lactose hydrolysis in individuals with genetic lactase persistence and
occurs as a result of GI conditions such as coeliac disease (83), radiation enteritis
(84), chemotherapy (85), tropical sprue (86) or Crohn’s disease (87-89).
CONGENITAL ABSENCE OF LACTASE ENZYME SYNTHESIS
Congenital lactase deficiency [CLD] is a very rare autosomal recessive
gastrointestinal disorder. It affects approximately 1:60000 newborns in Finland
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(90) whilst worldwide less than 50 cases have been reported (91). Affected babies
present with watery diarrhoea soon after starting drinking milk containing lactose.
This causes weight loss, dehydration and acidosis (90). There is an almost total
lack of lactase activity in jejunal biopsies of these individuals (91) which is due to
distinct mutations in the coding region of the lactase gene (82, 92). These children
grow and develop normally when placed on a lactose free diet (90).
LACTOSE MALDIGESTION/MALABSORPTION
This indicates that a significant proportion of the ingested lactose is not absorbed
in the small bowel which is then delivered to the colon. This is objectively
demonstrated via measurements of hydrogen/methane in breath or blood glucose
concentrations following ingestion of a lactose load.
LACTOSE INTOLERANCE
Lactose intolerance [LI] refers to the gastrointestinal and systemic symptoms
associated with the incomplete digestion of lactose. The prevalence of lactase
non-persistence or LM could exceed the prevalence of LI as the latter is a
symptomatic response that is linked to the quantity of lactose malabsorbed. In the
literature the term “lactose intolerance” is sometimes incorrectly used to mean
lactose maldigestion (93).
1.2.2: LACTOSE
Lactose is a disaccharide that consists of galactose and glucose in
equimolar quantities bonded through a β1-4 glycosidic linkage as shown in figure
1.5. Lactose is made by lactose synthase in the mammary gland during late
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pregnancy and lactation before it is excreted in milk. Lactose makes up around 2-
8% of the solids in mammalian milk (89, 94-95). Cow’s milk, which is the most
commonly consumed milk by humans contains 5% lactose i.e. one ml of cow’s
milk contains 47.2mg of lactose (89, 94-95). Lactose is an important energy
source for newborns as it is solely the carbohydrate present in the breast milk
which accounts for 45% of total caloric content of the breast milk.
Figure 1.5: Structure of Lactose showing glucose and galactose joined by β1-4
glycosidic linkage.
1.2.3: LACTASE - THE ENZYME
Lactose cannot be absorbed by the small intestinal mucosa and therefore has to be
broken down into its constituent monosaccharides glucose and galactose by the
enzyme lactase. Hydrolysis of lactose occurs at approximately half the rate of
sucrose (96). After hydrolysis, glucose and galactose are absorbed from the
intestine by the sodium dependent glucose transporter 1. Galactose is metabolized
mainly in the liver into glucose, most of which then enters the body’s glucose
Galactose Glucose
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pool (97). Lactase is located on the apical surface of the brush border of the
intestinal epithelium. It is anchored into the membrane by its C-terminal end, with
the bulk of the molecule projecting into the lumen. Lactase is encoded by a single
gene [LCT - is the official nomenclature for Lactase] of 55 kb located on the long
arm of chromosome 2 (98, 99). and the DNA sequence contains 17 exons, and lies
within a 70 kb sequence containing regulatory response elements (82) [Figure
1.6]. It is on the reverse strand. In humans regulation involves both transcriptional
and post-transcriptional mechanisms, transcriptional regulation controlling
appearance of lactase in the foetus just before birth, and its loss on weaning. In
spite of extensive searching, no mechanism causing hypolactasia after weaning
has been identiﬁed.
Figure1.6: The Lactase gene taken from Campbell 2005 (89).
Lactase gene showing the position of the 17 exons and number of base pairs in
each of these
Lactase is a large glycopeptide with two active sites within one polypeptide chain.
One hydrolyses lactose, while the other was identiﬁed originally by its ability to
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hydrolyse glycoside phlorizin to glucose and phloretin. Phlorizin is a competitive
inhibitor of the lactose site but lactose does not appear to inhibit the phlorizin site
(89). Lactase-phlorizin hydrolase is the full name of lactase with two enzyme
commission [EC] numbers – EC 3.2.1.62 for its phlorizin hydrolase (100) activity
and EC 3.2.1.108 for its β-galactosidase activity. The natural substrates for the
phlorizin site are cerebrosides, hydrolysis of which provides sphingosine, found in
the cell membranes of the brain. This explains why we need to keep some lactase
after weaning (89).
Lactase activity is present in a characteristic gradient from the proximal to
the distal small intestine mucosa with maximal activity in the proximal to mid
jejunum and lower activity in the duodenum & ileum (101). The expression of
enzyme activity is high from the late third trimester until the weaning period.
Lactase enzyme activity then decreases after weaning to the lower levels as found
in adults (102, 103). In certain groups of the world population, Caucasians and
nomadic tribes of Africa, the capacity to digest lactose after weaning is
maintained by a genetically determined process (104). This is probably caused by
the selection of a spontaneous mutation in the lactase-phlorizin hydrolase gene
(105).
1.2.4: PREVALENCE OF ADULT-TYPE HYPOLACTASIA
The prevalence of adult-type hypolactasia has a marked variation between races
and populations. The prevalence of adult hypolactasia in different populations is
affected by the use of different indirect diagnostic methods of varying sensitivity
and specificity, differing diagnostic criteria and the numbers of participants (106,
107). The worldwide prevalence of adult-type hypolactasia is lowest in
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populations of Northern Europe with a higher prevalence in the south of the
continent. In Denmark and Sweden, its frequency is said to be only around 1-5%
(107) however, based on the molecular diagnosis (108) the prevalence in one
Swedish cohort was found to be about 10% (109). The prevalence in the UK has
been found to be 10-15% (89). In general, adult-type hypolactasia is more
common in populations outside Europe. However, in Caucasians and their
descendents in North America and Australia the prevalence of adult-type
hypolactasia is still low. In American whites, the prevalence is in the order of
15%, in African Americans about 80% and in Mexican American approximately
53% (106, 107). The prevalence in Latin America is generally high, around 70%
in Mexico and 65% in Uruguay. In Asia, the prevalence is lower in the western
parts: in Northern India around 30% and in Southern India 60-70%. The world’s
highest prevalence is in the populations of the Far East: in Thailand it is as high as
97-100%, and in Indonesia 91%. In China, a prevalence of adult-type hypolactasia
of approximately 90% is observed (106, 107). The prevalence of adult-type
hypolactasia in the black African populations ranges from 70 to 95%. Prevalence
figures greater than 90% are observed among populations with low milk
consumption such as those in Nigeria and Zaire in contrast to the populations with
a tradition of milk consumption, nomads and the people who raise cattle, amongst
whom the prevalence of hypolactasia is around 10-20% (107).
1.2.5: GENETICS OF ADULT-TYPE HYPOLACTASIA
Lactase non-persistence is controlled by a single gene defect, inherited in an
autosomal recessive manner (102). This finding was originally based on an
analysis of segregation for adult-type hypolactasia in Finnish families (102). The
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lactase phenotype had a complete concordance in monozygous twins whereas in
dizygous twins the adult-type hypolactasia prevalence was compatible with the
prevalence in the background population (110). A trimodal distribution in lactase
activity, representing the homozygous recessive, heterozygous and homozygous
dominant subjects has been reported in several studies (103, 105 & 111). This
meant that the lactase persistence/non-persistence trait is most likely due to
polymorphisms within or near the lactase gene on chromosome 2. Despite the
cloning and the sequencing of the complete cDNA and 1 kb of the promoter
region of the lactase gene, no sequence differences segregating with the lactase
persistence trait were identified until recently (112). Several polymorphisms have
been found in the introns and exons of the lactase gene and its promoter, but none
consistently correlate with lactase persistence/non-persistence (82). There are four
common haplotypes world wide, designated A, B, C and U. Only A, B and C are
found in Europe, A being found in well over 80% of northern Europeans. The four
haplotypes, A, B, C, and U are not related and have different distributions. The
haplotypes appear to be in a large region of linkage disequilibrium, where there is
evidence of genetic drift in evolution, but they do not help in identifying the true
basis of lactase persistence. Haplotype A is associated significantly with high
lactase expression (104) and is the most frequent one found in northern
Europeans, consistent with the high frequency of lactase persistence in these
populations (113).
Enattah and his colleagues (108) analysed the region flanking the LCT
gene for microsatellite polymorphisms in nine well-characterised Finnish families
which showed a 200 kb region of linkage disequilibrium. The locus for lactase
persistence was restricted to a 47-kb interval, covering only one gene, MCM6
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[mini chromosome maintenance 6]. They felt that this region was identical by
descent and this region was not disrupted by ancestral re-combinations. Full
sequence analysis of the 47 kb region upstream of the LCT gene resulted in the
identification of a total of 52 non-coding variants. Two of the variants, C to T-
13910 and G to A-22018, showed complete co-segregation with lactase
persistence. The C/T variant is located 13,910 base pairs from the initiation codon
of the LCT gene, in intron 13 of the MCM6 gene, and the G/A variant 22,018
base pairs upstream of LCT, in intron 9 of MCM6 [Figure 1.7].
Figure 1.7: Location of the single nucleotide polymorphisms [SNPs] suggested of
being associated with adult-type hypolactasia taken from Enattah 2002 (108).
This was found in both Finnish and non Finnish subjects and provided
support for the complete association of the C/T-13910 polymorphism with the
lactase persistence/non-persistence trait however, the G/A-22018 did not
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segregate with lactase activity in all cases. The C/C-13910 genotype, based on
these findings, was concluded to associate with adult-type hypolactasia, whereas
subjects with the genotypes C/T-13910 and T/T-13910 were shown to be
associated with lactase persistence (108). CC and GG homozygotes had the lowest
level of lactase. Homozygote TT/AA had full levels of lactase, with heterozygotes
being in the middle. The genetics of lactose intolerance have been studied
extensively in white European populations and non-white populations throughout
the world (82, 114). People who are homozygous for lactase persistence retain
high levels of lactase into adulthood whilst those who are homozygous for lactase
non-persistence have low levels of lactase in adult life. Adults who are
heterozygous have intermediate lactase levels. However, lactase persistence
behaves as a dominant trait because half levels of lactase activity are sufficient to
allow signiﬁcant digestion of lactose. There is a huge variation between individual
phenotypes, both in hypolactasia and the threshold for lactose intolerance.
Quantification of relative expression of the LPH mRNA transcripts from the C-
13910 and T-13910 alleles by allele - specific reverse transcription polymerase
chain reaction in Finnish adults, showed several times higher expression of LPH
mRNA from the T-13910 allele (115). Although there have been reports that these
lactase polymorphisms can regulate lactase expression in vitro, it is not clear
whether either of the two polymorphisms are mechanistically the cause of
hypolactasia. There appears to be no correlation between the expression of mRNA
for MCM6 and lactase in the gut cells of individuals with hypolactasia or lactase
persistence (89). The possible explanation suggested for this are the C/T and G/A
polymorphisms are simply a closely linked marker to lactase persistence/non-
persistence and there is genetic heterogeneity (89). Two molecular mechanisms
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can be responsible for a low level of lactase - a down-regulation of the lactase
gene or a reduction in the number of villi cells expressing lactase. The patchy
occurrence of lactase in the mature small intestine of humans and animals,
suggests that the latter developmental mechanism is most likely to be responsible
for hypolactasia in adults (116-120).
1.2.6: METABOLISM OF LACTOSE IN HUMANS
The β1, 4-glycosidic linkage between glucose and galactose is hydrolysed by
lactase. Glucose enters directly into the body’s glucose pool, but galactose is first
metabolised to glucose, mainly in the liver. Galactose which is not metabolised in
the liver is excreted in urine or metabolised by red blood cells (121). If the lactose
in not absorbed in the small bowel it reaches the colon. The colonic cells do not
absorb lactose but it can be metabolised by colonic bacteria. It is first hydrolyzed
by bacterial ß-galactosidase into glucose and galactose. Galactose is converted
into glucose via the ‘Leloir’ pathway, and is subsequently fermented. Short-chain
fatty acids [SCFA] such as acetate, propionate and butyrate as well as the gases
CO2, H2 and CH4 are the end-metabolites from the bacterial fermentation of
lactose [Figure 1.8]. Some intermediates, for instance, lactate, ethanol and
succinate, are produced and then further metabolized to SCFA. Gases and SCFA
are thought to be readily absorbed from the colon (97, 122). Acetate is the
principal SCFA produced [~50%] and it passes through the liver before being
finally metabolised in the peripheral tissues (123). Absorbed propionate and
butyrate are metabolised in the liver (123). Gases are partially absorbed from the
intestine into the blood and partially excreted through the lung whilst some is
passed as flatus or used for the synthesis of other bacterial metabolites (124).
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Figure 1.8: Fermentation of lactose by the colonic bacteria taken from Rombeau
1990 (122).
1.2.7: CLINICAL FEATURES OF LACTOSE SENSITIVITY
The peak age of presentation for lactose sensitivity is around 20-40 years. Males
and females are affected equally. The classical symptoms are abdominal pain,
bloating, flatulence, diarrhoea, and borborygmi (125, 126). These symptoms
usually begin about 30 minutes to 2 hours after eating or drinking foods
containing lactose. Recently, lactose sensitivity has been associated with systemic
symptoms like headaches, fatigue, muscle and joint pains, palpitations, cognitive
dysfunction, increased micturition, eczema and mouth ulcers (89, 127-131).
Osteopenia has also been reported as a complication of this disorder (132). The
severity of the symptoms correlates with not only the amount of lactose
consumed, but also with the diet in which lactose is consumed, the rate of gastric
emptying, the small-intestinal transit time, individual sensitivity to the stretching
of the intestinal wall and also the degree of adaptation to lactose (133, 134).
26
1.2.7.1: MECHANISM FOR THE SYMPTOMS OF LACTOSE
SENSITIVITY
The mechanisms by which lactose malabsorption causes symptoms of lactose
sensitivity are not fully understood yet. Generally it is felt that they are related to
the osmotic load of maldigested lactose which increases the secretion of fluid and
electrolytes into the lumen. This causes intestinal dilatation which increases small
intestinal transit and thereby further aggravates maldigestion of lactose (133). The
symptoms are also due to the distension caused by the additional water and the
gaseous products of fermentation together with the possible effects of SCFA’s on
colonic motility (96). However, these symptoms can persist for some time after
lactose is ingested, suggesting other mechanisms beyond this osmotic effect may
be responsible. These systemic and GI symptoms experienced by people with
lactose sensitivity can be explained by the ‘bacterial toxin’ hypothesis (95, 135)
which is shown in figure 1.9. This proposes that the carbohydrate metabolites
influence the balance of microﬂora in the large intestine, through effects on gene
expression and growth. This affects host cells, by acting on cell signalling
mechanisms and ion channels in gut bacteria which in turn influence many
different host cells including neurons, skeletal, smooth and cardiac myocytes,
mast cells and cells of the immune system. This would explain the range of GI
and systemic symptoms that have been described in lactose sensitivity (95, 135 &
136). Bacteria anaerobically metabolise carbohydrates to produce hydrogen, and
toxic metabolites such as alcohols, diols such as butan 2, 3 diol, ketones, acids,
and aldehydes e.g. methylglyoxal (89, 95, 128, 135, 137-139). This is because in
order to generate ATP, under the anaerobic conditions of the gut, bacteria have to
get rid of the hydrogen equivalents if glycolysis is to continue.
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Figure 1.9: Hypoxic metabolism of lactose and production of metabolic toxins
taken from Campbell 2009 (95).
These ‘toxins’ induce calcium signals in bacteria and affect their growth, thereby
acting to modify the balance of microﬂora in the gut (131, 137-139). These
bacterial ‘toxins’ also affect signalling mechanisms in cells around the body,
modifying molecules, such as hormones and neurotransmitters, thereby affecting
their biological activity (95, 135).
Disordered peristalsis and water absorption in the colon caused by
products of lactose fermentation leads to the development of loose stool (140).
However, as it is generally believed that SCFA’s are rapidly absorbed from the
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colon. Colonic fermentation is suggested to help to reduce the amount of lactose
present in the lumen thereby reducing the osmotic load in the colon (96, 141).
When the threshold to do this is exceeded, water is retained which retards the
absorption of SCFA’s. When lactose is converted to SCFA by fermentation, an 8
fold increase in osmotic load occurs, which makes the efficiency of the colon to
absorb these fermentation metabolites an important determinant as to whether
symptoms are produced (142). There are differences in the absorption of
individual SCFA’s (141).
The osmolar load of malabsorbed lactose in the colon is determined by the
balance between the ability of the faecal bacteria to ferment lactose and the
efficiency with which the colonic mucosa absorbs these fermentation products
(142). Colonic fermentation of 50 g of lactose is thought to produce 17 L of
hydrogen. Most of the gas produced is consumed by intestinal bacteria. Intestinal
gas tolerance is normally high as expeditious gas transit and evacuation prevent its
accumulation. When gas transit and/or evacuation is impaired, gas retention
occurs, which causes abdominal symptoms and distension.
Colonic fermentation of lactose may also be involved in the development
of symptoms in patients with lactose sensitivity. Colonic bacteria are involved in
the metabolism of lactose (97) individuals with similar oro-caecal transit and
degree of lactose digestion in the small intestine develop symptoms of different
severity (143). Also adaptation of long-term lactose ingestion may be related to
changes in the microflora and function of the large intestine. Continuous lactose
consumption reduces breath hydrogen excretion, increases the bacterial ß-
galactosidase activity and improves lactose intolerant symptoms (144, 145).
Adaptive changes in colonic functions [motility, transit, and pH] and the colonic
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bacterial population lead to reduced bacterial hydrogen production and a
decreased perception of symptoms by subjects, however placebo effects have been
suggested as explanations for these observations (146, 147). The composition and
metabolic activities of the colonic bacteria, the ability of the colon to remove
fermentation metabolites and visceral sensitivity also determine the nature of
symptoms experienced by lactose intolerant people (133, 142).
1.2.8: TESTS USED TO DETERMINE LACTOSE DIGESTION
There are many methods to measure lactose digestion in humans, these tests are
based on different principles [“direct & indirect”] and have variable accuracy as
well as diagnostic reliability. In clinical practice, judging the symptomatic
response after the withdrawal of lactose from the diet is often suggested to
patients who describe symptoms after ingesting dairy products. However, the
diagnosis of the adult type hypolactasia based on symptoms alone is inaccurate
(126). There are a number of different tests that have been used to try and
determine hypolactasia and lactose sensitivity.
1.2.8.1: MEASUREMENT OF LACTASE ENZYME ACTIVITY IN SMALL
BOWEL BIOPSY
Biochemical methods can be used to measure lactase activity from the small
bowel mucosa. Specimens are obtained distal to the ligament of Treitz (126) either
by endoscopy or capsule. It has been shown that both the biopsy techniques have
no effect on the enzyme measurement (148). The tissue is subsequently
homogenised and incubated with lactose. Lactase hydrolyses the substrate into
glucose and galactose and the glucose concentration of the supernatant is
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measured. Dahlqvist first described this method in 1968 (149). To correct for
confounding influences of the variable water content in the specimen, results are
expressed as activity units per gram of protein. This test has been said to be the
gold standard for the diagnosis of hypolactasia which is diagnosed when lactase
activity is < 10U/g protein (126). Similarly sucrase levels can be measured in the
biopsy sample using sucrose instead of lactose and hypolactasia is diagnosed if
lactase to sucrase ratio is < 0.3 (150). Recently Kuokkanen (151) described a
Quick Lactase Test [Biohit PLC, Helsinki, Finland] for diagnosing adult-type
hypolactasia. The endoscopic biopsy from the post-bulbar duodenum is incubated
with lactose on a test plate, and a colour reaction develops within 20 minutes as a
result of hydrolysed lactose [a positive result] in patients with normolactasia. No
reaction [a negative result] develops in patients with severe hypolactasia. When
compared with biochemical lactase assays, the sensitivity and specificity of this
test was 95 % and 100 %, respectively.
Since only a very small part of the mucosa can be tested by biopsy
techniques, the relation between the measured lactase activity with the overall
physiological lactase activity of the whole small intestine has not been well
established.
1.2.8.2: STOOL ACIDITY TEST
This measures the amount of acid in the stool and has been traditionally used in
paediatric practice. Undigested lactose fermented by bacteria in the colon creates
lactic acid and other short-chain fatty acids that can be detected in a stool sample-
they produce a pH of less than 5.5. In addition, if reducing substances are found in
the stool it indicates that carbohydrates are not being absorbed.
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1.2.8.3: LACTOSE TOLERANCE TEST [LTT]
The lactose tolerance test is based on the principle that, after consumption of
lactose, the substrate will be hydrolysed into glucose and galactose. These
monosaccharides are then absorbed with much of the galactose being converted
into glucose by the liver. The lactose tolerance test is based on determining the
increase in blood glucose from samples taken at intervals after 15 to 30 min and
then up to two hours after an oral load of 50 g of lactose. A rise in blood glucose >
1.7 mmol/l is indicative of normolactasia and that of < 1.1 mmol/l suggests
hypolactasia. Symptoms after the test also need to be recorded – if these occur in
conjunction with a marginal rise in blood glucose then this is said to suggest
hypolactasia (126). It has been estimated, using assays of lactase from mucosal
biopsies as reference methods, that the specificity of the LTT is 77-96% and the
sensitivity is 76-94% (126). It should be noted that the test is not reliable in
diabetics (152) and false positive results can occur with delayed gastric emptying
(153). This test is not routinely used in clinical practice due to the above problems
and the need for repeated blood sampling.
There is a modification of the LTT where ethanol is given in addition [50-
150mg/kg orally depending on laboratory protocol]. Ethanol inhibits the hepatic
conversion of galactose into glucose. Galactose is subsequently released by the
liver into the blood stream and cleared by renal excretion. The concentration of
galactose in the urine or blood therefore represents the hydrolysis of lactose in the
intestine. Blood galactose concentration is determined in a single blood sample
taken 40 minutes after an oral lactose load. Blood galactose concentration of < 0.3
mmol/l at 40 min after the ingestion of lactose and ethanol indicates hypolactasia.
The measurement of galactose instead of glucose increases the specificity (126)
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between 96% to 100% and sensitivity of 81% to 100% (126). Galactose can also
be measured in a urine sample taken 40 minutes after the lactose-ethanol load and
hypolactasia is diagnosed if the urinary galactose is < 2.0mmol/l. The sensitivity
and specificity of this method are 94 and 98% respectively. The test is suitable for
diabetics as well, and is less vulnerable to changes in gastric emptying rates (126).
This test is not recommended in infants, children and pregnant women due to the
unwanted effects of ethanol in these vulnerable groups.
1.2.8.4: RADIO-LABELLED LACTOSE BREATH TEST
After the consumption and hydrolysis of lactose labelled with radio carbon, the
exhaled labelled CO2 can be measured. The cumulative amount of exhaled CO2 is
related to the hydrolysis of the substrate. It has been shown that there is a good
correlation [r=0.77- 0.87] of radio labelled carbon with jejunal biopsies in the
diagnosis of lactose malabsorption (154, 155). A study by Heile (156) using
naturally enriched 13C-lactose as a substrate showed a 14.5% 13CO2 excretion was
the best cut-off point for discrimination between patients with low and normal
lactase activity. The 13CO2 breath test was found to be more sensitive [0.84 versus
0.68] and more specific [0.96 versus 0.89] than the H2 breath test. The
radioactivity of the substrate limits its applicability in medical practice, especially
in infants, children and pregnant women.
1.2.8.5: OTHER BREATH TESTS
The colonic bacteria ferment lactose and produce gasses including Hydrogen [H2]
and methane [CH4] as well as lactate and SCFA’s. These gases are absorbed by
the colonocytes and transported via the blood and exhaled in breath air. Biological
33
processes in the human body do not produce H2 or CH4, the concentration of these
gases in exhaled breath represents the fermentation of carbohydrate in the colon.
After a standard oral load of lactose, breath samples are collected at intervals of
15 to 60 min for two to six hours, and the change in hydrogen concentration in the
expired air determined. The result of the test is positive [lactose malabsorption] if
the breath H2 concentration rise by 20 ppm or rise in methane by 5 ppm above the
base line or nadir. The specificity of the breath hydrogen test varies between 89-
100% and sensitivity ranges from 69-100% (126).
There are several factors that could influence the results include exercise
before the test, the ingestion of antibiotics and cigarette smoking all of which will
increase the rise in hydrogen concentration (157-160). In addition bacterial
fermentation of other carbohydrates can also produce gaseous products in breath
similar to lactose. As a result subjects undergoing the test should not eat or drink
anything other than water for the period of the test.
This technique introduced in the 1970’s (161-163) is the most widely used
test that is employed to try and diagnose lactose digestion in clinical practice. The
advantages are the simplicity of the test and its low cost. The major drawback is
that there is no standardised protocol and it is also time consuming, taking 2-6 hrs
depending on the protocol. There are different ways in which the test is carried out
i.e. the substrate used [lactose or milk], the quantity of lactose administered [25g
or 50g], sampling time intervals [15-60mintes], the duration of the test [from 1hr
to 6hrs], the measurement of gases [i.e. hydrogen, methane or both] and the
equipment used to measure the gases [handheld devices or gas chromatography].
There is also a lack of consensus regarding whether symptoms should be recorded
after a lactose challenge and if so which ones are to be noted and for how long.
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There is limited information on the sensitivity and specificity of symptoms which
developed after a lactose challenge.
1.2.8.6: GENETIC TEST
The test is used to detect adult-type hypolactasia. DNA is extracted from buccal
swabs or blood samples and analysed to detect either of the two single nucleotide
polymorphisms [SNPs] located about 14 kb and 22 kb upstream of the lactase
gene [LCT-13910 C/T and LCT-22018 G/A] (108). The CC or GG genotype is
associated with genetic adult type lactase non-persistence and genotypes CT, TT,
GA & AA with lactase persistence.
In a sample of 236 individuals, C/T–13910, was found to be completely
associated with lactase non-persistence when compared to their biochemically
verified lactase persistence/non-persistence status by disaccharide assay (108).
The C/C genotype was associated with very low lactase activity [<10 U/g protein]
in the majority of children tested at 8 years of age and in every child older than 12
years of age giving a specificity of 100% and sensitivity of 93% for this genetic
test (164). In a study by Kuokkanen (115), all individuals with genotype
CC−13910 and GG−22018 had both low lactase activity and a low lactase:sucrase
ratio whereas all those either heterozygous for CT−13910 and GA−22018 or
homozygous for T−13910 and A−22018 had lactase activities >13 U/g and
lactase:sucrase ratios >0.35 U/g.
Recent studies have demonstrated an excellent correlation between the CC
genotype and a positive H2-breath test with 97%-100% of people with the CC
genotype having positive lactose HBT (117, 136 & 165). In those with a CT or a
TT genotype suggestive of lactase persistence, 72%-86% tested negative, whilst
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the remainder had a positive HBT. In another recent study in patients who had a
positive HBT, the sensitivity, specificity, positive and negative predictive values
for the CC genotype variant were 91.4, 96.0, 98.1 and 82.8%, respectively (166).
In a study with Austrian subjects, the 24% frequency of the C/C was concordant
with the frequency of lactose intolerance diagnosed by the HBT (167). In another
Austrian study (165), a 97% correlation was observed between the C/C genotype
and a positive test result in HBT. Of those with C/T and T/T genotypes 14%,
however, had a positive HBT. In a German cohort, the frequency of the C/C
genotype was 21.4%; somewhat higher than that diagnosed by HBT [5%] (168).
In a Swedish study, the results from the LTT correlated perfectly with the
genotyping results in subjects with C/C and T/T genotypes, whereas in three
subjects with a C/T genotype, LTT results were suggestive of lactose
malabsorption (169). In a study from the UK, a perfect association between the
C/T-13910 genotypes with lactase persistence/non-persistence phenotypes was
seen in northern European samples studied but not in 2 out of 40 samples from
southern European (82, 170).
Unlike the HBT, results of LCT genotyping are not influenced by factors
such as incomplete fasting, antibiotic therapy or disease states. There are several
limitations to this test. However, genotyping could only be used as a rule out test
since it does not tell anything about the age at which a child with the CC genotype
begins to express less lactase. Secondly, in patients where secondary hypolactasia
is suspected e.g. coeliac disease or IBD, genotyping should be done together with
other tests in order to establish hypolactasia is present. Also the same genotype
abnormalities may not be responsible for lactose sensitivity in different
populations. A recent study reports the C/T-13910 variant frequencies in 20
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distinct African cultural groups (171). In the sub-Saharan groups, the T-13910
allele was found too seldom in order to underlie the lactase persistence phenotype,
thus it was suggested that C/T-13910 might not be the causing variant in these
groups (171).
The results of the various tests used in the diagnosis of adult type
hypolactasia are summarised in table 1.10.
Table 1.10: The specificity and sensitivity of the methods used in the diagnosis of
adult-type hypolactasia. [LTT: Lactose tolerance test, LTTE: LTT with ethanol,
HBT: Hydrogen Breath Test]
Test Sensitivity Specificity
LTT 76-94% 77-96%
LTTE 81-100% 96-100%
HBT 69-100% 89-100%
13CO2Breath Test 84% 96%
Genetic test [C/T-13910] 93% 100%
Jejunal Biopsies 100% 100%
The current best practice to diagnose lactose sensitivity is to initially ascertain the
lactase genotype which avoids invasive testing or provoking significant symptoms
in susceptible individuals after a lactose challenge. There appears to be an
excellent correlation between C/T-13910 polymorphism and lactase
persistence/non-persistence phenotype in all populations- except for the sub-
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Saharan Africans- studied so far. In the UK population, if the CC status is
detected then this is in keeping with lactase non-persistence and the patient will
have a positive breath test therefore no further evaluation is necessary. If they are
CT or TT this is associated with genetic lactase persistence, then a breath test and
analysis of symptoms after lactose challenge should be carried out where there is
suspicion of lactose sensitivity.
In addition to the problems associated with the individual tests described
earlier there are other issues which cause difficulties in measuring products of
lactose metabolism. Factors which affect the amount of the H2 in the breath
sample include smoking, diet and antibiotic treatment (157, 172). Colonic
metabolism of carbohydrates by bacteria is a pH dependent and fall in pH can lead
to decreased metabolism of the carbohydrates as seen by decreased breath H2
excretion, (146) this can occur with chronic lactose ingestion in maldigesters.
Factors which affect colonic bacterial production of H2 include the ingested
amount of disaccharides, the functional status of the small bowel and the type of
colonic bacteria present (173, 174). Regional or ethnic differences are partly a
result of different dietary habits. These factors may explain some of the
difficulties in the measurement and the results seen in several studies. Brummer et
al recommended that the test should be carried on for up to 4 hours to improve the
accuracy. Sampling time duration negatively inﬂuences the accuracy of the HBT,
with its sensitivity lower as the time is shortened (175). The bacterial ﬂora adapt
to chronic lactose exposure, producing less hydrogen and causing fewer
symptoms with repeated ingestion which may also account for decreased
symptoms and lower response to lactose challenge seen in chronic lactose
intolerance (144, 176).
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There are a number of issues relating to the use of symptoms in the diagnosis of
lactose intolerance. Firstly, there are no studies that report symptoms following a
blinded lactose challenge i.e. GI or systemic symptoms occurring after ingestion
of lactose that are not observed when compared to ingestion of a placebo. All
published studies that have looked at symptoms of LI following a lactose
challenge are un-blinded. If subjects without prior GI symptoms are given a
lactose load, 4-23% develop them thereafter (177, 178), in those who had baseline
symptoms prior to challenge it was 32 to 71% (179, 180) and in those studies
which had subjects with or without symptoms prior to challenge it was 38-72%
(181-183). The problems in the studies that are published report symptoms in
subgroups of their populations [participants with positive tests or only in people
who previously had symptoms]. Self reported history of LI related symptoms
without empirical evidence of symptoms following a lactose challenge is very
difficult to interpret. The prevalence of LI is 12% to 16% in three such studies
(184-186), based on self reported symptoms of LI in Caucasians. The results from
the above studies show that the prevalence of LI from self-reported symptoms is
lower than those that report symptoms after lactose challenge. Studies that
reported results in people both with and without LM, reported significantly greater
frequency of symptoms in those with positive breath hydrogen tests compared to
those with negative tests (178, 183 & 187).
Some of the difficulties in assessment of symptoms are related to the age
of the participants [paediatric Vs adult subjects], the ethnic origin of the study
population and to individual variations in the daily dose of lactose that is tolerable
to subjects with LS. Hypolactasia generally manifests at an earlier age in
populations who have a high prevalence than in those with a low prevalence. In
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high prevalence populations, symptoms can start at the age of 2 to 7 years whilst
in lower prevalence areas they begin 4 to 5 years later (107). A study by Suarez,
however, has shown no difference in the metabolism and tolerance of lactose
between young adults and the elderly (188). Men and women have the same
prevalence of hypolactasia (189, 190). However, women seem to report higher
symptom scores than men after a standard lactose challenge - the reason for this is
not known (190).
A lower rate of symptoms was observed with lower doses of lactose
challenge [50g Vs 12 g] (178, 187). Symptom perception is susceptible to
psychological factors. It is generally thought that a small amount of lactose [6-7 g]
does not induce symptoms of lactose intolerance (191) and the amount of lactose
[12 g] in one cup of milk [240 ml] can be tolerated by most people with
hypolactasia (192). This is not absolutely correct as symptoms have been reported
in sensitive people ingesting smaller quantities than this (89). Ingestion of 50 g of
lactose causes symptoms in 80% to 100% of those with hypolactasia (193, 194)
and this is the quantity that is most commonly used in the diagnostic tests. It
should be noted, however that a small percentage of people with hypolactasia
remain symptom-free even after the ingestion of this amount of lactose (106), the
reason for this is not known. Some individuals, whether they had the ability to
digest lactose or not, report symptoms suggestive of intolerance after taking
various placebos used in double-blinded studies (195-197). Familiarisation with
the test procedure also influences symptom recording (144). These observations
suggest the possible involvement of psychological factors and that some GI
complaints may therefore be mistakenly attributed to the consumption of lactose
or milk. People with hypersensitivity of the GI tract such as IBS are likely to
40
report more symptoms from lactose ingestion when compared to others. Tests
have used milk and lactose to record symptoms, lactose should only be used to
avoid confusion from symptoms that can occur from the non-lactose fraction of
milk. When using self reported symptoms for analysis, there may be variations if
lactose is ingested throughout the day which may result in fewer symptoms than if
a similar quantity of lactose is taken as a single dose. It is also thought that
tolerance can develop if lactose is ingested chronically and this can therefore
cause under reporting by patients.
Gastric emptying of lactose is reduced if it is consumed with other foods.
Delayed gastric emptying and slowing intestinal transit enable a longer contact
between lactase and lactose; this may improve lactose digestion and reduce any
symptoms. It may be the mechanism behind the observed differences in many
studies where full fat milk or ingestion of milk with meals, both of which prolong
gastric emptying, was compared with skimmed milk or milk drunk on its own
(198, 199). Studies have shown that a prolonged oro-caecal transit time
contributes to fewer symptoms (143, 200 & 201), but this may not be a consistent
finding as no difference was seen in another study (202).
Drugs which alter GI motility could also have an influence on the
digestion and absorption of lactose. Loperamide is shown to prolong oro-caecal
transit time has shown to reduce breath hydrogen concentration and reduced
gastrointestinal symptoms (201), whilst propantheline improves symptoms by
reducing the rate of gastric emptying and metoclopramide which causes the
opposite effect has shown to worsen the symptoms of LI (203, 204). Finally,
biases in attributing abdominal symptoms following un-blinded challenges can
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make it difficult to accurately identify the prevalence of symptoms truly
attributable to lactose.
1.2.9: MANAGEMENT, TREATMENT AND NUTRITIONAL
CONSEQUENCES OF LACTOSE INTOLERANCE
The basis of the treatment of lactose sensitivity is to reduce the amount of lactose
in the diet; the degree of the restriction depends on the individual’s tolerance
(205). In primary hypolactasia, a diet which completely excludes milk and dairy
products is needed to obtain symptom remission. In the secondary form, a
temporary lactose-free diet may only be necessary until a complete recovery of
the causative pathological condition. Primary hypolactasia is a lifelong
phenomenon, and so long term reduction in lactose intake is necessary to control
symptoms (205). Lactose content varies between different dairy products, and for
example cheese which has low lactose content is well tolerated, meaning that not
all milk products need to be restricted in the diet. Some of the common foods
which contain lactose and the quantity of lactose contained in them are shown in
table 1.11. After exclusion, a gradual reintroduction of dairy products can then be
made to a level determined by the threshold at which symptoms appear. Some of
the strategies which will help in this are consumption of fermented dairy products,
eating lactose containing products with other foods or dividing the total quantity
consumed between several meals (206). Yogurt delays gastric emptying and
intestinal transit leading to slower delivery of lactose to the intestine, thus
optimising the action of residual lactase in the small bowel (200).
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Table 1.11: Lactose content of some common foods (207).
Food Type Percent by weight
Whole Milk 4.6
Semi-skimmed 4.7
Skimmed 4.8
Evaporated 8.5
Condensed 12.3
Milk
Goat 4.4
Single 2.2
Double 1.7
Cream
Sour 2.7
Feta 1.4
Cheddar 0.1
Cottage cheese 3.1
Stilton 0.1
Cheese
Mozzarella Trace
Plain 4.7
Fruit 4.0
Yoghurt
Fromage frais 4.0
Milk Shake 4.5
Ice cream 5.2
Puddings
Custard 5.2
It has also been demonstrated that commercially available plain yogurt is
as effective in reducing H2 and symptoms as pre-hydrolysed milk (208, 209).The
tolerance to fermented milk is based on the presence of endogenous lactase
activity of yogurt microorganisms. The bacterial ß-galactosidase is structurally
different to lactase found in small bowel mucosa. The ingestion of fat improves
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carbohydrate absorption by slowing down gastric emptying and intestinal transit
time which as a consequence increases the contact time between the enzyme and
the substrate which may one of the reasons why full-fat milk tolerated when better
compared to skimmed milk and aqueous lactose solution (210). The addition of
exogenous β- galactosidase in the form of tablets or capsules with meals or drinks
has shown to be effective, practical and with no side effects (211, 212).
Furthermore, the absorption of lactose can be facilitated by exogenous lactase
preparations (213). In some countries, low-lactose products in which lactose has
been pre-hydrolysed, as well as lactose-free milk in which lactose is removed
from the milk with chromatographic separation, are available.
The main nutritional consequences of avoiding lactose containing products
may be a reduced calcium intake in the diet which may impair bone health (214,
215). Moreover, several studies have shown an increased incidence of adult-type
hypolactasia, among subjects with osteoporosis or bone fractures (167, 216). The
effect of lactose on calcium absorption is dependent on intestinal lactase activity
(217). Calcium absorption is increased in subjects with normal lactase activity,
when accompanied with lactose, whereas in subjects with adult-type hypolactasia
lactose decreases calcium absorption (217). On the other hand, it has been
observed that lactose does not have a beneficial effect on calcium bioavailability
in lactose tolerant subjects (218). The mean calcium absorption from both lactose-
hydrolysed and un-hydrolysed milk is significantly greater in subjects with adult-
type hypolactasia in comparison to subjects who have lactase persistence (219).
Calcium supplementation may be required in patients on a restricted lactose diet
and the recommendation of calcium fortiﬁed foods should also be considered.
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1.3: LACTOSE SENSITIVITY IN GI DISORDERS
Although primary lactose sensitivity has been increasingly recognised as a
clinically significant entity, the importance of secondary lactose intolerance in
patients with established GI diseases is less clear. It has been described in several
disorders of the GI tract including Inflammatory Bowel Disease which will be
discussed later on.
1.3.1: LACTOSE SENSITIVITY IN IRRITABLE BOWEL SYNDROME
Irritable bowel syndrome [IBS] is a very common diagnosis, with a prevalence of
up to 25% in the western world (220). Patients present with at least one of the
following symptoms: abdominal pain, bloating, constipation and/or diarrhoea. IBS
symptoms are often indistinguishable from those of lactose sensitivity, but it has
been shown that lactose sensitivity does not lead to IBS per se (182). However,
LM is reported as being very common in those with IBS symptoms with reported
rates of 24–27% (220, 221). In an Italian study (222) LM was diagnosed in as
many as 68.2% of participants with IBS. In this study, 43.6% of the patients who
complied with the lactose free diet reported that their symptoms subsided, in 39%
they were reduced and in 17% they remained unchanged. In another study by
Alpers, 45% of IBS patients had lactose sensitivity, but only 30% related their
symptoms to milk and dairy products; dietary exclusion improved symptoms in
52% of the cohort (223). On the other hand, some IBS patients without objective
evidence of lactose malabsorption, describe symptoms of lactose intolerance
(223). Lactose sensitivity should be excluded before the diagnosis of IBS is made
(221, 224) as it is apparent that a large number have clinically unrecognised
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lactose malabsorption, which cannot always be discriminated by symptoms and
dietary history alone but may be effectively treated with a lactose-restricted diet.
1.3.2: LACTOSE SENSITIVITY IN COELIAC DISEASE
Coeliac disease is a life-long inflammatory condition of the gastrointestinal tract
that affects the small intestine in genetically susceptible individuals. It improves
morphologically when gluten, the causative agent, is removed from the diet. It is
much more common than previously suspected, recent studies show a prevalence
of up to 1% of UK population (225). The inflammation of the small bowel leads
to an alteration in the brush border with villous atrophy and a subsequent
reduction in the activity of the lactase enzyme. It is well known that patients
affected by coeliac disease have a higher incidence of lactose malabsorption. This
is present in many patients with untreated coeliac disease giving rise to more
frequent and more watery stools. In well-treated coeliac disease, lactose
malabsorption is not more common than the general population (226). In addition,
a high prevalence of coeliac disease has been observed in patients with a positive
HBT compared to healthy controls (227). Here, lactase deficiency seemed to be
the only manifestation of coeliac disease. As a result, serologic screening for
coeliac disease in all patients with a positive H2-lactose breath test should be
carried-out before beginning a milk-exclusion diet (227).
1.3.3: LACTOSE SENSITIVITY IN GI INFECTIONS
Lactose malabsorption may also occur as a result of acute infection with agents
such as rotavirus which cause small intestinal injury and the resultant loss of the
lactase-containing epithelial cells from the villi. The immature epithelial cells that
46
replace these are often lactase deficient, leading to secondary lactose deficiency
and lactose malabsorption (228). Giardiasis, cryptosporidiosis, and other parasites
that infect the proximal small intestine often lead to lactose malabsorption from
direct injury to the epithelial cells by the parasite.
1.3.4: LACTOSE SENSITIVITY AFTER RADIOTHERAPY
Approximately four out of 10 people with cancer will have radiotherapy as part of
their treatment. During the course of this treatment, partly because of mucosal
damage, 80% of patients who receive abdominal or pelvic radiotherapy will
develop gastrointestinal problems such as diarrhoea, abdominal cramps, tenesmus
or faecal incontinence (229). Small bowel bacterial overgrowth and lactose
intolerance [15%] may occur during radical pelvic radiotherapy and are likely to
contribute to acute and also long term gastrointestinal symptoms in some patients
(230).
1.3.5: LACTOSE SENSITIVITY AND RISK FOR COLORECTAL
CANCER
In the Finnish population low lactase enzyme activity [C/C−13910 genotype], was
found to be significantly associated with the risk of colorectal cancer [p = 0.015],
with an odds ratio of 1.40 (231). It has been proposed that the change in the
colonic flora from the products of lactose metabolism, i.e. butyrate and galactose
protect against development of colorectal cancer. This finding has not been
replicated in other populations.
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1.3.6: LACTOSE SENSITIVITY IN INFLAMMATORY BOWEL DISEASE
Lactose sensitivity has been suggested as a cofactor that predisposes to a clinical
attack of IBD or alternatively as an accompanying phenomenon of the disease. There
have been several studies that have looked at the prevalence of lactose malabsorption
in IBD- these have reported very variable findings. This could be ascribed to different
study populations, with varying ethnic backgrounds, differing disease activity and a
variety of different testing protocols and definitions. These studies are summarised in
table 1.13 at the end of this discussion.
After Binder reported a 49% incidence of lactose malabsorption in patients
with UC in 1966 based both on the results from lactose tolerance test and
biopsies, increasing attention was paid to the correlation between these two
conditions (232). In 1970, Gudmand-Hoyer (233) investigated the incidence of
lactose malabsorption in 85 patients with ulcerative colitis and 71 patients with
Crohn’s disease by means of lactose tolerance tests and the measurement of
disaccharidases in small intestinal mucosa. They found that just 9% with
ulcerative colitis and 6% with Crohn’s disease had lactose malabsorption. A
control group displayed a similar incidence and as a result it was concluded that
LM is not more prevalent in IBD (233). A British study in 1973 (234) found no
difference in hypolactasia between patients with UC and healthy controls [12.5%
vs. 9.5%] using jejunal biopsies and a disaccharide assay. However, they did
highlight 5 patients who demonstrated a temporary reduction in lactase activity
during an acute attack of UC.
A study from Denmark (235) of 120 patients with ulcerative colitis,
reported the prevalence of lactose malabsorption based on a lactose tolerance test
± jejunal biopsy to be 9.2%, which is not significantly higher than that in the
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normal Danish population. They found no difference according to age, sex or the
severity of ulcerative colitis. Bernstein (236) reported no statistical difference of
lactose intolerance between ulcerative colitis [44%] patients and matched controls
[36%] using the HBT. When they analysed the results based on ethnicity of all
participants, an abnormal HBT occurred in 68% of Jews compared with 23% in
those of Northern European origin. LM was studied, with HBT, in 72 adults
suffering from IBS, 20 UC patients, and in 69 healthy subjects by Sciarretta (237).
The incidence of LM was 70% of the healthy subjects, 86% in IBS and 85% in
UC, respectively. In the IBS and UC groups, symptoms occurred with a smaller
rise in breath hydrogen; the authors presumed that this was in association with a
greater individual sensitivity of the colon to distension.
In Pironi’s study (238) of 37 adult patients with CD [19 with intestinal
resection, and 18 without] and 67 healthy controls, again using the HBT, the
prevalence of LM was increased to 49% in CD in comparison to 16% of controls.
They also found a higher proportion of positive breath test in patients with CD
who have undergone intestinal resection when compared to those who did not
[58% vs. 33%]. LM also occurred at a lower dose of lactose in patients who
previously had surgery. In addition, the prevalence was higher if the disease
involved the small bowel when compared to involvement of large bowel alone
[62% vs. 20%].
A study by von Tirpitz (88) enrolled 49 patients with CD and 24 controls,
and also used the HBT to detect LM which was present in 32.7% and 20.8%
subjects respectively. In addition, all individuals underwent endoscopy of the
upper gastrointestinal tract, where biopsies were taken from the distal duodenum.
In CD, duodenal lactase levels correlated to disease activity i.e. decreased lactase
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levels were found during an acute exacerbation; however there was no obvious
relationship with symptoms, site of disease or a history of previous surgery.
Mishkin (87) carried out a study to compare the prevalence of LM in 121
patients with CD and 139 with UC compared with 158 controls using hydrogen
breath testing. The prevalence of LM was 58.2% in CD and 46.8% in UC. This
was not significantly different to the 46.9% found in healthy controls. Analysis
based on low ethnic risk for LM yielded interesting results where the control
group had a prevalence of 29.2% compared with 40.0% in CD [p < 0.025] and
13.3% of UC patients [p < 0.025]. In the moderate ethnic risk group it was 68% in
CD, 56% in UC & 65% in controls. In CD, the results based on the segment of
bowel involved showed that 68.1% of patients with CD limited to the terminal
ileum were lactose malabsorbers compared with 43.5% of patients with Crohn’s
colitis [p < 0.05]. In patients with UC, the extent of the disease did not have any
effect on the result. Additional analysis according to anatomical location indicated
that Crohn’s disease of the proximal small bowel [duodenum, jejunum], terminal
ileum, terminal ileum plus colon, and colon alone were associated with a LM
prevalence of 100, 68.1, 54.5, and 43.5% respectively. Similar results based on the
location of CD were seen in a Japanese study (239).
HBT were performed in 70 children and adolescents 20 with UC and 50
with CD by Kirschner (240). 29% of these patients demonstrated LM and the
prevalence was not significantly different whether the diagnosis was UC [15%] or
CD [34%]. With the exception of those with diffuse small bowel disease, the
location of intestinal involvement with CD and the severity of clinical symptoms
did not affect LM. Also, it was not more commonly seen in patients with IBD
than in a group of children with recurrent abdominal pain. Significant differences
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were again seen in the prevalence of LM between participants with different
ethnic background. It was noted that there was no difference in the prevalence of
LM between hospitalised participants compared to patients from the out-patient
clinic.
The two single nucleotide polymorphisms C/C 13910 and G/G 22018
associated with the adult-type hypolactasia have been studied in 232 patients with
IBD and 307 healthy controls in a German cohort (168). It revealed a frequency of
21.4% of these 2 genotypes, which is higher than previously reported in German
subjects of 15% by Flatz which was based on the HBT (241). There was no
significant detectable difference in the frequency of the C/C and G/G genotypes in
patients with CD 21.7% & 22.3% compared to first-degree relatives 21.7% &
20.8%, patients with UC 20.3% & 20.3% and healthy individuals 21.4% & 21.4%
respectively They concluded that the C/C and G/G genotype of adult-type
hypolactasia is not associated with susceptibility to the pathogenesis of CD and
UC (168). In contrast to this study a subsequent study from New Zealand of 333
individuals with CD and 612 healthy controls (242) showed that individuals
homozygous for the T allele [T/T genotype] showed a significantly increased risk
of having CD as compared with those homozygous for the C allele [OR = 1.61,
95% CI = 1.03-2.51]. Additionally, a significant increase in the frequency of the T
allele was observed in CD patients [OR = 1.30, 95% CI = 1.05-1.61, p = 0.013],
suggesting that the T allele encoding lactase persistence is associated with an
increased risk of CD in this New Zealand Caucasian population. The T allele was
also associated with early onset of disease,[<40 years Vs >40 years], the presence
of ileal disease, the inflammatory phenotype of CD, a family history and previous
bowel resection (242). Similarly Juste et al from Spain (243) also reported an
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increased frequency of the T allele in CD patients [61.9%] compared with controls
[47.1%, p = 0.0275].
IBD patients avoid dairy products more often than they may need, possibly
due to incorrect patient perceptions and arbitrary advice from physicians (87, 236,
244 & 245). 80% of responding physicians stated that they recommend avoidance
of milk products at some time to their IBD patients (236). Also, 66% patients
reduced or eliminated milk products from their diet, but only 45% of these
patients were lactose intolerant (236). In a study by Peroni in patients with CD,
only 8% of the total with LM experienced symptoms of intolerance after the
ingestion of 250 mls of milk and they concluded that this amount can be
empirically taken in the daily diet of an adult with CD (238). There is a strong and
highly signiﬁcant negative correlation between raw country annual incidence of
Crohn’s disease and the frequency of lactase persistence in adulthood [p = 0.0017]
(246), this is illustrated in figure 1.10.
Figure1.10: Association between Crohn’s disease incidence and lactose
intolerance taken from Juste 2010 (246).
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The data included in this study was from 20 countries which are Belgium,
Canada, China, Croatia, Denmark, Estonia, France, Germany, Greece, Hungary,
Iceland, Ireland, Israel, Italy, Japan, Lebanon, Netherlands, New Zealand,
Norway, Portugal, Saudi Arabia, Spain, Sweden, UK and USA. The data of
incidence and prevalence of CD for each country from 1990-2005 was obtained
from relevant medical literature, official national authorities and organisation with
an interest in gastroenterology or IBD. It included both adult and paediatric
populations. The LI frequency for each country was taken from published data in
medical literature and official authorities. A similarly strong correlation between
the country incidence of Crohn’s disease and cattle heads per capita was also
observed on a slightly larger sample [p = 0.0013] (246). Shrier et al. showed that
an inverse correlation between yearly capita intake of dairy foods and national
prevalence of lactose non-persistence status (247). In this study, there were
statistically signiﬁcant [p ≤ 0.05] increases in risk for UC with dairy food
consumption and a similar trend [P < 0.1] for CD (247).
Antigens from milk are homologous with proteins present in colonic
mucosa which could stimulate the development of antibodies through antigenic
cross reactivity. Alternatively, colonic antigens released from the inflamed
mucosa of milk sensitive individuals could initiate the immunological reaction
(248). Milk and milk products have been considered among the dietary factors
that may initiate the IBD process, or exacerbate the disease once established (249,
250). It has been suggested that milk proteins may be pathogenic by acting as
foreign antigens stimulating gut immunological responses; however this concept
53
of allergic response does not fit with the current concepts of IBD pathogenesis.
Also, reports have been inconclusive and inconsistent in relation to antibody
levels to various proteins in cow’s milk (251-253).
In a study by Glassman (254), 35 patients with CD and 43 with UC were
compared with a control population of 36 children without organic disease. They
were surveyed to determine the frequency of symptoms compatible with cow's
milk-protein sensitivity during infancy. The incidence of a history compatible
with cow's milk sensitivity was 8.5% in patients with Crohn’s disease and 2.8% in
controls. Patients with ulcerative colitis had a significantly greater prevalence of
symptoms, compared with the other patient groups [20.9% in UC, 8.5% in CD
and 2.8% in the control group]. In addition, patients with a history of cow milk
sensitivity, who subsequently developed UC, did so at an earlier age [6.68 vs.
10.62 years & p < 0.02] than those without this sensitivity. They concluded that
there appears to be a potential relationship between early cow's milk sensitivity
and the development of ulcerative colitis. In another study, 21 patients with UC
and 9 with CD, none of whom had LM, were placed on milk-free diets. A
beneficial effect was noticed in five of the patients with UC, and in three of those
with CD. The mechanism is unknown but milk allergy is not responsible for the
beneficial effect of a lactose free diet in patients with associated lactose
malabsorption (233). In a study by Von Tirpitz (88), the prevalence of milk
intolerance in healthy controls was 16.6% versus 46.9% in patients with CD, with
a high frequency [83.3%] in patients with active disease [CD activity index >150].
54
Milk intolerance was correlated to the duration of IBD [p = 0.023] but not to its
location in the GI tract or previous bowel resection (88).
Jejeunal villous atrophy was common during the active phase of UC (255)
though this was not shown in other studies which have shown abnormal brush
border lactase levels. (256) Also, there appears to be a normal permeability to
lactose in patients with UC (257). A low content of several disaccharidases has
been reported in UC and the levels of lactase, the most sensitive of the enzymes,
may be particularly lowered (234, 258 & 259). The proportion of hypolactasics
was low among the UC patients in clinical remission [2.8%], higher in patients
with a mild attack [16%] and was higher still in patients with a severe attack
[33%].
To summarise, the prevalence of LM ranges in reported studies varies from 6-58%
in CD and 9-85% in UC [Table 1.13]. It should always be compared with the
background incidence which varies with the ethnicity of the study population. LM
in CD is more common if the disease involves the small bowel [68%] when
compared to the large bowel [43%]. Any risk of developing IBD or affecting its
activity that has been attributed to dairy foods may also be due to breakdown
products, bacterial changes, or because a patient’s lactase status may dictate their
choice and quantities of dairy food they ingest. As stated earlier it should be
remembered that these have used different definitions and diagnostic criteria in
testing as well as a variety of patient types and disease activities. Very few have
also recorded the symptoms generated after a lactose challenge, although this
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could be influenced by subjectivity. The genetic studies have not conclusively
shown a ‘primary’ association however, no-one has yet done the genotyping in
parallel with breath testing to determine if any association could be related to the
presence of the disease itself. This secondary association could have several
explanations such as villous atrophy, an allergic reaction or immunological
response to milk proteins, change and/or composition of colonic microbial flora in
the presence of IBD or a chronic infection by an unknown pathogen. It is also
thought that the lactose malabsorption in Crohn’s disease may be determined by
factors other than lactase enzyme activity, such as bacterial overgrowth and/or
accelerated small bowel transit time (87).
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Table 1.13: Summary of the studies looking at lactose malabsoprtion [LM] in
inflammatory bowel disease.
Tests
Used
Patients &
Numbers
% of LM Comments Made
Gudmand-Hoyer
1970 (233)
Denmark
Hospital based
Blood
Glucose &
Biopsies
UC 85
CD71
9
6
Biopsies in 22 UC
and 40 CD
Results similar to
controls
Pena 1973 (234)
UK
Hospital based
Biopsies
&
Assay
UC 72
Controls 21
12.5
9.5
Proportion of
hypolactasics
increased with
severity of UC
Busk 1975 (235)
Denmark
Hospital based
Biopsy &
LTT
120 UC 9.2 No difference
between active and
inactive disease
Kirschner 1981
(240)
USA
Hospital based
LHBT 20 UC
50 CD
15
34
Children &
adolescents, No
significant
difference between
UC & CD
Sciarretta 1984
(237)
Italy
Hospital based
HBT 69 HV
20 UC
72 IBS
70
85
86
Italian study all
groups similar
results no
significant
difference seen
Pironi 1988 (238)
Italy
Hospital based
HBT CD 37
HV 67
49
16
Increased
incidence if
surgery [58%] vs.
no surgery [33%]
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Bernstein 1994
(236)
USA
Hospital based
HBT UC 29
Controls 14
45
36
Family controls
No difference seen
Mishkin 1997 (87)
USA
Hospital based
HBT UC 139
CD 121
Controls 60
47
58
47
25 g of Lactose
Crohn’s of SB
100%, TI 70%, IC
55% & Colonic
44%
Von Tirpitz 2002
(88)
Germany
Hospital based
HBT 24 HV
49 CD
20.8
32.7
HBT was more
positive if active
CD 54% when
compared 12.5%
inactive CD
Bunning 2006
(168)
Germany
Community based
Genotype
CC 13910
UC/controls
63/187
CD/Controls
166/120
22 vs. 22
21 vs. 22
Healthy
individuals
First degree
relatives
Nolan 2010 (242)
New Zealand
Community based
Genotype
CC 13910
CD/Controls
333/612
9.6 Vs.
13.4
Healthy
individuals and
first degree
relatives. Increased
frequency of T
allele in CD Odds
ratio 1.3 &
p=0.013
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1.4: SCOPE OF THE THESIS
Controversy still exists as to the prevalence and the role of lactose intolerance in
inflammatory bowel disease. Studies report a wide variety of findings which range
from a positive association between through to no relationship. In addition, this
association is different based on the type of IBD [UC/CD] and also on the extent
of the disease; it is especially common in small bowel CD. LI is conventionally
diagnosed using breath test and or symptoms after a lactose challenge, recently
genetic testing has become available. The hypothesis that the increased prevalence
of lactose sensitivity in IBD is related to the lactase non persistence status and this
may also be responsible for the high level of positive breath test results obtained
in these patients after the lactose challenge. The results from these studies will
help in understanding this complex interaction between lactose sensitivity and
IBD and in addition has the potential to improve the lives of patients with these
conditions. No one has yet performed a study involving the combination of
genetic, breath testing and symptom analysis in a defined IBD cohort, all in
clinical remission and compare the results obtained with healthy controls. Patients
with UC and CD who are all in remission will be recruited together with healthy
disease free volunteers to act as controls. The study will be limited to people of
European Caucasian origin to remove any bias due to ethnic origin.
The overall objective of this dissertation is to determine the significance of
Lactose Sensitivity in Inflammatory Bowel Disease. The specific questions to
be addressed by this thesis are a] the frequency of the genetic polymorphism of
lactase persistence in inflammatory bowel disease, b] the relationship between the
genotype results with the breath testing as well as symptoms of lactose sensitivity
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with breath test results, c] the benefits of lactose exclusion on the symptoms and
quality of life reported in a small cohort of patients with Crohn’s disease with
proven lactose sensitivity, d] the presence of ‘hidden’ sources of lactose in the
commonly used drugs to treat IBD and common GI disorders, e] the advantages or
disadvantages in the techniques used for genotyping [Restrictive Fragment Length
Polymorphism vs. Real Time Polymerase Chain Reaction] and breath testing
[Quintron MicroLyzer vs. Micro H2] in the diagnosis of lactose sensitivity.
To address the specific questions described above the following studies have
been carried out:
1. Lactose sensitivity and inflammatory bowel disease
a. Lactase persistence status in patients with inflammatory bowel
disease
The frequency of lactase persistence/non-persistence status will be
determined in patients with UC and CD by analysing for the presence
of C/T polymorphisms on chromosome 2. These results will be
compared with a group of healthy volunteers. This will provide the
necessary evidence to support the hypothesis that lactose intolerance in
IBD is related to the individual’s lactase non-persistence status.
b. The results of breath test and symptoms after lactose challenge
and comparison with the genotype
Patients with ulcerative colitis and Crohn’s disease along with healthy
controls will be challenged with 50 grams of lactose. The results of
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this will address whether the cause of intolerance to lactose is primary
[i.e. genetic] or secondary to their disease state. In addition it will also
provide information if the type of IBD has a role in the differences
seen in the results. In addition, it will possible to see if there are any
differences in these diseases by the type of breath gases produced
[hydrogen or methane].
2. Role of minimal lactose diet on patients with Crohn’s disease.
The proposal that dietary intervention with minimal lactose diet could lead to
reduction in the symptoms experienced and improves the health related quality
of life [HRQOL] will be tested in patients with Crohn’s disease and lactose
sensitivity. Patients with CD and LS will have their symptoms and HRQOL
recorded whilst they are on their normal diet and then these will be compared
with the results obtained on a minimal lactose diet.
3. Lactose in the drugs commonly used to treat IBD and common GI
disorders.
Medications used primarily in the management of IBD and co-existent GI
disorders will be analysed for lactose content using High Performance Liquid
Chromatography [HPLC]. Lactose is thought to be present in most drugs in
quantities that could cause symptoms and identify if there are lactose free
alternatives available.
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4. To determine the optimal techniques which detect lactose
malabsorption by breath testing [Micro H2 compared with the
Quintron MicroLyzer]?
Since the development of hand held device to measure hydrogen, they have
been used increasingly to diagnose lactose malabsorption. However, they are
not accurate in measuring all of the gaseous products of lactose malabsorption
[including methane]. This will test the hypothesis that using these devices will
lead to under-reporting of malabsorption in clinical practice.
5. The symptoms that occur after a lactose challenge are predictive of a
positive breath test.
Does an association exists between the gastrointestinal symptoms [abdominal
pain, diarrhoea, bloatedness, borborygmi and nausea] developed after lactose
challenge and a positive breath tests after 50g of lactose challenge. If there is
an association then it may be possible to use the symptoms developed after
lactose challenge in diagnosis of lactose intolerance. To test this hypothesis,
the presence and number of GI symptoms will be recorded after lactose
challenge and correlated to the results of the breath tests.
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CHAPTER 2
MATERIALS AND METHODS
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2.1: SUBJECTS
The two groups of subjects were recruited prospectively; patients with known
IBD who were attending the gastroenterology clinic of Cardiff and Vale
University Health Board and healthy volunteers from the staff who worked for the
health board. None of the participants had previously been assessed for lactose
sensitivity.
2.1.1: INFLAMMATORY BOWEL DISEASE PARTICIPANTS
Participants with UC and CD were diagnosed according to clinical, endoscopic,
radiological and histological criteria. They were included if they were aged 18
years or more and of North European Caucasian origin. Patients with IBD were
excluded if they had life threatening co-morbidity that was apparent from the
initial assessment, those who were pregnant or regularly consumed alcohol above
the recommended limits [more than 21 units of alcohol in a week in men and 14
units of alcohol in a week for women]. Patients with IBD were only included if
they were in remission as defined by a Harvey-Bradshaw index (260) score of 4 or
less in those with Crohns disease and by the Simple clinical colitis activity index
(261) score of 3 or less in those with ulcerative colitis. These were chosen as they
are simple to use, depend on clinical parameters only, can also be accurately self
administered, correlate well with a more complicated disease activity index, and
can be used to define relapse with high specificity & sensitivity. These scoring
systems are given in tables 2.1 and 2.2 respectively.
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Table 2.1: Harvey Bradshaw Index (260) to assess severity of Crohn’s disease
which is based on five items.
Features Scores
General well being 0= very well, 1=slightly below par
2=poor, 3= very poor, 4= terrible
Abdominal Pain 0= none, 1=mild, 2=moderate, 3= severe
Number of liquid stools per day
Abdominal Mass 0= none, 1=dubious, 2=definitive,
3= definitive and tender
Complications Arthralgia, Uveitis, Erythema Nodosum,
Apthous ulcers, Pyoderma Gangrenosum, Anal
Fissure, New Fistula, Abscess [score 1 per item]
Table 2.2: Simple clinical colitis activity index (261) for assessment of severity
of ulcerative colitis which is based on six items.
Features Scores
Bowel frequency [day] 1-3= 0, 4-6=1, 7-9=2, >9=3
Bowel frequency
[night]
1-3= 1, 4-6=2
Urgency of defecation Hurry = 1, Immediately = 2, Incontinence = 3
Blood in stool Trace = 1, occasional Frank = 2, Usually frank = 3
General well being 0= very well, 1=slightly below par, 2=poor, 3= very
poor, 4= terrible
Extra-colonic features 1 per manifestation
The data collected from participants included: age, sex, smoking status, weekly
alcohol consumption and family history of IBD. In addition the date of diagnosis,
co-existing illness, current medications, nature and type of surgery for IBD was
also recorded. This was obtained by direct questioning and reviewing the medical
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notes of the participants. If the participant had a first degree relative [the
individual's biological parents, direct siblings, or own children] who was afflicted
with IBD then they were considered as having a positive family history. Both
forms of IBD were sub-classified as per the extent of the disease. There are many
different classifications in use and for this study the Montreal classification was
used which is shown in tables 2.3 & 2.4.
Table 2.3: Crohn’s disease based on Montreal classification (3)
Age of onset Location Behaviour
≤16 years [A1] Ileal [L1] Non structuring, non penetrating [B1]
17-40 years [A2] Colonic [L2] Stricturing [B2]
>40 [A3] Ileo-colonic [L3] Penetrating [B3]
Isolated Upper GI disease L4 this can be added to L1-3 if concomitant disease
present. Add + P for peri-anal disease
Table 2.4: Distribution of ulcerative colitis based on Montreal classification (3)
Distribution Description
Proctitis [E1] Involvement limited to the rectum
Left sided [E2] Involvement limited to the proportion of the colon
distal to the splenic flexure
Extensive [E3] Involvement extends proximal to the splenic flexure,
including pancolitis
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2.1.2: HEALTHY VOLUNTEERS
The control group comprised of healthy volunteers, recruited from staff working
in the hospital. They were included if they were aged 18 years or more and of
North European Caucasian origin. They were excluded if they had gut symptoms
such as abdominal pain, distension or bloatedness, and/or change in stool
frequency or form on most days in the preceding 12 months. Those with
inflammatory bowel disease, previous gastro-intestinal surgery, coeliac disease,
known lactose intolerance or irritable bowel disease were also excluded. In
addition participants who could not attend for the tests, or who had concurrent life
threatening illness, consumed alcohol above the recommended limit or were
pregnant, were also excluded. The data collected from healthy volunteers
included: age, sex, smoking status, weekly alcohol consumption, co-existing
illness, current medications and family history of IBD.
2.2: GENOTYPING
2.2.1: DNA EXTRACTION METHOD
Patient DNA was extracted from EDTA blood samples using Qiagen Kit [Qiagen
Ltd, Sussex, UK], as per the manufacturers instructions and it was then diluted in
10 mmol/L Tris–HCl, 0.5 mmol/L EDTA at pH 9.0 and was used immediately or
stored at -20°C. The purity of the DNA sample from each participant was
analysed by determining the spectrophotometric absorbance of the sample at
260nm to that of 280nm and this A260/280 ratio was greater than 1.7 (262).
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2.2.2: REAL TIME POLYMERASE CHAIN REACTION FOR DNA
ANALYSIS
Lactase genotype was determined by RT-PCR for C/T13910 lactase non-persistence
using Assays-by-DesignTM. Service for custom SNP genotyping assays [Applied
Biosystems Ltd., Cheshire, UK]. Designed sequences were subject to BLAST
[Basic Local Alignment Search Tool], http://www.ncbi.nml.nih.gov/BLAST and
Repeat Masker [http://repeatmasker.genome.washington.edu] in order to detect
sequence similarities and repetitive elements respectively prior to submission for
manufacture. The custom assay was designed to discriminate between the C/T
13910 lactase non-persistence polymorphism located in an intron of the MCM6
gene. Probes were as follows: Forward primer sequence coded JPWLPHCTL1-
CTF:CTCTGCGCTGGCAATACAG; Reverse primer sequence coded
JPWLPHCTL1-CTR: AAATGCAACCTAAGGAGGAGAGTTC; Reporter 1
sequence coded JPWLPHCTL1-CTV1 VIC;
ATAAGATAATGTAGCCCCTGGC; Reporter 2 sequence coded
JPWLPHCTL1-CTM1 FAM; ATAAGATAATGTAGTCCCTGGC. The reagent
type manufactured was small scale, human, 40X concentration [part no. 4331349]
and Taqman®Universal PCR master mix No Amperase UNG X2 [part no.
4324018] was used. 12.5μl of TaqMan® Universal PCR Master Mix No
Amperase®UNG[X2], 0.625μl of 40X Assay mix was made up to 20μl with
sterile water and added to each well of a 96 well plate [Applied Biosystems,
Cheshire, UK]. 5μl of patient DNA was added and mixed prior to RT-PCR
analysis. Each 96 well plate contained duplicate control samples and sample
blanks in which no DNA was added. RT-PCR was performed using an Applied
Biosystems 7500 Real Time PCR System and ABI Prism 7500 SDS software
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[Applied Biosystems Ltd., Cheshire, UK]. Following a pre-run cycle, PCR
amplification was performed for 10mins at 95˚C [1 cycle] then 15sec 92˚C, 1min
60˚C [40 cycles]. A post read run was then undertaken to determine allelic
discrimination with automatic call [typically 98.43 – 99.9% quality was
observed]. The assay clearly discriminated between allelic variants and sample
blanks.
2.2.3: RESTRICTION FRAGMENT LENGTH POLYMORPHISM FOR
DNA ANALYSIS
DNA sequences were obtained from the UCSC genome assembly version hg16
[http://genome.ucsc.edu/] based on the NCBI Build 34 produced by the
International Human Genome Sequencing Consortium. C/T13910 polymorphisms
are in an intron of the MCM6 gene at 13910. In the PCR reaction [50 µL],
C/T13910 polymorphism primers were: MCMF2 –
GGACATACTAGAATTCACTGCAA and MCMR2 –
GGTTGAAGCGAAGATGGGACG. 25 pmol/L of each primer was added to a 50
µL PCR, 200 mmol/L deoxy-nucleotide triphosphates, 1.25 U Taq, 500ng DNA,
Magnesium 1.5 mmol/L, buffer was added as per manufacturer’s
recommendations and sterile water to 50 µL. The PCR amplification was carried
out as follows: HotStart 95°C for 15 min, followed by 35 cycles at 93°C for 40 s,
62°C for 60 s and 73°C for 100 s. Finally, for one cycle, the PCR was heated to
72°C for 7 min, then cooled to 4°C and either used immediately or stored frozen
until further analysis. The amplification product was digested with BsmFI [3 U]
as per the manufacturer’s protocol for a minimum of 3 h at 65°C for the C/T13910
polymorphism. Following restriction digestion, the amplification product bands
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were visualized under ultraviolet illumination using an ethidium bromide-
impregnated agarose gel comprising 3% NuSieve and 1% regular agarose.
The results of all genotyping in both the methods were assessed independently
and in duplicate. Controls of known lactase genotype and a blank in which no
DNA was added were used to assure the quality of the PCR amplification in each
run.
2.3: LACTOSE CHALLENGE TEST AND LACTOSE SENSITIVITY
The key clinical criterion for diagnosing lactose sensitivity in this study was the
effect of an oral lactose challenge on breath hydrogen and methane, together with
the appearance of gut and systemic symptoms.
2.3.1: LACTOSE CHALLENGE TEST
The subjects were given 50grams of lactose [Lactose powder BP: BN:
M07001589 MS/13880/1 North Staffordshire Hospital Trust Pharmacological
Services] dissolved in 300mls of water. Participants were told not to eat or drink
anything other than water from midnight the night before the test which
commenced at 9am. They were also told not to smoke for at least 4 hours before
the test. In addition, they were advised to choose lactose-free food and avoid those
foods that they recognise will produce gastrointestinal symptoms in the preceding
3 days. This was confirmed on the day of the test and in addition it was also
ascertained that they had not received any antibiotic treatment or had bowel
preparation for gastro-intestinal investigations during the preceding 4 weeks.
Breath samples were obtained before the ingestion of the lactose and at 30 min
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intervals for 3 hours and then one hour later. On each occasion, the subject
exhaled into a polyethylene bag via a one way valve. Once the bag was fully
inflated the collected sample was stored to be analysed. For the entire duration of
the test they were not allowed to eat or drink except water. This was done to
ensure that lactose and other sugars in food/drink do not affect the results of the
breath test. They were also not allowed to smoke during the test period.
2.4: BREATH GAS ANALYSERS
The analysers used to measure hydrogen and/or methane by a static analyser
Quintron MicroLyzer Self Correcting Model SC and a hand held device Micro H2.
The lactose breath test was defined as positive if the rise in hydrogen by ≥ 20 ppm
and/or methane by ≥ 5 ppm above the lowest value respectively.
2.4.1: QUINTRON MICROLYZER SELF CORRECTING MODEL SC
The Quintron MicroLyzer Self Correcting Model SC [Quintron Instrument Co.
Inc., Milwaukee, WI, USA] contains sensors that measure both breath hydrogen
and methane values in the patients’ samples after separation by gas
chromatography. A thermal conductivity detector also measures carbon dioxide
[CO2] in the sample and a correction factor is applied to account for any dilution
of alveolar CO2 with dead space or inspired air during collection. The exhaled air
was collected through a small one way valve into a 500 ml polyethylene bag, from
which it is transferred though a sampling valve into a 50mls syringe and then
injected into the analyser. The result obtained after analysis was recorded on a
chart. The calibration of the Quintron MicroLyzer was carried out each time the
analyser was used for the first time and then at hourly intervals with Microcan-
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Disposable Calibration Gas from MicroGas UK Batch [3335/1006] which
contains 100 ppm of Hydrogen, 50ppm of Methane and 6% Carbon Dioxide and
balance Air [UN1956] 20 litres at 20°C and 300 psig.
2.4.2:MICRO H2
The Micro H2 [Micro Medical Limited, Kent, UK] is a portable, hand-held,
hydrogen monitor which is designed to give instant results. The measurements are
obtained by exhaling through a 22-mm mouthpiece [Bedfont EC50-MP/200] for
adults that is connected to the analyser. The Micro H2 was calibrated at monthly
intervals using Microcan gas [MCG 100] which contains 50ppm of Hydrogen UK
batch [3330/0075].
The Quintron MicroLyzer Self-Correcting Model SC is the standard used in the
laboratory for the measurement of the break down products of lactose metabolism.
Increasingly portable breath analysers are used in the diagnosis of lactose
malabsorption in clinical practice. A study was carried out to compare the
accuracy of portable breath hydrogen analyser Micro H2 in the measurement of
breath gases in the diagnosis of lactose malabsorption compared with Quintron
MicroLyzer Self-Correcting Model SC and the results of this study are
demonstrated in Appendix 5.
2.5: GUT AND SYSTEMIC SYMPTOMS
Gastro-intestinal symptoms [total = 7; abdominal pain, bloatedness, diarrhoea,
flatulence/belching, borborygmi, constipation and nausea/vomiting], and systemic
symptoms [total = 14; headache, memory impairment, loss of concentration,
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dizziness, fatigue, muscle and joint pain, skin itching, rhinitis, asthma, increased
micturition, heart palpitations, hot and cold, mouth ulcers, altered taste] were
recorded by the participants [0= no symptoms, 10= severe symptoms] on a
symptom chart for 48 hours [Table 2.5]. The symptom chart was not specifically
validated for this study, but it was used in a previously published study (136) and
is used as a part of the lactose breath test in the institution where the study was
carried out. Patients and healthy volunteers were advised on how to fill the chart
and assess the severity of any symptom. These were recorded before and after the
lactose challenge at the time intervals indicated on the symptom chart. They were
provided with a stamped envelope to return the chart after completion of the
monitoring period.
Lactose sensitivity was defined as development of symptoms and / or a positive
breath test after the lactose challenge.
If there is a correlation between the results of lactose breath tests and gastro-
intestinal symptoms reported after a lactose challenge, then lactose sensitivity
could be diagnosed by assessing symptoms only. In order to ascertain this, the
sensitivity and specificity of the gastro-intestinal symptoms reported after lactose
challenge was compared with a positive breath test after an oral lactose challenge.
The results of such a study are shown in Appendix 6.
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Table 2.5: Chart for recording symptoms after lactose challenge
SYMPTOMS CHART
Symptoms Severity: 0: No symptoms, 1-3: Annoying, 4 – 6: Discomfort, 6 – 8: Having to stop/sit down & 10: Severe
SYMPTOMS Mins 30 60 90 120 150 180 4hr 5hr 6hr 7hr 8hr 9hr 10hr 11hr 12hr Sleep Day
1
Day
2
Day
3
Stomach pains
Diahorrea
Nausea/sickness
Bloated stomach
Rumbling stomach
Burping/ Flatulence
Constipation
Tiredness
Hiccups
Headaches
Palipitations
Rashes/Dry skin
Asthma
Hay fever
Muscle pain
Joint pain
Swelling feet/fingers
Itching
Dizziness
Light headedness/Lack of
concentration
Feeling hot or cold
Mouth ulcers
Sore throat
Tingling feet/fingers
Irritable eyes
Bad taste
↑ Urine
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2.6: APPROVAL
The study was approved by the Research and Development committee of Cardiff
and Vale NHS Trust, Cardiff. Reference number: 05/CMC/3319.
The study was scrutinised by the South Wales Research & Ethics Committee,
Cardiff, and Project Reference Number: 05/WSE04/74 & Approval Date on 21st
June 2005.
Written informed consent was obtained from each participant prior to recruitment.
These materials and methods were used throughout the studies performed and
they are described in further detail in the following chapters.
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CHAPTER 3
COMPARISON OF A REAL-TIME POLYMERASE
CHAIN REACTION AND RESTRICTIVE FRAGMENT
LENGTH POLYMORPHISMS IN THE DIAGNOSIS
OF GENETIC LACTOSE SENSITIVITY
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3.1: AIM
This study aims to compare the techniques of Real Time Polymerase Chain
Reaction [RT-PCR] and Restrictive Fragment Length Polymorphism [RFLP] for
the diagnosis of genetic lactose intolerance.
3.2: INTRODUCTION
Polymerase Chain Reaction [PCR] is a revolutionary method developed by Kary
Mullis in the 1980’s (263-265). It is based on using the ability of DNA
[Deoxyribonucleic acid] polymerase to synthesize a new strand of DNA
complementary to the offered template strand. Because DNA polymerase can add
a nucleotide only onto a pre-existing 3'-OH group, it needs a primer on to which it
can add the first nucleotide. This requirement makes it possible to delineate a
specific region of template sequence that needs to be amplified. At the end of the
PCR reaction, the specific sequence will be accumulated in billions of copies
[amplicons]. The applications of PCR are in cloning, genetic engineering or
sequencing of DNA & RNA. Real-Time PCR [RT-PCR] as well as the Restrictive
Fragment Length Polymorphism [RFLP] are techniques that are widely employed
in the identification of DNA sequences.
RT-PCR (266, 267) is used to amplify and simultaneously quantify a
targeted DNA molecule in “real time”. RT-PCR is also called a quantitative
polymerase chain reaction [qPCR] and is one of the most powerful and sensitive
techniques that is available for gene analysis. It is used for a broad range of
applications including quantitative gene expression analysis, genotyping, SNP
analysis, pathogen detection, drug target validation and the measurement of RNA
interference. RT-PCR data is collected during the exponential growth [log] phase
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of PCR when the quantity of the PCR product is directly proportional to the
amount of template nucleic acid. There are a number of techniques that are used to
allow the progress of a PCR to be monitored. Each technique uses some kind of
fluorescent marker which binds to the DNA - as the number of gene copies
increases during the reaction so the fluorescence increases. This is advantageous
because the efficiency and rate of the reaction can be seen. Intercalating
fluorescent dyes such as SYBR green are the simplest and cheapest way to
monitor a PCR in real-time. These dyes fluoresce only when bound to double-
stranded DNA but their major disadvantage is a lack of specificity as this dye will
report the amplification of any DNA not just the gene of interest. This can be
resolved by employing fluorescent probes which are pieces of DNA
complimentary to the gene of interest that are labelled with a fluorescent dye. The
simplest and most commonly used type of probe is the Taqman-type probe. These
probes are labelled with a fluorescent reporter molecule at one end and a quencher
molecule [capable of quenching the fluorescence of the reporter] at the other.
Therefore under normal circumstances the fluorescent emission from the probe is
low. However during PCR, the probe binds to the gene of interest and becomes
cleaved by the polymerase. Hence the reporter and quencher are physically
separated and the fluorescence increases. An increase in reporter fluorescent
signal is directly proportional to the number of amplicons generated & the cleaved
probe provides a permanent record amplification of an amplicon (266-268).
RFLP involves fragmenting a sample of DNA by a restriction enzyme
which can recognize and cut DNA wherever a specific short sequence occurs, in a
process known as a restriction digest (265, 269). The resulting DNA fragments are
then separated by length via electrophoresis on ethidium bromide impregnated
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agarose gel. The gel is then illuminated with an ultra violet lamp in a light box
and an image is viewed. Ethidium bromide fluoresces reddish-orange in the
presence of DNA, into which it has intercalated and these images are usually
shown in black and white. The technique measures the amount of accumulated
product at the end of the PCR cycles by comparing the intensity of the amplified
band on a gel to standards of a known concentration and therefore gives 'semi-
quantitative' result (265, 269 & 270).
Enattah and his team (108) analysed the region flanking the Lactase gene
at 2q21 by genotyping - sequence analysis of the 47 kb region upstream of the
LCT gene resulted in the identification of a total of 52 non-coding variants. Two
of the variants, C to T-13910, and G to A-22018, showed complete co-segregation
with lactase persistence. The C/T variant is located 13,910 base pairs from the
initiation codon of the LCT gene, in intron 13 of the MCM6 gene, and the G/A
variant 22,018 base pairs upstream of LCT, in intron 9 of MCM6. This enabled a
genetic test for the detection of lactose persistence/non persistence i.e. CC equates
to lactase non-persistence, CT and TT to lactase persistence.
3.3: METHODS
3.3.1: PATIENT POPULATION:
Samples from 48 participants who took part in the study outlined in Chapter 4
were included. They were all of Caucasian origin and included 10 healthy
volunteers, 19 with Crohn’s disease and 19 with Ulcerative colitis.
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3.3.2: DNA EXTRACTION METHOD
Patient DNA was extracted from EDTA blood samples using a Qiagen Kit
[Qiagen Ltd, Sussex, UK], diluted in 10 mmol/L Tris–HCl, 0.5 mmol/L EDTA at
pH 9.0 and was then used immediately or stored at -20°C. The purity of the DNA
sample from each participant was analysed by determining the spectrophotometric
absorbance of the sample at 260nm to that of 280nm and this A260/280 ratio was
greater than 1.7 (262).
3.3.3: DNA ANALYSIS METHODS
Lactase genotype was determined by the RT-PCR and RFLP methods for C/T13910
lactase non-persistence/non persistence genotypes on the extracted DNA as
described in chapter 2.
3.3.4: STATISTICS
Sensitivity, specificity and positive and negative predictive values were calculated
in order to evaluate the RT-PCR method compared with the RPLF. Sensitivity
[%] = true positives / [true positives + false negatives] X 100, Specificity [%] =
true negatives / [true negatives + false positives] X 100, Positive predictive value
[%] = true positives / [true positives + false positives] X 100 & Negative
predictive value [%] = true negatives / [true negatives + false negatives] X 100.
3.4: RESULTS
48 participants had their DNA analysed by both methods. There were 24 men and
24 women. The age range was 19-86 years with a mean of 42 years, [41.6 for men
and 43.2 for female]. The results obtained were CC in 5 cases [10.4%], 17 CT
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[35.4%] & 26 TT [54.2%] by both methods i.e. the results were exactly the same
in every participant by the 2 methodologies as shown in table 3.1 and summarised
in table 3.2. This means that the sensitivity and specificity of the RT PCR with
RPLF was 100%. Of those genotyped as CC by both methods 2 were male and 3
female, 7 male and 10 female were CT and of those found to be TT there were 15
males and 11 females. The computerised software reporting system gives a result
that is clear and easy to interpret e.g. 13910C for CC, 13910T for TT or both for
CT. The results as obtained by RT-PCR are shown in Figure 3.1 where each
sample is represented by a block on the chart. In the RFLP method, each column
on the agarose gel represents an individual sample - see figure 3.2. Each column is
compared with a known sample of CC, CT or TT to read the results of the test
sample.
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Table 3.1: Results of allelic discrimination by RT-PCR and RFLP
Patient Number Sex RFLP RT-PCR
1 M TT TT
2 F CT CT
3 M TT TT
4 M CT CT
5 F TT TT
6 F TT TT
7 F TT TT
8 F CT CT
9 M TT TT
Healthy
Volunteers
10 M CT CT
1 M TT TT
2 F CT CT
3 M TT TT
4 M CT CT
5 F TT TT
6 F TT TT
7 F TT TT
8 F CT CT
9 M TT TT
10 M CT CT
11 F CC CC
12 M TT TT
13 F CT CT
14 M TT TT
15 M CT CT
16 F TT TT
17 F TT TT
Ulcerative
Colitis
18 M CC CC
82
19 F CT CT
1 M TT TT
2 F CT CT
3 F TT TT
4 M CT CT
5 F TT TT
6 M TT TT
7 F CC CC
8 F CT CT
9 M TT TT
10 M CT CT
11 F CC CC
12 M TT TT
13 M CC CC
14 M TT TT
15 F CT CT
16 M TT TT
17 F TT TT
18 M TT TT
Crohn’s
Disease
19 F CT CT
Table 3.2: Summary of the results comparing the allelic discrimination by RT-
PCR and RFLP – number of patients are given in each cell.
RFLP RT-PCR
CC 5 5
CT 17 17
TT 26 26
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Figure 3.1: Allelic discrimination from individual patients using the RT-PCR
method.
Blue Circles: CC Red Rhombus: TT
Green Triangles: CT Grey Squares: Blanks
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Figure 3.3: Allelic discrimination as obtained by RFLP in 30 patients.
3.5: DISCUSSION
The results obtained by both methods were identical in all subjects that were
included. The RFLP was the standard method used in the laboratory at the time
that I did this work however there are several potential disadvantages of this
technique. There may be poor precision, low sensitivity and a short dynamic
range. The images may be low resolution and it affects size-based discrimination.
It is also non-automated and results are not expressed as numbers. In addition,
Ethidium bromide for staining is not very quantitative, and there is a need for
CT
TT
Blanks
CC
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post-PCR processing (265, 266 & 269). 2 hours was the hands on time for 40
samples and the processing time was 12 hours.
In contrast, RT-PCR is a rapid, robust technique that is suitable for the
screening of large numbers of samples, and is considerably less labour-intensive.
The RT-PCR method is associated with an increased dynamic range of detection
and there is no post-PCR processing. It is highly sensitive as it is capable of
detecting a 2-fold change (267, 268, 271 & 272). The RT-PCR was easy to do, the
number of steps involved was less, and it was less time consuming [3 hours vs. 12
hours] for the whole process from the start of the reaction to the generation of the
results. RT-PCR could analyse 96 samples whereas 16 samples were analysed
with RFLP method in a single setting. Costs for consumables and reagents per
sample are higher for RT-PCR but this is balanced by less labour time. Hands-on
time with this assay would be only 1 h for the analysis of up to 96 samples.
3.6: CONCLUSION
Real-time PCR assay provides a rapid means for the genotyping of LPH C/T
13910. Given the advantages as described above the RT PCR has now become the
standard method for analysis of lactase polymorphisms in the laboratory where I
undertook this work and will be used in the work described in this thesis.
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CHAPTER 4
ASSESSMENT OF LACTOSE SENSITIVITY IN
PATIENTS WITH INFLAMMATORY BOWEL
DISEASE BY THE ANALYSIS OF LACTASE
GENETIC POLYMORPHISMS, THE LACTOSE
BREATH TEST AND SYMPTOMS.
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4.1 AIM
The aim is to investigate the prevalence of lactose sensitivity in ulcerative colitis
and Crohn’s disease when compared to healthy volunteers.
4.2 INTRODUCTION
Sensitivity to lactose occurs as a result of reduced activity of the small intestinal
brush border enzyme lactase phlorizin hydrolase [LPH] resulting in a deficient
hydrolysis of lactose (95, 107 & 125). As a result lactose is metabolised in the
large intestine by colonic bacteria, producing hydrogen, methane and a variety of
other metabolites. The gases and bacterial metabolites cause abdominal (125, 126)
and systemic symptoms (89, 127, 128 & 136). There have been several studies
which have looked at the rates of hypolactasia and sensitivity to lactose; these
have been detailed in section 1.3. Breath testing, after oral lactose, is widely used
in clinical practice to assess LI. However, it has been shown that measurement of
breath hydrogen/methane alone, without a record of symptoms, detects less than
50% of people who are lactose sensitive (95, 136). Some of the protocols for
breath testing after lactose challenge record symptoms but there is limited
information about their importance. There are only few studies evaluating the
relationship between symptoms and the results of the breath test (136, 179, 180 &
273). These showed that a positive breath test is associated with a higher
frequency and intensity of symptoms and concluded that recording symptoms
with breath test results improved sensitivity and specificity in identifying people
with lactose sensitivity. In the review of literature, I have detailed the known
information regarding the genotyping and its correlation with primary adult type
hypolactasia. The polymorphism involving a T to C change at position 13910 base
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pairs on chromosome 2 exhibits a close association with hypolactasia (108) The
three genotypes, CC, CT and TT respectively, correlate with the levels of lactase
activity in intestinal biopsy samples and their lactase: sucrase ratio (108, 115). To
date, there have not been any published studies in patients with IBD where the
polymorphism which is associated with hypolactasia C/C13910, has been correlated
properly with lactose sensitivity by concurrently performing breath tests
measuring both hydrogen and methane as well as analysing symptoms.
4.3: MATERIALS AND METHODS
4.3.1: SUBJECTS
This was a prospective study enrolling patients with known IBD from the
gastroenterology clinics as well as healthy volunteers from hospital staff who had
not been previously assessed for lactose sensitivity. The inclusion and exclusion
criteria for both the groups to participate in the study are detailed in chapter 2. All
patients and healthy volunteers were white Northern Europeans and over the age
of 18 years. Milk allergy was also excluded in all patients and healthy volunteers
by a negative blood test for IgE milk proteins using Phadia 250 [Phadia Ltd,
Milton Keynes, UK]. Coeliac disease was also excluded in all patients by
serological tests.
4.3.2: GENOTYPING
Lactase genotype was determined by RT-PCR for the C/T13910 polymorphism. The
methodology is described in detail in Chapter 2.
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4.3.3: LACTOSE CHALLENGE TEST AND LACTOSE SENSITIVITY
The diagnosis of lactose sensitivity was made by the effect of an oral lactose
challenge on breath hydrogen/methane, and/or the appearance of symptoms.
Participants were given 50 grams of lactose, the full details of the methods used in
the breath testing is described in chapter 2. Both hydrogen and methane gas
concentration was analysed by Quintron MicroLyzer Self Correcting Model SC
again as described in Chapter 2. Raised basal hydrogen or methane, before
lactose, was defined as > 2 standard deviation over the mean of the control group
of HV. Raised hydrogen or methane, after lactose, was defined as ≥ 20 ppm or ≥ 5
ppm over the nadir for hydrogen or methane respectively
4.3.4: GUT AND SYSTEMIC SYMPTOMS
The presence of GI and systemic symptoms were recorded by the participants
along with their severity before a lactose challenge and afterwards for up to 48 h
in a symptom chart [Table 2.5] as described in chapter 2.
DNA analysis was undertaken blind, and precautions were taken to
minimise bias in the analysis of symptoms and breath hydrogen and/or methane.
The results of DNA, breath tests and symptoms were not available until the end of
the study when the results were collated.
4.3.5: STATISTICAL ANALYSIS
Quantitative variables are given as mean ± standard deviation; results between
groups are compared using t test & Mann-Whitney test. Categorical variables are
given as total numbers and percentages; differences between groups were
compared using Chi squared statistics. Comparison of the frequency of the DNA
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and breath test results between patients groups, healthy controls was performed
using Chi-squared statistics. The comparison between each sub-group was also
performed using Chi Squared statistics. Differences in the mean age of patients
with positive and negative breath test were compared by using the unpaired
Student’s t-test. The Cochran-Mantel-Haenszel test was used to compare the
effect of T allele [lactase persistence] association with risk of IBD. P values less
than 0.05 considered to be significant. The data was entered into statistical
program SPSS version 12 [Chicago, USA] for analysis.
4.4: RESULTS
4.4.1: PATIENTS
A total of 165 patients with IBD were recruited [95 with UC, 70 with CD], all
were in remission and on a range of treatments. In addition 30 healthy volunteers
[HV] were recruited. Their basic characteristics are shown in table 4.1. The mean
age of HV was 31± 11 years [mean ± SD], CD 47 ± 15.6 years and 48 ± 14 years
for UC patients. The duration of the disease was 10.8 ± 10.1 years [mean ± SD],
9.1 ± 9 years for CD and UC subjects respectively. None of the HV took any
medications, they were all non-smokers and no one had undergone any abdominal
surgery. 96% UC patients were either ex-smokers or lifelong non smokers.
However, 14% of CD patients were currently smokers. The 3 groups [HV, CD, &
UC] were equally matched for sex distribution and family history of IBD, but not
for age, smoking status, current medications and previous abdominal surgery.
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Table 4.1: Patient details: Baseline characteristics of 195 subjects who participated in the study, this includes 70 with CD, 95 with
UC & 30 HV. The results displayed as per the extent of disease in patients with UC and CD.
Crohn’s disease [CD] Ulcerative colitis [UC]
Total Ileal Colonic Ileo-
colonic
Total Extensive
colitis
Left
sided
Proctitis
Healthy
volunteers
[HV]
Number 70 18 28 24 95 35 46 14 30
Age range 19-86 24-86 22-70 19-72 20-81 25-78 20-81 29-66 21-56
Sex M:F 32:38 10:8 13:15 9:15 51:44 20:15 24:22 5:9 15:15
Duration of Illness [year] 0.5-48 0.5-39 0.5-30 1-48 0.5-43 0.5-43 0.5-43 3-22 NA
Family History of IBD 14 5 3 6 16 7 6 3 2
Never/Ex 32/28 8/9 13/12 11/7 51/40 19/15 23/20 9/5 30/0Smoking
Current 10 1 4 5 4 1 3 0 0
Yes/No 54/16 14/4 24/4 16/8 82/13 32/3 41/5 9/5 0
5 ASA 32 6 19 7 59 26 28 5 0
Thiopurines 24 8 8 8 20 12 6 2 0
Steroids 7 2 2 3 4 2 2 0 0
Current
Medications
Rectal Therapy 0 0 0 0 9 0 6 3 0
Surgery Yes 17 8 1 8 1 1 0 0 0
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HV were significantly younger [p<0.001], were less likely to smoke [p=0.006],
used fewer medications [p=0.001] & were less likely to have a history of previous
abdominal surgery [p=0.001] when compared to those with IBD. There was no
difference between patients with CD and UC with regards to age, sex distribution,
disease duration, family history of IBD and smoking status. However,
significantly more patients with CD had surgery [p=0.001] and less frequently
were on medications [p=0.03] when compared to UC patients.
13 patients with UC were on no medications at the time of the study. 3 of
these had extensive colitis including one patient who had previously had a total
colectomy. The second was a 74 year old man who was previously on
Azathioprine for 8 years and in remission for 7 years with normal colonoscopy on
2 occasions in this time period – he had elected to come off all his medications.
The third was a 36 year old woman who did not want to take 5ASA’s as she was
in symptomatic remission for the previous 10 years and wanted to start a family. 5
patients with left sided colitis were not taking any medications when the tests for
the study were carried out: 2 used enema’s as required and another one [48 years
old man] used short courses of oral steroids only when their condition flare up.
The fourth was a 56 years old man who was in remission for 4 years and his
thiopurine was stopped a year prior to entry into this study and finally the fifth
patient was a 26 years old man who on rectal nicotine treatment. 5 patients with
proctitis were not on any medications, 4 used 5-ASA suppositories and one used
steroid enema’s when their condition flared up.
The patient with UC and a prior colectomy, as mentioned above, only
underwent genotyping and not the breath test. 17 patients with CD had previously
under gone 24 surgical procedures which included 10 patients who had undergone
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a right hemi-colectomy, 5 ileal resections, 4 stricutoplasties, 3 Seton placements, 1
fistula repair & 1 segmental colectomy.
4.4.2: GENETICS
The C to T polymorphism on chromosome 2 was analysed in all 165 patients [95
with UC; 70 with CD], and compared with 30 HV [Table 4.2].
Table 4.2: Genetic analysis results for patients with Crohn’s disease, ulcerative
colitis & healthy volunteers who were included in the study. It is sub-divided in
patients with IBD as per the extent of the disease.
CC [homozygous for lactase non persistence], CT [heterozygous] & TT
[homozygous] for lactase persistence.
Genotype Result
CC CT TT
Healthy Volunteers [30] 0 [0%] 15 [50%] 15 [50%]
Inflammatory Bowel Disease [165] 12 [7.3%] 58 [35.2%] 95 [57.5%]
Total [95] 7 [7.4%] 35 [36.8%] 53 [55.8%]
Left Sided [46] 5 18 23
Proctitis [14] 1 4 9
Ulcerative
Colitis
Extensive colitis [35] 1 13 21
Total [70] 5 [7.1%] 23 [32%] 42 [60%]
Colonic [28] 1 10 17
Ileal [18] 1 8 9
Crohn’s
Disease
Ileo-Colonic [24] 3 5 16
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The results showed that 7% of IBD patients were CC, 35% and 58% were CT and
TT respectively. No HV had the CC genotype and the CT/TT genotypes were
equally divided. There were no significant differences of the genotype results
between IBD and HV [χ2 = 3.94 & p = 0.14]. When the results of UC patients was
compared to HV there was no significant difference [χ2 = 3.34 & p = 0.19] and
similarly no difference was seen in CD [χ2 = 4.14 & p = 0.13 respectively]. In UC
the genotypes results did not differ based on the extent of colitis [χ2 = 2.63 & p =
0.6] again there was no relationship between genotype and the segment of bowel
affected by CD [χ2 = 3.87 & p = 0.4]. The 3 genotypes showed no statistically
significant association based on age [p = 0.38], sex [p=0.93] and patient groups
i.e. UC, CD & HV [χ2 = 4.24 & p = 0.36].
Additionally, the increased frequency of the T allele [table 4.3] that was
observed in IBD patients was not significant [OR= 1.357, 95% CI = 0.62-2.9, p =
0.44], indicating that the T allele encoding lactase persistence was not associated
with risk of IBD. Similar results were also seen in the T allele frequency when
IBD patients were sub-divided by the type of IBD i.e. CD or UC.
Table 4.3: The frequency of the C & T alleles in healthy volunteers and patients
with IBD. CMH [Cochran Mantel Haenzsel] Trend
Patient GroupsGenotype
Allele
HV IBD
Odds Ratio
[Confidence
Interval]
T Allele 15 95 1.00
C Allele 15 70 1.36 [0.62-2.9]
χ2CMH=0.589
p= 0.44
95
4.4.3: EFFECT OF LACTOSE CHALLENGE ON BREATH HYDROGEN
AND METHANE
Breath hydrogen and methane were analysed, just before and up to 4 hours after a
50g oral lactose challenge. All the 30 healthy volunteers who had genotyping
done completed this part of the study and their details are as in table 4.1. Several
patients with IBD were not able to take part in the lactose challenge test so, the
total number of people who were analysed with the breath test following lactose
challenge were 110 [59 with UC and 51 with CD] and their base line
characteristics are shown in table 4.4. Therefore, 55 [33%] patients with IBD
could not take part in the lactose challenge, the reasons for non-attendance were:
10 [18%] requested withdrawal from this part of the study, 20 [37%] could not get
time off from work and 25 [46%] did not respond to multiple appointment letters.
Of the IBD cohort who underwent the LTT, 50.7% were women [n=71]
with an average age of 45.1 years [range 20-86 years] and 49.3% were men
[n=69] with an average age of 44.9 years [range 19-81]. The mean age of patients
with CD was 48.2 ± 16.2 years [mean ± SD] and 50.4 ± 15 years for UC patients.
The duration of the disease was 10.9 ± 10.5 years [mean ± SD], 9.8 ± 9.2 years for
CD and UC subjects respectively. The 3 groups [HV, CD, & UC] were equally
matched for sex distribution and family history of IBD, but not for age, smoking
status, current medications or previous abdominal surgery. Once again HV were
significantly younger [p<0.001], less likely to smoke [p=0.004], used fewer
medications [p=0.0001] & less likely to have a history of previous abdominal
surgery [p=0.005] compared to those with IBD. There was no difference between
patients with CD and UC with regards to age, sex distribution, and duration of
disease, family history of IBD or smoking status.
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Table 4.4: Patient details: Baseline characteristics of 110 subjects who had a lactose breath test this includes: 70 with Crohn’s
disease [CD], 95 with Ulcerative colitis [UC]. For UC & CD, they are also shown as per the extent of disease. The details of the
healthy volunteers [HV] are same as outlined in table 3.1.
Crohn’s disease [CD] Ulcerative colitis [UC]
Total Ileal Colonic Ileo-
Colonic
Total Extensive
colitis
Left sided Proctitis
Number 51 15 20 16 59 24 25 10
Age range 22-86 31-86 22-70 22-70 20-81 25-73 20-81 32-66
Sex M:F 24:27 8:7 10:10 8:8 30:29 14:10 13:12 3:7
Duration of Illness [year] 0.5-48 0.5-39 1-48 1-48 0.5-43 0.5-43 0.5-43 3-22
Family History of IBD 7 3 3 1 13 5 5 3
Never/Ex 24/22 6/8 10/9 8/5 31/25 9/14 15/8 7/3Smoking
Current 5 1 1 3 3 1 2 0
Yes/No 40/11 11/4 17/3 12/4 52/7 22/2 22/3 8/2
5 ASA 17 3 7 7 44 19 20 5
Thiopurines 23 7 8 8 12 6 4 2
Steroids 2 1 0 1 2 1 1 0
Current
Medications
Rectal Therapy 0 0 0 0 5 0 2 3
Surgery Yes 11 4 1 6 0 0 0 0
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However, significantly more patients with CD had surgery [p=0.001] and were
less frequently on medications [p=0.02] than those with UC. 7 patients with UC
who took part in the lactose breath test were on no medications [for full details see
section 4.4.1]. 2 with extensive colitis were on no medications this included the 74
year old man and 36 year old woman previously described in section 4.4.1. Three
patients with left sided colitis were not taking any medications – these included a
patient who was on thiopurines until a year previously but stopped as he was in
prolonged remission, the second who only used 5-ASA enema’s during
exacerbations and the third was on rectal nicotine treatment again as detailed in
section 4.4.1. Similarly 2 patients with proctitis were not on any medications, they
used 5ASA suppositories only when their condition flared up. 11 patients with CD
had previously under gone 13 surgical procedures which included 6 who had
undergone a right hemi-colectomy, 2 Seton placement, one fistula repair, 2 ileal
resections, 2 stricutoplasties & 1 segmental colectomy.
The results for all the 140 subjects are shown in table 4.5; figures 4.1 &
4.2. There was a considerable variation in the absolute value in both the basal
breath gases and the maximum after lactose. The maximum breath hydrogen
ranged from 0 – 227 ppm, and the maximum methane ranged from 0 – 157 ppm,
the lowest maximum breath hydrogen or methane values being 22 and 7
respectively [Figs. 4.1 and 4.2]. Interestingly, a significant number of IBD
patients had raised basal hydrogen and/or methane before the lactose challenge
[Table 4.5; Figs.4.1 and 4.2], 12% of UC patients having raised basal methane,
compared with only 2 % in patients with CD, there being no relationship with
large or small bowel disease distribution. None of the healthy volunteers showed a
significant increase in hydrogen or methane levels after the lactose challenge. All
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subjects with high basal breath hydrogen or methane exhibited a gradual fall to
levels < 20 ppm or < 5 ppm respectively during the 4 h after ingestion of lactose.
Table 4.5: The effect of a lactose load on breath hydrogen and methane.
110 Patients with IBD and 30 healthy volunteers ingested 50 g lactose, after an
overnight fast, and breath hydrogen and methane measured every 30 min for 3h
and then an hour later. Results are expressed as parts per million [ppm], and the
percentage of each group calculated. SD [standard deviation].
Breath analysis CD
[n=51]
UC
[n=59]
HV
[n=30]
Hydrogen range [ppm] 0 - 60 0 - 55 0 - 9
Methane range [ppm] 0 - 19 0 - 132 0 - 19
High hydrogen [> 2 SDs over
mean]
41.0 42.0 14.3
Basal [before
lactose load]
High methane [> 2 SDs over
mean]
2.0 12.0 7.1
Hydrogen range [ppm] 0 – 227 0 – 217 0
Methane range [ppm] 0 – 157 0 -157 0
Number with high hydrogen
only [% > 20 ppm]
31.0 6.8 0
Number with high methane
only [% > 5 ppm]
16.0 17.0 0
Number with both high
hydrogen and methane [%]
2.0 3.0 0
Maximum
within 6 h
after lactose
load
Total positive either or both
hydrogen and methane[%]
49.0 26.8 0
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Figure 4.1: The breath hydrogen levels before and after a lactose challenge.
Patients and healthy volunteers were given a 50 g oral dose of lactose, and breath
hydrogen measured 30 min for 3h and then an hourly later. Results were plotted as
parts per million [ppm] for basal values before the lactose challenge, and
maximum values after the lactose challenge.
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Figure 4.2: The breath methane levels before and after a lactose challenge.
Patients and healthy volunteers were given a 50 g oral dose of lactose, and breath
methane measured 30 min for 3h and then an hourly later. Results were plotted as
parts per million [ppm] for basal values before the lactose challenge, and
maximum values after the lactose challenge.
A substantial number of IBD patients i.e. 41 [37%] had raised hydrogen and/or
methane after lactose [Table 4.5; Figs 4.1 and 4.2] and this was statistically
significant when compared to healthy volunteers [χ2 = 15.81 & p = 0.00007]. 69
[63%] with IBD had a negative breath test as did all the 30 healthy volunteers.
The mean age of patients with a positive test was 49.6 ± 19.1 years [mean ± SD]
and negative test 43.1 ± 15.3 years which did not differ signiﬁcantly [p=0.31].
Similarly, no statistically signiﬁcant association was found between gender and
the result of the breath test [p=0.65], nor was any association found with the
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smoking status [p=0.62], use of medications [p=0.5] or history of GI surgery
[p=0.49].
When the results of IBD are divided by the type of IBD, a positive breath
test occurred in 16 [27%] of UC patients compared with 26 [49%] who had CD.
These differences were highly significant when CD was compared to HV [χ2 =
21.27 & p <0.0001] and also when UC was compared to HV [χ2 = 9.92 & p =
0.0016]. The rise in both the gases was also significantly higher in CD patients
when compared with UC patients [χ2 = 5.61 & p = 0.018]; these are shown below
in the table 4.6. Raised breath gases [hydrogen and/or methane] occurred in 73%,
56% & 33% of patients with CD affecting the ileum, ileo-colon and colon
respectively. The rise in breath gases was highly significant [χ2CMH = 9.11 & p =
0.003], with a statistically greater number in those patients with CD affecting the
ileum compared to both ileo-colonic and colonic disease, additionally ileo-colonic
disease was significantly higher when compared to colonic disease [χ2 = 4.94 & p
= 0.026]. In contrast, the prevalence of high breath hydrogen in patients with UC
affecting the whole colon [extensive], left colon and rectum [Proctitis] was not
statistically different - 25%, 24% & 30% respectively. Breath hydrogen was raised
in 2 out of 3 smokers with UC and 3 out of 5 smokers with CD. This should not
be due to any acute effects of smoking, as patients were instructed not to smoke
immediately prior to the breath sample being taken. The breath test was positive
in 41 patients with IBD, this was on the basis of a significant rise in hydrogen in
20 patients [18%], but importantly, a substantial number 18 [16.4%] of patients
had raised breath methane, with no detectable rise in breath hydrogen. In 3 [2.7%]
there was a rise in both the gases. Based on the sub-type of IBD, 16 [27%] cases
of UC had a positive breath test result, which was based on rise in hydrogen in 4
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[25%], methane in 10 [62.5%] and both gases in 2 [12.5%]. 25 [49%] patients
with CD had a positive breath test, which was based on the rise in hydrogen in 16
[64%], methane in 8 [32%] and both gases in one patient [4%]. These are shown
in table 4.5. The breath test in UC patients was positive with a significant
production of methane compared to hydrogen [χ2 = 4.6 & p=0.03] in contrast with
CD patients where an opposite effect was seen i.e. more hydrogen than methane
and this was also significant [χ2 = 5.13 & p= 0.024]. There was no statistically
significant difference in the gases produced based on the segment of the bowel in
either form of IBD.
The comparison of genotype and the results of the breath test are shown in
table 4.7. As previously reported (95, 136), all patients of genotype CC [100%]
had a significantly raised maximum breath hydrogen or both hydrogen and
methane, none had just a raised breath methane. In comparison significantly raised
breath gases were seen in 34% of those CT and 31% of those TT. The CT and TT
genotypes were more likely to have a positive breath hydrogen and/or methane in
CD than UC and HV [χ2 = 20.01 & p<0.0001]. There was no difference in the
positivity of the breath gases in the genotypes CT or TT when analysed by the
disease extent in UC. However, in CD both CT and TT genotypes, there was a
significant difference when the CD affected just the ileum compared with that
involving the ileo-colonic region when compared to colonic involvement alone [χ2
= 7.2 & p=0.027]. These results show that both breath hydrogen and methane
must be measured if a correct assessment of lactose sensitivity is to be made in
IBD patients.
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Table 4.6: Breath Test results for patients with Crohn’s disease, ulcerative colitis
& healthy volunteers before and after lactose challenge up to 4 hours. It is sub-
divided in patients with IBD as per the extent of the disease.
A positive test is defined as raised hydrogen or methane, after lactose, was defined
as ≥ 20 parts per million or ≥5 ppm over the nadir for hydrogen or methane
respectively.
Patient Group Sub Type Positive Test Negative Test
Healthy
Volunteers
Total [n=30] 0 30 [100%]
IBD Total [n=110] 41 [37%] 69 [63%]
Total [n=51] 25 [49%] 26 [51%]
Ileal [n=15] 11 [73%] 4 [27%]
Ileo-colonic [n=16] 9 [56%] 7 [44%]Crohn’s Disease
Colonic [n=20] 5 [33%] 15 [67%]
Total [n=59] 16 [27%] 43 [73%]
Extensive [n=24] 7 [29%] 17 [71%]
Left-sided [n=25] 6 [24%] 19 [76%]Ulcerative Colitis
Proctitis [n=10] 3 [30%] 7 [70%]
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Table 4.7: The rate of positive breath tests seen after an oral lactose challenge in
healthy volunteers [HV], patients with ulcerative colitis [UC] and Crohn’s disease
[CD] based on genotype results and sub-classified based on the extent of the
disease.
4.4.4: GUT AND SYSTEMIC SYMPTOMS FOLLOWING LACTOSE
CHALLENGE
After the oral lactose challenge, GI [abdominal pain, distension, borborygmi,
flatulence, diarrhoea, constipation, nausea], and systemic symptoms [headache,
muscle and joint pain, tiredness, a range of allergies, such as eczema, sinusitis,
rhinitis and asthma, increased micturition, and heart palpitations] were recorded
GenotypeGroups Sub Types
CC CT TT
HV[n=30] 0/0 0/15 [0%] 0/15 [0%]
IBD
[n=110]
8/8 [100%] 11/32
[34.4%]
22/70
[31.4%]
Total 4/4 [100%] 4/16 [25%] 8/39 [21%]
Proctitis 1/1 [100%] 0/1 [0%] 2/8 [25%]
Left sided 2/2 [100%] 2/9 [22%] 2/14 [14%]
Ulcerative
Colitis
[n=59] Extensive 1/1 [100%] 2/6 [33%] 4/17 [24%]
Total 4/4 [100%] 7/16 [37.5%] 14/31 [42%]
Ileal 1/1 [100%] 4/6 [67%] 6/8 [75%]
Ileo-colonic 3/3 [100%] 1/3 [33%] 5/10 [50%]Crohn’s Disease
[n=51]] Colonic 0/0 2/7 [29%] 3/13 [23%]
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for 48 hours. A substantial number of patients with IBD exhibited these symptoms
after the lactose challenge - 69% for UC and 73% in CD as shown in Table 4.8.
39% of UC and 47% of CD patients reported both gut and systemic symptoms but
less than 20% reported only GI symptoms in both the types of IBD. Furthermore,
13% and 6% with UC or CD respectively recorded systemic symptoms without
any apparent GI symptoms [Table 4.9]. The gut and/or systemic symptoms
reported as per the results of the genotype is also shown in table 4.9
Table 4.8: Symptoms experienced by participants after lactose challenge.
Patients with ulcerative colitis [n=59] or Crohn’s disease [n=51] and Healthy
Volunteers [n=30] were given an oral dose of 50 g lactose. The presence of gut
[abdominal pain, distension, borborygmi, flatulence, diarrhoea, constipation,
nausea], and systemic symptoms [headache, muscle and joint pain, tiredness, a
range of allergies, such as eczema, sinusitis, rhinitis and asthma, increased
micturition, and palpitations] were recorded, together with their severity on a scale
of 0 – 10.
None of the healthy volunteers exhibited symptoms
Symptoms Ulcerative colitis [n=59] Crohn’s disease [n=51]
No 18 [31%] 14 [27%]
Yes 41 [69%] 37 [73%]
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Table 4.9: The relationship between symptoms and genotype
Patients with ulcerative colitis [n=59] or Crohn’s disease [n=51] were genotyped
as described in Chapter 3 and given an oral dose of 50 g lactose. Breath hydrogen
and methane were recorded every 30 min for 3 hours and then an hour later. The
presence of gut [abdominal pain, distension, borborygmi, flatulence, diarrhoea,
constipation, nausea], and systemic symptoms [headache, muscle and joint pain,
tiredness, a range of allergies, such as eczema, sinusitis, rhinitis and asthma,
increased micturition, and palpitations] were recorded, together with their severity
on a scale of 0 – 10. Results were expressed as total number of participants within
each clinical group.
Disease Genotype Both
symptom [GI
or systemic]
GI symptoms
only
Systemic
symptoms
only
No symptoms
reported
CC [n=4] 4 0 0 0
CT [n=16] 3 3 1 9
TT [n=39] 16 7 7 9
UC
All [n=59] 23 [39%] 10 [17%] 8 [13%] 18 [31%]
CC [n=4] 4 0 0 0
CT [n=17] 5 5 2 5
TT [n=30] 15 5 1 9
CD
All [n=51] 24 [47%] 10 [20%] 3 [6%] 14 [27%]
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The recording of both breath hydrogen and methane, with GI and systemic
symptoms, increased the detection of lactose sensitivity from 31% to 73% in CD
and in UC from 10% to 69%, compared with an assessment using raised breath
gases alone [Table 4.10]. Furthermore, UC patients exhibiting the most symptoms
after the lactose challenge had raised breath methane, but not elevated breath
hydrogen.
Table 4.10: The diagnosis of lactose sensitivity based on breath gases and
symptoms after an oral lactose load.
110 inflammatory bowel disease patients and 30 healthy volunteers were given an
oral dose of 50 g lactose, as described in Chapter 2. Each individual filled in a
questionnaire, recording gut and systemic symptoms, scoring the severity from 1
– 10. Patients with positive symptoms were then assessed as to whether they had a
positive breath test. None of the healthy volunteers exhibited symptoms.
Results were expressed as total number of participants and as a % of the total
number of patients within each clinical group.
Breath test result Ulcerative colitis [n=59] Crohn’s disease [n=51]
Positive hydrogen [> 20
ppm]
6 [10%] 15 [31%]
Positive hydrogen [> 20
ppm] & methane [5 ppm]
16 [27%] 25 [49%]
Positive hydrogen [> 20
ppm] & methane [5 ppm]
& positive symptoms
41 [69%] 37 [73%]
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All patients with the CC genotype had significantly elevated breath
hydrogen and/or methane levels after lactose challenge and also had both GI and
systemic symptoms [Table 4.9]. A significant number of UC patients with the TT
genotype [13%] exhibited only systemic symptoms after lactose. This compared
with only 6% of CD patients who were TT genotype. There were no other major
correlations of symptoms with genotype. The numerical range of GI and systemic
symptoms reported by the IBD patients after the lactose challenge ranged from 0
to 20. Interestingly, UC patients who exhibited most gut symptoms, i.e. 3 or more,
and had the highest elevated breath methane, in the range 28-157 ppm, after a
lactose load, compared with patients with Crohn’s, who showed much lower or no
elevation in breath methane after lactose [p<0.03]. There was no obvious
correlation between the breath test results and symptoms after the lactose load in
patients when comparing those who had previous surgery for CD with those who
had no previous abdominal operation.
Information about the GI and systemic symptoms after the 4 hour
monitoring period was collated for the next 44 hours [symptoms recorded for total
duration of 48 hours]. None of the healthy volunteers reported any symptoms.
Diarrhoea after the lactose challenge was a common symptom, in 20 patients the
diarrhoea continued until the second day after the lactose load. Similarly 18
patients documented abdominal bloating and 15 abdominal pains up to 24 hours
after lactose load whilst 14 nausea and 11 borborygmi reported up to 12 hours.
Among the systemic symptoms headache and tiredness continued for 48 hours in
18 and 12 patients respectively. The timing of both gut and systemic symptoms
often correlated closely. For example, several patients suffered both diarrhoea and
headache for at least 48 h. There was a trend suggesting CC genotype patients
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symptoms persisted longer when compared to CT and TT though this was not
statistically significant.
New or additional symptoms were reported in several patients after the
monitoring period and these included both GI and systemic ones. Among the GI
symptoms, diarrhoea occurred in 6, bloatedness in 9, flatulence in 17, abdominal
pain in 5, nausea in 8 and constipation in 3 patients. Muscle aches and joint pain
started in 15, sore throat in 5, lack of concentration in 7, dizziness in 5,
palpitations in 5, headache in 9, and tiredness in 13 patients. The CC patients
reported new symptoms which were muscle aches and joint pain more often than
CT and TT individuals. The rest of the systemic symptoms were reported more
frequently by the other genotypes. There was no difference in the intensity or
frequency of the symptoms expressed after 4 hours based on the breath test result
or on the type of gas produced [methane or hydrogen].
4.5: DISCUSSION
The results show that sensitivity to lactose occurs in a high proportion
[approximately 70%] of patients with IBD, even when they are in remission. The
reason for the incidence being higher than that previously reported is because of
the comprehensive tests used. These are a combination of three parameters - the
C/ T polymorphism on chromosome 2, both breath hydrogen and methane
measurement after an oral lactose dose and a record of both gut and systemic
symptoms up to 48 h after the lactose load. The results from this study show
genetic polymorphism analysis alone is insufficient in identifying all patients who
are lactose sensitive suggesting that it is predominantly a secondary phenomenon
related to the presence of IBD.
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There have been several studies that have investigated whether there is a
correlation between the CC/CT/TT genotype and different GI disorders (165, 274-
280). An increased prevalence of lactose sensitivity has been reported in Crohn’s
disease when using breath testing (87, 88) but this has not been shown to arise
from a genetic basis. Given the fact that only 7% of IBD patients in my study
were the CC genotype, the results confirm previous reports (246, 281) that this
genotype is not associated with IBD. A high incidence of IBD was seen in
patients who were TT [Table 4.2], these results do not support an increased risk of
IBD in people who have the T allele when compared with C allele, as has been
reported elsewhere (242, 246). As in previous studies (95, 136), substantial
numbers of the other two genotypes, CT and TT were found to be lactose sensitive
as they had raised breath hydrogen and/or methane as well as symptoms. In the
current study, only 7% of IBD patients were CC, 35% and 58% being CT or TT
respectively – this is in contrast to the study of IBD patients from Germany by
Buning (168) where 21% were CC, 56.8% CT and 22.2% TT. However, my
results are similar to a study also from Cardiff, where the frequencies of
genotypes in a cohort of IBS with lactose sensitivity were 14.5% CC, 39% CT and
46.5% TT (136). The higher percentage of CC in this study of IBS patients is to
be expected as these patients had been specifically referred to a food intolerance
clinic because of possible lactose sensitivity. My results also confirm the findings
of studies where all patients with the CC genotype are lactose sensitive (165, 274-
276, 282 & 283). I have found that this cohort develop multiple GI and systemic
symptoms, as well as having higher hydrogen levels and symptom severity after
lactose challenge. If genotyping is done first, those who are CC do not need the
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oral lactose challenge test, thereby avoiding major symptoms, which these
patients are known to suffer (128, 129 & 136).
A positive breath test occurred in patients with IBD more frequently than
in healthy volunteers. This lactose sensitivity is therefore due to the presence of
the disease itself rather than a genetic predisposition. Crohn’s disease was
associated with a higher breath test positivity compared to UC. In CD, the results
were higher if the disease involved the ileum [73%] than the ileo-colon [56%] and
lowest in pure colonic disease [33%]. However UC patients also had a higher
frequency of positive breath tests when compared to healthy volunteers with no
effect based on the extent of disease. These results are similar to a study by
Mishkin (87) for Crohn’s disease but not for Ulcerative Colitis. However, other
publications have shown similar results to my work. In a recent study from
Australia (284) a high prevalence of lactose malabsorption was shown by the
hydrogen breath test in 148 patients with IBD [92 CD, 56 UC] – it was 42% in
CD and 40% in UC, compared with 18% in 71 HV. They also showed a higher
incidence of lactose malabsorption of 68% in ileal CD compared to 39% in ileo-
colonic and 18% in isolated colonic disease. Again, no difference was seen when
the results was examined based on the extent of disease in UC as was seen in my
study. Measurement of both hydrogen and methane may account for the slightly
higher rates of positive breath test results that I found.
My study included CD patients who had surgery which could be
considered as a confounding variable. However, of the 51 patients with CD who
underwent lactose breath testing, it was positive in 6 [54%] of the 11 patients who
had previous surgery for CD compared with 20 [50%] of the 40 who did not have
any surgery – a non-statistically significant difference.
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Other factors such as smoking, non-compliance with dietary restriction, GI
transit and bacterial overgrowth may lead to high hydrogen and methane at
baseline [i.e. prior to lactose challenge]. An early rise of hydrogen [90-120 min]
has been used to indicate bacterial overgrowth, rapid oro-caecal transit or a
combination of these factors - differentiating between these may be problematic.
In my study, this early rise in breath gases was not taken as positive test to
identify lactose malabsorption. Instead, a sustained rise in breath gases or rise in
breath gases after this period was interpreted as a positive result. In addition,
considerable variations in the basal levels of hydrogen and methane could be due
to residual starches in the colon or from incomplete fasting. To counter this,
baseline gases were measured prior to the lactose challenge to act as a comparator.
In the patients who have elevated baseline gases, levels fell during the test
probably due to digestion of products in colon. In some patients the high levels of
either of these gases was seen before the lactose load – this is possibly from slow
digestion of food consumed the day before. These levels fell over the next 90-
120minutes and in order to improve the assessment of positivity during the breath
test, I used the lowest level of the breath gases [the nadir] as the baseline against
which any rise was measured, which was the method originally suggested by Flatz
et al in 1984 (285). In a study by He (286), a lactose challenge demonstrated a
faster oro-caecal transit in LI when compared to those who are lactose tolerant and
it was hypothesised that this could be a direct effect of lactose on intrinsic factors
regulating intestinal motility rather than the effect of osmotic load of lactose.
Elevated levels of breath hydrogen have been reported in IBD (287) I have
shown high breath methane levels with or without an elevated breath hydrogen.
This elevation in breath hydrogen and/or methane in a significant number of both
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UC and CD patients are consistent with an on-going carbohydrate malabsorption,
even when the disease is in apparent remission. Whilst carbohydrate
malabsorption could be expected in small bowel Crohn’s, the findings here also
shows that diseases of the large bowel i.e. colonic Crohn’s disease and UC also
lead to malabsorption of lactose. Lactase is only found in small intestine therefore,
it is understandable why small bowel disease like Crohn’s disease may lead to the
malabsorption of lactose by causing inflammation of the mucosa which leads to
loss of enzyme lactase and therefore problems in hydrolysing lactose. However,
large bowel disorders like UC and CD also cause lactose malabsorption. There is
no definitive explanation identified so far to explain this. It is likely in some
patients with CD of the large bowel they may have associated small bowel disease
which is not identified by current tests. One of the possibilities for LM in large
bowel IBD is that, this could result from the higher prevalence of lactase non-
persistence status in colonic disease compared to healthy population, but this is
not the case from the data available from the studies published on this topic.
Several possibilities could explain this abnormality in large bowel inflammatory
disorders. The number of intestinal cells expressing lactase may be reduced or
they may have a defective function despite lactase persistence status; the result
would be an inadequate hydrolysis of lactose. These could result from the
bacterial by products [similar to the model proposed for symptoms i.e. the
‘bacterial toxin’ hypothesis], drugs used to treat IBD or as a consequence of
cytokines produced by inflammation in the large bowel. Colonic inflammation
could also lead to colonisation of the small bowel by unidentified micro-
organisms. Jejeunal villous atrophy was common during the active phase of UC
(255). The other mechanism which could play a role is an increased intestinal
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transit resulting in reduced contact time between lactose and lactase. The products
that arise from cleavage of lactose are taken up via the sodium-activated glucose
transporter SGLT1. This transporter is inhibited by tri- and tetra-saccharides, such
as stachyose and rafﬁnose, found particularly in many root vegetables and soya
(288). Eating carbohydrates with these non-metabolisable sugars causes
signiﬁcant amounts of sugars reaching the bacteria in the large intestine which
produce large amounts of gas causing symptoms. These observations may be due
to co-existing changes in the small bowel intestinal lining, a different bacterial
population, changes in transit times or other mechanisms and need to be explored
further. The lactose sensitivity in IBD cannot be solely attributed to any
significant ongoing inflammation, since all of my patients were apparently in
remission based on recognised clinical indices. It would, however, be interesting
to have checked faecal calprotectin levels or confirmed mucosal healing to
provide further objective evidence of remission.
The rise in breath methane may have an important implication for the
pathogenesis of IBD or it could have occurred as an epiphenomenon but again
warrants further investigation., The pathogenesis of IBD may involve an
inappropriate activation of the intestinal mucosal immune system in predisposed
hosts (289), so it is possible for this immune response to be elicited in response to
methanogenic bacteria, disruption of tolerance to these organisms or these bacteria
may generate metabolic toxins. Higher methane levels were associated with IBS,
healthy volunteers than with IBD patients in some previous studies (290-292).
The difference that was seen in this study could be due to the way healthy
volunteers were selected.
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Methane production is limited to only a few species of micro-organisms
which are called methanogens e.g. Archaea. This group of micro-organisms are
widely distributed in natural environments and include Methanobrevibacter
smithii, Methanobacterium ruminatum and Methanosphaera stadtmanae (293-
295) and halophilic Archaea [genus Halobacteriaceae] (296). Methanobrevibacter
smithii is the predominant archaeal species present in the human large intestine
(297, 298) and is responsible for almost all CH4 produced in the intestine (292,
299 & 300). whilst Methanosphaera stadtmanae is another common one isolated
(301). Methane is produced by utilising substrates such as hydrogen, CO2, acetate,
formate, methanol and methylamines, this process is called methanogenesis.
There is a complex interaction between H2 and CH4 production which is not fully
understood. Methanogenic micro-organisms are able to convert H2 to CH4 within
the colon (292, 299, 300).
Measurement of breath methane is an indirect means of determining
methane production (302). Despite the absence of CH4 in the breath of some
subjects, methanogenic micro-organisms can be cultured from faeces in many of
them (292). Methane production occurs primarily in the left colon in 54% of
normal subjects (292) and hydrogen is produced primarily in the right colon. The
development of high concentrations of methanogens depends on a continuous
supply of high H2 concentrations from exogenous or endogenous sources that
exceeds the capacity of removal. The advantage of methanogenesis to the host is
that it lowers the pressure that would normally be exerted by a given amount of H2
because 4 litres of H2 are used to produce 1 litre of CH4 (303). It has been shown
that as many as 40-50% of people are methane producers (304, 305). In some
subjects, at least part of the hydrogen is used to produce methane (304, 306). A
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study by Bjorneklett showed the prevalence of CH4 production in a group of 120
healthy subjects, determined by a single midday breath sample, was 44%, with no
significant difference between sexes and no correlation with age (304, 307).
Methane has been shown to reduce small bowel transit time. In a study
with healthy subjects by Cloarec, methane production was associated with
reduced oro-caecal transit time [111 Vs 68 min] when compared with subjects not
producing methane. In another study (308) of patients with IBS patients and
animal models, methane was shown to slow small intestinal transit and this effect
was caused by triggering non-propulsive or segmental contractions in the small
bowel. The effect of methane on colonic motility has not been studied but its
production has been shown to be elevated in constipation predominant IBS (290,
291, 309-311).
Both luminal and breath methane production in IBD patients has
previously been reported to occur at lower levels than controls (290, 291). In a
study by McKay methane excretion was detected in 54% of healthy controls, 53%
of non- gastrointestinal patients and 32% of GI patients (292). Patients within the
GI disease group with IBD had significantly lower methane detection; 13% for
CD and 15% for UC. In another study by Pimentel, methane production in
ulcerative colitis and Crohn’s disease was reported to be almost non-existent
(312). This could be due to the effect of diarrhoea which occurs in active IBD and
is known to reduce or eliminate methane production and lower the incidence of
methanogens (290, 312). In contrast to these studies, higher levels of breath
methane have been detected in patients with colonic polyposis as well as cancer of
the colon than in healthy patients (313). In a study by Scanlan et al (314) using
PCR to amplify methanogenic DNA in faecal samples, the frequency of
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methanogens ranged 45-50% in HV, colorectal cancer, in those who had polyps
removed and IBS groups. In the same study, patients with IBD were also studied.
There were significantly fewer patients who had methanogenic micro-organism -
30% for Crohn’s disease and 24% for ulcerative colitis compared to the control
group of 48%. The difficulty in all these studies is that they have included IBD
patients in different phases of illness [i.e. active disease, remission etc]. It is not
known whether there is a difference based on the activity of the disease and if the
effects of methane or the organisms that produce it influence the disease process.
It could be postulated that this may be the case. In a recent study of Boros (315),
methane was shown to confer a protective effect on the oxidative stress and
inflammation in ischemic and reperfusion induced intestinal injury in canines.
Sulphate reducing bacteria have been proposed to be involved in the aetio-
pathogenesis of IBD and colon cancer (316, 317). These bacteria consume some
of the hydrogen produced in fermentation (318) and in vitro data has shown that
sulphate reducing bacteria out compete methanogens for hydrogen (319). This
limited substrate range could be a factor in competition between methanogens and
the sulphate reducing bacteria may play a role in IBD activity and complications.
The presence of such a bacterial population is also dependent on host factors, diet,
intestinal transit time and other environmental factor.
Patients who suffered from diarrhoea after the lactose challenge often
started to experience it several hours, even a day, after the lactose would have
disappeared from the intestine, as was also reported in a previous study (128). In
fact, 50% of the patients with CD, and over 75% of those with UC, who had the
diarrhoea after the lactose challenge, still had this 48 h later; long after the lactose
would have gone from the intestine. This supports the ‘bacterial metabolic toxin’
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hypothesis [chapter 1.2] i.e. the mechanism causing diarrhoea involves cell
signalling, analogous to the diarrhoea in gut infections (95, 128, 135 & 139), and
is not simply an osmotic effect of the lactose.
The ingestion of sugars other than lactose can induce gut and systemic
symptoms in patients with IBD. They can also occur due to anticipation or as an
independent event. The questionnaire about the symptoms was given to the
participants to complete at base line for documentation of their symptoms prior to
consumption of lactose and administered at regular time intervals as per the
protocol. This questionnaire was not validated for this purpose but has been
utilised in a previously published study by Waud et al (136). It is also used as a
part of breath test in the institution where my study was carried out. None of the
healthy volunteers exhibited symptoms after the lactose challenge suggesting that
these symptoms in patients are less likely to be due to a ‘nocebo’ effect (320),
although this should be explored further. The nocebo effect is a phenomenon in
which inert substances or mere suggestions of substances actually bring about
negative effects in a patient or research participant. It is the opposite phenomenon
to the placebo effect which is more widely understood. Like the placebo effect, it
is thought to be brought about by a combination of pavalovian conditioning and a
reaction to expectations. During the recruitment phase of the study, I encountered
just 2 patients in clinic who had been diagnosed with lactose sensitivity and were
on a restricted diet - these were not recruited into the present study to avoid bias,
and potential nocebo effects. A weakness of my study was the lack of a placebo
element to breath testing as all were done after a standardised lactose load. This
makes it difficult to quantify the significance of the symptoms that were reported
by the subjects.
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None of the healthy volunteers showed features of lactose sensitivity. They
did not have had any gut symptoms, such as abdominal pain, distension or
bloatedness, and/or change in stool frequency or form on most days in the
preceding year. This could potentially exclude anyone with possible lactose
intolerance [LI]. I acknowledge that the inclusion/exclusion criteria used to recruit
healthy volunteers could have contributed to the results seen here. The HV were
also not on any medications when compared to IBD participants. The lactose in
medications could have been a cause of the symptoms in some of the lactose
sensitive individuals. The criterion for recruitment was to avoid these confounding
variables, but they could also lead to selection bias. When setting up this study we
elected to use IBD patients who were attending clinics so that they can participate
in various components of the study. The advantage of recruitment from a data
base which is based on a community [i.e. those attending hospital clinics and
those who are not] is to ensure that the cohort is more representative of the local
population. This will also include patients in different stages of the disease
process. By recruitment from the clinics alone, you are likely to recruit those who
are conscious of their health needs, highly motivated and are able to attend.
Smoking has no direct or indirect casual effect on LS therefore the fact
that all of the healthy volunteers are non-smokers will not have any effect on the
result. The age difference between healthy volunteers and IBD patients should
also have no bearing on the results. All were over the age of 18 years, there is
evidence that intestinal lactase activity does not continue to decline with age after
childhood, because there were no differences in the prevalence of hypolactasia
between older and younger adults (321). There are very few studies to date
looking at the effect of age on symptom tolerance. One described there was no
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difference in the symptoms between the age groups of over 65 years and 20 to 40
years (188). Some parts of the world have high incidence of lactose intolerance.
This confounding variable needs to be matched to exclude any bias and this is the
reason why my study is focussed on Caucasian population.
It can be concluded that it is essential to record both gut and systemic
symptoms when assessing lactose sensitivity after an oral lactose challenge. The
results are restricted to the Caucasian population and they should be interpreted
with caution when the test is carried out in non Caucasian subjects. The study is
also limited to IBD in apparent remission using clinical criteria and may be
different with greater activity.
My results show the value of genotyping, measuring both breath hydrogen
and methane for up 4 h after an oral lactose challenge, as well as recording both
gut and systemic symptoms for up to 48 hours.
4.7 CONCLUSIONS
This study shows that there is a much higher prevalence of lactose
sensitivity in all types of IBD when compared to healthy volunteers. This has been
shown when the disease is in remission. The question that now arises is what
active disease will do to this sensitivity as it would be expected to make it worse.
The results argue strongly for a full clinical trial to investigate the effect of
removing lactose from the diet in patients – a small pilot study of this is outlined
in the next chapter.
The fact that subjects report symptoms up to 48 hours after a lactose
challenge cannot be solely due to its osmotic effect and would give temporal
support for the ‘bacterial toxin’ hypothesis. The role of putative toxins and the
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need to further exclude subjective factors when reporting symptoms after a lactose
challenge both need to be tested further. The raised breath methane, particularly in
ulcerative colitis is intriguing and the potential role of Archaea, in the
pathogenesis of IBD should also be explored.
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CHAPTER 5
A PILOT STUDY OF THE AVOIDANCE OF
LACTOSE IN THE DIET OF PATIENTS WITH
CROHN’S DISEASE AND LACTOSE SENSITIVITY.
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5.1: AIM
In chapter 4, a substantial number of people with IBD were identified as having
lactose sensitivity on the basis of genotyping, breath test and symptoms. The aim
of this chapter is to determine whether there is any relationship between
inflammatory bowel disease and lactose sensitivity by exploring if the avoidance
of lactose in the diet of patients with IBD and lactose sensitivity, can lead to
improvements in symptoms.
5.2: INTRODUCTION
Diet is thought to play a role in the immuno-pathogenesis of inflammatory bowel
disease, whether this is primary due to formation of antibodies to antigens from
diet or secondary to intestinal inflammation is not clearly known yet. Review of
some of the dietary factors implicated in the pathogenesis of IBD is in section
1.1.2.3.3.
Dietary factors have been proposed to be involved in the pathogenesis of
IBD and dietary modification has also been used as a treatment. The precise role
of enteral nutrition in inflammatory bowel disease [IBD] remains to be defined.
Enteral nutritional support in addition to normal food is indicated in
undernourished patients with CD or UC to improve nutritional needs. In children
with active CD, enteral nutrition is often used as a first line therapy. However, a
recent Cochrane meta-analysis (322) of ten trials showed no statistically
signiﬁcant difference between CD patients treated with elemental and non-
elemental diets. Enteral nutrition therapy in active UC has not been adequately
evaluated. Exclusion diets have been shown to prolong remission in Crohn’s
disease (323, 324). In a study of 40 participants with CD by Riordan et al (323)
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they instructed participants to introduce one new food daily, excluding any that
precipitated symptoms. They observed sensitivity to corn in seven patients; wheat,
milk and yeast in six; egg, potato, rye, tea and, coffee in four; and apples,
mushrooms, oats and chocolate in three. IgG4-guided exclusion diets have
resulted in significant symptomatic improvement in symptoms and a fall in
inflammatory markers in some studies and this approach may be useful in certain
patients. The advice provided by doctors to their patients is very variable, some
tell their patients to avoid dairy products at the time of diagnosis, but others do not
consider dairy products play a role in the IBD symptom management (244). In
addition IBD patients also avoid dairy products by their own choice or due to a
lack of clear advice from their doctors.
Milk and related lactose containing products are thought to cause problems
by patients with inflammatory bowel disease especially those with CD – many of
these may alter their diet accordingly. Lactose metabolism occurs in the small
bowel which is the primary site of inflammation in many patients with CD and
this leads to secondary LS. Milk is also reported commonly by patients IBD as
causing symptoms on reintroduction. The reasons for this being, the increased
prevalence of lactose intolerance in IBD compared to controls and the allergy to
milk proteins, both of which are discussed in section 1.3. The prevalence of dairy
sensitivity in IBD patients is thought to be in the range of 10-20% (250, 325).
In a recent study from New Zealand (326) using a dietary questionnaire,
patients with CD perceived worsening of symptoms if they consumed dairy
products such as cream, ice-cream, cheese and milk. In addition symptoms were
perceived less when CD patients consumed cow’s milk compared to the other
dairy products. These patients felt yoghurt was more tolerable compared to above
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mentioned dairy products. The authors felt the lactose content of the dairy
products did not influence the self-reported symptoms, but they did not collect the
quantity of the dairy food that is required to cause symptoms. This also shows
variations in symptoms experienced based on the type of dairy product consumed.
Interestingly, an increased frequency in self reported symptoms in CD patients
was noticed if they had colonic disease compared to ileal disease. The
consumption of dairy products made no difference to CD symptoms for the
majority of participants in this study.
Studies have attempted to identify dietary risk factors in the expression of
IBD, but the overall conclusion appears equivocal, at least in part because of
serious methodological limitations and inconsistencies. Dietary habits are usually
recalled either before the onset of the disease or as what is being currently eaten.
However, the present diet may not necessarily reﬂect the previous one,
elimination diets are difficult to follow-up due to a high drop-out rate and patients
seem to have difficulty in identifying foods that trigger symptom exacerbation.
Despite these factors, the results of the previous chapter, where a large
proportion of IBD patients had evidence of lactose sensitivity, naturally leads to
an enquiry of what will happen if such patients exclude lactose in diet. An initial
pilot is presented here in a cohort of patients with small bowel Crohn’s disease in
clinical remission and documented lactose sensitivity.
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5.3: METHODS
5.3.1: STUDY POPULATION
20 participants were initially invited to take part in this study from those who took
part in the study outlined in chapter 4. The study population were all of Caucasian
origin and were patients with Crohn’s disease in clinical remission as defined by a
score of ≤ 4 on the Harvey Bradshaw Index. They were all diagnosed with lactose
sensitivity based on a positive breath test and symptoms following a 50g lactose
challenge.
They were asked to fill a food diary which outlined a complete record of
what was eaten each day [Appendix 1] and a daily symptom diary [Appendix 2]
which consisted of the following questions Wellbeing [0= very well, 1=slightly
below par, 2=poor, 3= very poor, 4= terrible], Abdominal Pain [0= none, 1=mild,
2=moderate, 3= severe], Number of loose stools in a day and as well as recording
other symptoms like flatulence, bloatedness, nausea, vomiting, rash, headache,
fatigue, muscle and joint pain, palpitations, itching etc. Both diaries were kept
daily for 2 weeks whilst the participants ate their normal diet. At the end of this
period they completed a health related quality of life questionnaire [HRQOL]. The
short inflammatory bowel disease questionnaire [SIBDQ] was chosen for this and
is given in Appendix 3 (327). The license for its use in this study was obtained
from McMaster University [Copyright ©1989, McMaster University Hamilton,
Ontario, Canada]. Each item is scored on the seven point graded scale from 1 [a
severe problem] to 7 [not a problem], giving an absolute SIBDQ score range from
10 [poor HRQOL] to 70 [optimum HRQOL].
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Participants were then asked to go on a minimal lactose free diet for 4
weeks during which time they maintained a daily food diary. The minimal lactose
free diet information sheet that is used within clinical practice in the health board
where this study was carried out was provided to all participants [Appendix 4].
During the last 2 weeks on this diet they completed the symptom diary again
along with another SIBDQ at the end of this period. They were provided with a
pre-paid envelope to return the food and symptom diaries together with the
HRQOL questionnaire at the end of the 2 week period on normal diet and then
after a minimal lactose free diet. The symptoms and SIBDQ scores whilst eating a
normal diet were compared to those recorded during the minimal lactose free diet.
Written informed consent was obtained from each participant. The study was
approved by the South East Wales Research Ethics Committee.
5.3.2: STATISTICS
Quantitative variables are given as mean ± standard deviation and categorical
variables are given as total numbers and percentages. Comparison of the group
during normal diet and during lactose free diet was analysed by Wilcoxon Signed
rank test. P values less than 0.05 were considered to be significant. The data was
entered into the statistical program SPSS version 12 [Chicago, USA] and was
used for analysis.
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5.4: RESULTS
20 suitable participants with CD were invited to take part in this study. Three
participants did not respond to the invitation letter. Of the 17 who consented to
take part in the study 3 asked to drop out, as they felt the diet was too restrictive
for themselves and their family. In 3 cases, forms were only returned whilst on
their normal diet and this was incomplete in one. In one case only information
whilst on a lactose free diet was available. Complete information was therefore
only available in 10 participants.
The age range of these 10 participants was from 27-86 years and the
average age was 58.8± 21 years. There were 6 women aged 60.3 ± 18.2 years and
4 men 56.5 ± 27.6 years. The duration of the disease was 14.8 ± 10.8 years with
range from 1-39 years. 7 never smoked and 3 were ex-smokers.
All the ten participants had CD involving the small bowel. In 6
participants the disease was limited to small bowel and the remaining 4 had both
large and small bowel disease. 2 participants were not taking any medications but
the remaining 8 were on medication for their CD of which 3 patients were on
Azathioprine, 4 were on 5-ASA preparations and one was on a combination of 5-
ASA and Azathioprine. 5 had no surgery and 5 had surgery for CD which
included 3 patients with a previous right hemi-colectomy, one ileal resection and
one partial colectomy. During the study period, no changes were made to the
treatment of their CD. The baseline characteristics of the participants are
summarised in table 5.1 including the results of the genetic and breath tests. All
the 10 participants in this study had a positive breath test and symptoms after
lactose challenge test. The breath test was positive in seven with a rise in H2, in
two a rise in CH4 and one had a rise in both the gases after the lactose challenge.
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During the baseline fortnight when they were asked to continue with their
normal diet, all participants consumed milk which totalled 2.3±1.35 litres and
ranged from 250mls to 5.2 litres. In addition to this, patients consumed lactose
within a range of other foodstuffs and drugs. During the minimal lactose diet trial
period only 3 participants consumed milk; 30mls in one case whilst the other two
took 1.5 and 1.72 litres respectively of lactose free milk.
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Table 5.1: Details of individual participant in the study
Patient
Number
Age
[years]
Sex Duration of
Disease [years]
Extent of
Crohn’s disease
Smoking
Status
Genotype Breath
Test
Drugs Previous
Surgery
1 86 M 20 SB Ex TT H & M Y N
2 69 F 21 B N TT H Y Y
3 27 M 12 B N CC H Y N
4 80 F 7 SB Ex TT H N N
5 38 F 13 B Ex CT H N Y
6 73 M 17 SB N CC H Y Y
7 69 F 5 B N TT H Y Y
8 37 F 1 SB N CT M Y N
9 69 F 39 SB N TT H Y Y
10 40 M 13 SB N CT M Y N
Sex: M male, F female, Extent of CD: SB small bowel, B;-both large and small bowel, Genotype: TT lactose persistence, CT
Heterozygote’s & CC lactose non-persistence, Breath test: positive for gas produced, H [hydrogen> 20ppm] and M [methane >5ppm],
Smoking status: Ex- Past smokers & N Never smoked. Y Yes & N No
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The ‘wellbeing’ score was compared during the normal diet with that recorded
when on a lactose restricted diet – wellbeing is better if the score is lower. The
sum total of daily wellbeing scores of each individual in the two week period on
their usual diet averaged 9 [SD±7.2] with a range of 0-18 and this was 4.8±5.3,
with a range of 0-14 on minimal lactose free diet. The difference between the 2
diets reached statistical significance p=0.017. There was an improvement in 7
cases [by 2-13 points], no change in 2 however, both had a baseline score of zero
and worsening in one patient by a single point. These are illustrated in figure 5.1.
Figure 5.1: The sum total of wellbeing score of each participant during the two
weeks on normal diet compared with period on minimal lactose diet. The
perceived wellbeing is greater with lower scores
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The total number of loose stools passed by each individual during the two week
period ranged from 0-28 with an average of 11.8 [SD±10.5] during the normal
diet which improved with a reduced lactose intake to 9.1 [SD±7.9] with a range of
0-24. There was an improvement in 5 patients [range 2-21 occasions]; no change
in 3 [all had no episodes of loose stool at baseline assessment] and again
worsening in two patients- these are shown in figure 5.2. These changes did not
reach statistical significance.
Figure 5.2: The total number of loose stools passed by each participant during the
two weeks on normal diet compared with period on minimal lactose diet.
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The number of days when abdominal pain [figure 5.3] was experienced was not
significantly different between both diets. Higher scores indicate increased
number of days with pain or increased severity of pain. The abdominal pain was
slightly worse whilst on the minimal lactose free 3.3 [SD±5.3] when compared to
normal diet 2.4 [SD±4].
Figure 5.3: The total score of abdominal pain experienced by the participants
daily during the two weeks on normal diet compared with period on minimal
lactose diet. Higher scores reflect increased number of days with pain with or
without severity of pain.
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The daily score of wellbeing, abdominal pain severity and number of loose stools
passed each day were added up and the total score obtained during the 14 day
period whilst eating a normal diet – this was compared to the total score obtained
whilst on a minimal lactose diet. The average score on the normal diet was 23.2
[SD±14.3] with a range 0-42 and scores while on the minimal lactose diet was
17.2 [SD±15.6] with a range of 0-42. The score was therefore lower on a minimal
lactose diet and this was statistically significant p=0.028. There was an
improvement in 7 participants, no difference in 2 cases and worsening in just one
patient. The mean improvement in scores was 5.5 [SD±7.5]. The changes in each
individual are shown in the figure 5.4.
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Figure 5.4: The sum total of daily wellbeing score, abdominal pain score and
number of loose stools passed during the 14 day period of each participant on
normal diet compared with period on minimal lactose diet. The lower the total
score, the better the participant feels.
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The SIBDQ scores whilst on the normal diet were 48.6 [SD±6.7] which improved
on the minimal lactose free diet to 55.1 [SD±5.2] – higher scores reflect an
improved HRQOL. The score improved in all participants which was therefore
statistically significant [p=0.005]. The increase was by a minimum of 2 and a
maximum of 10 points with a mean of 6.5 [SD ±2.5] points. The changes in each
individual SIBDQ scores are shown in the figure 5.5. These results are also
summarised in table 5.2. They suggest that there is an improvement in quality of
life by switching to a minimal lactose diet in this small cohort.
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Figure 5.5: The Short Inflammatory Bowel Disease Questionnaire [SIBDQ] score
of each participant at the end of the two weeks on normal diet compared with
period on minimal lactose diet. The higher the SIBDQ score, the better the
HRQOL.
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Table 5.2: The well being, abdominal pain, total no of loose stools passed and the
SIBDQ scores whilst on normal diet and on minimal lactose free diet.
*Statistically significant difference, SD Standard deviation, p based on Wilcoxon
Signed Rank Test.
The average of the sum total of daily scores of abdominal pain and well being
reported by the patients during the 2 week period on normal diet and whilst on
minimal lactose free diet. The average of the sum total of the number of episodes
of loose stools passed each day during the same period.
The most common symptoms that were reported were flatulence, tiredness,
bloatedness, nausea, muscle & joint aches, but also itching, dizziness, pins &
needles and headache. The number of symptoms reported by each participant
ranged from 1-7 symptoms whilst on normal diet compared to 1-4 symptoms on
minimal lactose free diet [figure 5.6]. The average number of symptoms during
normal diet was 3.3 ± 2.2 and on minimal lactose free diet was 2.5 ± 1.2. The
number of symptoms experienced by each individual is lower whilst on minimal
Normal Diet Minimal Lactose Free Diet
Average±SD Range Average±SD Range
p value
Well Being* 9±7.2 0-18 4.8±5.3 0-14 0.017
Abdominal
pain
2.4±4 0-10 3.3±5.3 0-16 0.4
No of loose
Stool
11.8±10.5 0-28 9.1±7.9 0-24 0.147
SIDBQ score*
[HRQOL]
48.6±6.7 38-61 55.1±5.2 48-63 0.005
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lactose diet though the differences in symptoms experienced by the individuals
was not significant [p=0.084].
Figure 5.6: Total number of symptoms experienced by each participant whilst on
their normal diet to when they are on the minimal lactose diet.
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The percentage of participants experiencing the symptoms is shown in figure 5.7.
If the results are looked at more closely, the total number of days that the
participants experienced these symptoms is lower during the period when they
were on minimal lactose diet 136 versus. 96 days [figure 5.8].
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Figure 5.6: Percentage of patients experiencing symptoms on a normal and a minimal lactose diet
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Figure 5.8: Total number of days symptoms experienced on their normal diet and whilst on a minimal lactose diet
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5.5: DISCUSSION
The results in a very small number of patients with small bowel Crohn’s disease in
remission and known lactose sensitivity [all of whom had symptoms and a positive
lactose breath test as indicated by a rise in breath H2 and/or CH4] shows that a
minimal lactose free diet leads to an improvement in symptoms and health related
quality of life scores. There was a significant improvement in general wellbeing,
number of loose stools and quality of life scores but not abdominal pain in this pilot.
Whilst these findings could be explained by an incidental temporal change in the
activity of the disease itself which is characterised by waxing and waning of
symptoms, this was not readily apparent. Adherence to the diet is very important for
both the success of this pilot, and to support its efficacy. It is important to determine
whether the dietary changes were specifically responsible for reduction in symptoms,
rather than improvement being a reflection of a non-specific placebo response or the
desire of patients to give the ‘correct’ answers to the questions.
The results of the ten participants who completed the study protocol were
analysed [per protocol analysis] rather than an intention to treat analysis which is
useful when subjects are entered into randomised studies. There are only a very small
number of patients who completed the study and of course great caution should be
taken before extrapolating the results into wider clinical practice. Whether a
randomised control trial carried over a longer period of time would provide similar
results is to be seen. It is also unknown if those with lactose sensitivity with active
CD would benefit from this dietary change long term. Finally it is not known if a
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minimal lactose free diet will produce similar results in patients with CD who is
lactose sensitive compared with lactose tolerant individuals.
There are no published well constructed placebo controlled or randomised
studies evaluating the effect of lactose free diet [nor a diet which is sucrose/fructose
free] in patients with IBD. The specific carbohydrate diet [SCD] strictly limits
complex carbohydrates [disaccharides and polysaccharides] and eliminates reﬁned
sugar in diet and there has been only a single published case report of two patients
indicating symptomatic improvement following the SCD (328). In a randomised
control trial (329), 20 patients with Crohn’s disease were treated for an average of 18
months with a low carbohydrate diet [refined sugar excluded] compared to a high
carbohydrate diet [refined sugar-rich]. There was an improvement in activity indices
in patients who were on low carbohydrate diet. A recent pilot study suggests that
reduction of FODMAP’s [fermentable oligosaccharides, disaccharides,
monosaccharides and polyols] in the diet offers an efficacious strategy for patients
with IBD who have concurrent functional gut symptoms (330). The most common
symptoms described by these patients were abdominal pain, diarrhoea, bloating and
wind. These were also the symptoms that were most likely to respond to dietary
intervention, suggesting that a reduction in dietary FODMAP’s may be an effective
therapeutic option in such patients.
According to the Food Standards Agency of UK [FSA] and the European food
standards agency [EFSA] rules of 2005, pre-packed food sold should demonstrate on
its label if it contains milk. The term “lactose-free” in EU legislation has only been
defined for infant and follow-on formula as ≤ 10 mg/100 kcal and no such threshold
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exists for adult population. The EU, requested the EFSA Panel on Dietetic Products,
Nutrition and Allergies to deliver a scientific opinion on lactose thresholds in lactose
intolerance. The panel recommended that a single threshold of lactose for all lactose
intolerant subjects cannot be determined owing to the great variation in individual
tolerances (331). The food labelling to indicate the absence or reduction of lactose or
milk is not regulated. The practice regarding labelling terms and associated threshold
levels varies across the EU for e.g. in UK no threshold levels are present, in Ireland
“lactose free” means no lactose present whilst in Scandinavia it is less than 10mg of
lactose per 100g of the final product In some countries the manufacturers have set
their own unofficial thresholds for making such claims. In a research conducted by
the FSA (332) they found that the words ‘dairy’, ‘milk’ and ‘lactose’ used in labelling
is far from clear. The consumers, health professionals and food businesses understood
differently the meaning of terms, ‘dairy free’, ‘milk free’ and ‘lactose free’. As a
result, any patient who is embarking on a lactose free / reduced lactose diet needs
specific advice about how to avoid the inadvertent ingestion of lactose containing
foods.
The limitations to my study primarily centred around the fact that this is a
small pilot study with just 10 participants, but all were defined as lactose sensitivity
and were in remission. The participants included different subtypes of CD i.e. 6 with
small bowel disease and 4 with both large and small bowel disease. It is not known if
the benefits seen here would be reproducible if this was analysed in a larger group
with Crohn’s disease or if they had different segments of bowel affected and / or
active inflammation. The improvements seen were within a limited period of
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observation and whether the improvement is sustained over a longer duration of time
is not clear. Also, symptoms were self reported by the participants and this may
contribute to some bias.
Both the food diary to record what was consumed by the participants and the
diary used to record symptoms were designed for this study i.e. they have not been
validated before. The symptom diary is a modification of the Harvey-Bradshaw index
which includes its first 3 questions. The minimal lactose free diet leaflet which was
used is the standard leaflet used in the local health board where my study was
conducted. This is given to patients who are lactose sensitive and would like to
modify their diet. This has been used for at least 5 years and was the same leaflet
given to patients in a previous study carried out by Waud et al (136). On this basis it
was felt to be appropriate to use for this study. Patients were instructed on the dietary
principles and provided with minimal lactose free diet information leaflet. There was
no formal input for the dietetic team whether their support and guidance would have
had any influence on the results is not known. In addition due to factors discussed in
the earlier sections [perception, labelling, terminology and thresholds] setting up a
study to examine the effect of the presence or absence of lactose in diet is extremely
difficult.
5.6: CONCLUSION
Decreased lactose intake appeared to benefit this small group of patients with CD in
remission who are diagnosed with lactose sensitivity. It gives encouragement for
further large scale trials where patients are initially assessed for lactose sensitivity
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and appropriate patients are commenced on minimal lactose free diet with careful
documentation of symptoms and quality of life scores. The benefit of decreased
lactose intake in patients who are lactose sensitive and have active IBD should also
be assessed. In addition, the contribution from the ingestion of lactose unwittingly
taken from other sources such as that contained in drug preparations, should also
investigated – see chapter 6.
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CHAPTER 6
QUANTIFYING THE ‘HIDDEN’ LACTOSE IN DRUGS
USED FOR THE TREATMENT OF GASTRO-
INTESTINAL CONDITIONS
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6.1: AIM
To quantify the amount of lactose used as an excipient in medications that may be
taken for the treatment of inflammatory bowel disease and other gastro-intestinal
disorders. In addition, to assess if alternative ‘lactose-free’ medications are available
for patients with hypolactasia and co-existing GI conditions
6.2: INTRODUCTION
Excipients are defined as the constituents of the pharmaceutical form that is taken by
or administered to the patient, other than the active substance (333). The excipients
are said to have no effect on the action of active ingredients present in the medication
and are inert (333). The purpose of their presence is to improve the appearance and
palatability of the drug. In addition they may exert some effect on the bioavailability
and stability of the product. In general they make up the bulk of the mass or volume
of drug formulations. They are listed in the Medicines Compendium [MC] but not in
the British National Formulary [BNF] and are not generally quantified. Lactose is one
of the most widely used excipients by the pharmaceutical industry (334). There are
many reasons for its popularity as lactose is perceived to be inert, relatively
inexpensive, and non-toxic. It is also chemically stable and has no tendency to react
with the active ingredient or other components of a formulation (334). Lactose is also
freely soluble in water and it is very palatable providing sweetness without any
aftertaste (333, 334). Lactose has a long history of being utilised within many
formulations world-wide including dry powder inhalers, tablets, capsules and sachets.
Lactose was found in 20% of medical prescriptions drugs and in 6% of over the
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counter medications (335). Montalto et al looked in the Italian Physician's Desk
Reference and found that there were at least 950 of the 2900 available oral drugs
[33%] contained lactose as an excipient (336). Amongst these, capsule/tablet
formulations contain, when specified, no more than 400 mg of lactose. Sometimes,
labels of these medications warn that their administration is not recommended in
people with lactase deficiency (336).
Many of the drugs used in the treatment of inflammatory bowel disease
contain lactose as an excipient. Patients with IBD also have co-existent
gastrointestinal conditions such as dyspepsia, irritable bowel syndrome [IBS] etc and
may use drugs to control symptoms that contain lactose as an excipient. Of course,
they may also take medications for non-GI ailments. In those patients with concurrent
hypolactasia, the use of medications that contain lactose may be of clinical
significance.
6.3: METHODS
Medications used for the treatment of GI disorders or symptoms were identified from
the BNF [Vol. 53 March 2007]. The presence of lactose in each formulation was
assessed by referring to the 2007 edition of the MC. A selection of these medications
was obtained from the hospital pharmacy and analysed for lactose content using high
performance liquid chromatography [HPLC]. HPLC was performed using a Kontron
HPLC system. Carbohydrates were separated using a Thames Resek Pinnacle II
Amino [NH2] 5 150x4.6mm HPLC column [cat. 9217565] preceded by a
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Phenomenex guard column [containing NH2 [amino, aminopropyl] 4mmx3.0mm ID
cartridge filter [cat. KJ 0-4282]. The column was pre-heated to 35C using a Jones
chromatography column heater. The carbohydrates were detected using a Shodex
RA101 refractive index detector set at 32 or 64RIU at 35C. Mobile Phase was 75%
acetonitrile 25% HPLC water [v/v] filtered through a 0.45 nylon filter and degassed
prior to use. The mobile phase flow rate was 1.0 mls/min. -Lactose [L-3625], D [-]
Glucose [G7021], Fructose [F2543], Sucrose [S-7903], Maltose [M-5885] was
purchased from Sigma. HPLC grade Acetonitrile [A/0626/17] and HPLC water
[W/0106/17] was purchased form Fisher Scientific Ltd. 0.08M Phosphate buffer was
prepared at pH 7.3, pH 4.6 and pH 4.0 by dissolving 1.4g anhydrous dibasic sodium
phosphate [Na2HPO4] and 9.68g monobasic sodium phosphate monohydrate
[NaH2PO4.H2O] in 750mls of HPLC water. The pH was checked and adjusted as
necessary. The buffer solution was then made up to 1 litre with HPLC water.
6.3.1: SAMPLE PREPARATION
Pharmaceutical preparations in tablets, powders or capsule form were received in the
laboratory within their original packing. They were crushed with a pestle and mortar
and then transferred to a universal container where they were rehydrated or diluted in
5mls of phosphate buffer pH 7.3. This was then mixed on a flat bed rotor and
incubated overnight at 4ºC or until dissolved. The sample mixture was then
centrifuged for 10 minutes at 2500rpm before the supernatant was filtered through a
0.45 filter. Two ml of the supernatant was mixed with 2ml of acetonitrile [v/v] and
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mixed. The mixture was then left overnight at 4C, before microfuging it at
13,000rpm for 5 minutes and filtering the supernatant through a 0.45 filter. It was
then passed through a previously primed LC-NH2 SPE tube [As per manufacturers
instructions, Cat.504483 Supelco] using positive pressure [flow approximately
1ml/12seconds]. Finally the filtrate was dispensed into HPLC auto sampler vials and
analyzed for lactose content.
The concentration of lactose and other sugars including glucose, fructose,
sucrose and maltose was determined by reference to the calibrator peak height. The
peak data was integrated using Kroma 2000 chromatography software and quality
control was performed with known carbohydrate solutions (337). In order to calculate
the carbohydrate concentration the following formula was used. Sugars, g/g = [Test
Peak Height/Standard Sugar Peak Height] x buffer added to drug in l/ [amount of
sample injected x Sugar Concentration g]/test portion weight in grams.
6.4: RESULTS
I selected drugs used in the treatment of IBD that were identified in the MC as having
lactose present or absent. Drugs from each of the sub-sections listed in the Gastro-
Intestinal chapter of the British National Formulary [BNF] were also selected and
their lactose content analysed. As some medications are available from multiple
manufacturers, selections of drug preparations were obtained for assessment. In
addition to those used in GI disorders, I also analysed drugs that can be used for a
variety of symptoms including abdominal ones e.g. analgesics and anti-depressants.
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A total of 71 preparations were obtained and analysed, of these 31 [43.7%]
preparations contained lactose whilst 40 [56.3%] were lactose free. The results of this
HPLC based methodology correlated exactly with the summary of product
characteristics in the MC i.e. it detected lactose in all formulations which were stated
to contain it and did not measure lactose in those where it was not mentioned. To
ensure that the methodology was robust and the results obtained were reproducible,
three drugs were randomly selected and re-analysed on three different occasions. This
showed consistency with the quantity of lactose detected per tablet for prednisolone
[Pfizer] 31±1 mg, azathioprine [GlaxoSmithKline] 71±1 mg & colofac [Solvay] 95±2
mg. 17 drugs used in the treatment of IBD were tested - of those 8 contained lactose
but was not identified in the other 9. In preparations where lactose was detected, it
ranged from 28.9 mg [equivalent to 0.6mls of milk] in a single 2.5 mg tablet of
methotrexate [Cyanamid] to 600mg of lactose [equivalent to 12.7mls of milk] in a
3mg capsule of budenofalk [Dr Falk]. The maximum amount of lactose that patients
may consume per day from the ingestion of a single drug used at its maximum
recommended dosage in the BNF for the treatment of IBD was 1200mg [equivalent
to 26mls of milk] with asacol MR 4800 mg a day. In other preparations where lactose
was detected, it ranged from just 4mg [equivalent to 0.2mls of milk] in a single 40mg
capsule of losec to 125mg [equivalent to 2.7mls of milk] in immodium [Janssen-
Cilag] 2mg. The maximum amount of lactose that patients may consume per day
from the ingestion of GI drugs ranged from 4mg/day [0.2mls of milk] in losec 40mg
to 10.2 grams/day [equivalent to 216mls of milk] when the maximum BNF quoted
daily dosage, 150ml, of lactulose is ingested. The chromatogram produced by the
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standard sugars is shown in figure 6.1, loperamide 2mg [Tillomed] with lactose is
shown in figure 6.2, imodium instant melts [McNeil UK] which also has loperamide
with no lactose in figure 6.3 and figure 6.4 shows codeine phosphate 30mg [Teva
UK] which contains lactose.
Figure 6.1: Separation of standard sugars by high performance liquid
chromatography, time at which the sugars appear during chromatography is shown on
the X-axis and the amplitude is shown on Y-axis which depends on the quantity of
the sugar present.
Fructose                                         Sucrose       Lactose
Glucose                 Maltose
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Figure 6.2: A chromatogram showing Loperamide [Tillomed] containing lactose, on
the X-axis is time at which these sugars appear during chromatography and Y-axis is
the amplitude which depends on the quantity of the sugar preset.
Lactose
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Figure 6.3: A chromatogram showing another formulation of Loperamide Imodium
Melts [Mc Neil UK] without lactose, on the X-axis is time at which these sugars
appear during chromatography and Y-axis is the amplitude which depends on the
quantity of the sugar preset.
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Figure 6.4: A chromatogram showing Codeine Phosphate [Teva UK] containing
Lactose in addition has Fructose, on the X-axis is time at which these sugars appear
during chromatography and Y-axis is the amplitude which depends on the quantity of
the sugar preset
The results are presented in tables 6.1 to 6.6 using similar subgroups as the BNF i.e.
based on the actions and indications of a drug. For those with lactose present, the
results are summarised for each formulation in tables 6.1 to 6.4, giving potential daily
intake of lactose if maximum recommended daily dosages is ingested. For each
indication, lactose free alternatives were identified and these are listed in Tables 6.5
Fructose
Lactose
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& 6.9. The results show that lactose is present in drugs used for all GI symptoms but
lactose free alternatives are available for every indication. By taking the maximum
recommended daily dosage, it is possible to be exposed to quite large amounts of
lactose through the ingestion of drugs alone – this is in addition to what is ingested in
the diet. The tables show that 1,000mg per day of lactose [equivalent to 21.2mls of
milk] would be taken if 16mg of Imodium [Janssen-Cilag] were ingested for
diarrhoeal or functional abdominal conditions ; 450mg [9.5mls milk] of lactose would
be ingested if 80mg Domperidone [Winthrop] was taken as an anti-emetic ; 1,800mg
[38.1ml of milk] if 9mg of Budenofalk [Dr Falk] was taken for active IBD or the
treatment of microscopic colitis and by taking 150ml of Lactulose a patient would
ingest 10,200mg of lactose [216mls milk] each day.
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Table 6.1: Antispasmodics and drugs altering GI motility that contain lactose
Group Name Generic name Brand Name
& Dosage
Manufacturer Lactose per
tablet [mg]
Maximum no
of tablets per
day
Lactose
present if
maximal
daily dose
ingested [mg]
Equivalent
amount of
milk[mls]
Dicycloverine
Hydrochloride
Merbentyl
10mg
Florizel 74 6 444 9.4Antimuscarinics
Propantheline
Bromide
Pro-Banthine
15 mg
Concord 38 8 304 6.4
Colofac 135
mg
Solvay 95 3 285 6.0Other
Antispasmodics
Mebeverine
Hydrochoride
Mebeverine
Hydrochloride
135 mg
Merck
Generics
99 3 297 6.3
Codeine
Phosphate
Codeine
Phosphate
30mg
Teva UK 46 8 368 7.2
Imodium 2mg Janssen-Cilag 125 8 1000 21.2
Anti-motility
Drugs
Loperamide
Hydrochloride
Imodium 2mg Tillomed 108 8 864 18.3
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Table 6.2: Antacids & Ulcer healing Drugs that contain lactose
Group Name Generic name Brand Name
& Dosage
Manufacturer Lactose per
tablet [mg]
Maximum
no of tablets
per day
Lactose
present if
maximal daily
dose ingested
[mg]
Equivalent
amount of
milk[mls]
Omeprazole Losec 40 mg AstraZeneca 4 2 8 0.2Proton Pump
Inhibitors
Lansoprazole Zoton Fastab
30 mg
Wyeth 28 2 56 1.2
Domperidone Domperidone
10 mg
Winthorp 56 8 450 9.5
Metoclopramide Metocloprami
de 10 mg
APS 71 3 213 4.5
Anti-emetics
Prochlorperazine Prochlorperazi
ne 5mg
IVAX 70 6 420 8.9
Others Vitamins Valupak
Multivitamins
BR
Pharmaceuticals
38 2 76 1.6
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Table 6.3: Drugs for IBD that contain lactose
Group Name Generic
name
Brand Name
& Dosage
Manufacturer Lactose per
tablet [mg]
Maximum no
of tablets per
day
Lactose
present if
maximal
daily dose
ingested [mg]
Equivalent
amount of
milk[mls]
Asacol MR
400mg
Proctor &
Gamble
75 6 450 9.5Aminosalicylates Mesalazine
Mesren MR
400mg
Ivax 77 6 462 9.8
Budesonide Budenofalk
3mg
Dr Falk 600 3 1800 38.1
Delta-cortil
5mg
Pfizer 31 12 372 7.9
Corticosteroids
Prednisolone
Prednisolone
2.5mg
Alpharm 56 24 1344 28.5
Azathioprine Imuran 50mg Glaxo
SmithKline
71 3.5 248.5 5.3
6 Mercapto-
purine
Puri-Nethol
50mg
Glaxo
SmithKline
61 2 122 2.6
Immuno-
suppressants
Methotrexate Methotrexate
2.5mg
Cyanamid 28.9 6 173.4 3.7
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Table 6.4: The other drugs that may be used in GI patients that contain lactose
Group Name Generic name Brand Name &
Dosage
Manufacturer Lactose per
tablet [mg]
Maximum
no of tablets
per day
Lactose present
if maximal
daily dose
ingested [mg]
Equivalent
amount of
milk[mls]
Bowel cleansing
solutions
Picolax Ferring 4 2 sachets 8 0.2
Senna Senokot 7.5 mg Reckitt
Benckiser
16 4 64 1.4
Lactulose Lactulose Novartis 340mg/5ml 150ml 10200 216.1
Methylcelluose Celevac 500 mg Shire 27.7 12 332 7.0
Laxatives
Bisacodyl Dulco-Lax 5 mg Boehringer-
Ingelheim
41 2 82 1.7
Ursodeoxychol
ic acid
Ursodeoxycholic
acid
Destolit 150mg Norgine 78 7 546 11.6
Pancreatin Pancrex V Tablets Paines & Byrne 54 45 2430 51.5
Amitryptiline
10mg
Teva UK 43 20 860 18.2Tricyclic
antidepressants
Allegron 10mg King
Pharmaceuticals
38 15 570 12.1
Others
Selective serotonin
reuptake inhibitors
Citalopram 20mg Ranbaxy 45 3 135 2.9
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Table 6.5: Antispasmodics and drugs altering GI motility that are lactose free.
Group Name Generic name Brand Name & Dosage Manufacturer
Mebeverine hydrochloride Colofac MR Solvay
Alverine Citrate Spasmonal Norgine
Hyoscine Butylbromide Buscopan Boehringer Ingelheim
Colpermin Pharmacia
Antispasmodics
Peppermint Oil
Mintec Shire
Loperamide Imodium Instant Melts McNeil UKAnti-motility Drugs
Co-Phenotrope Lomotil 2.5/0.025 Goldshield
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Table 6.6: Antacids & Ulcer healing Drugs that are Lactose free.
Group Name Generic name Brand Name & Dosage Manufacturer
Ranitidine Zantac GlaxoSmithKline
Cimetidine Dexcel 200mg Dexcel
Nizatidine Axid Flynn
H2-Receptor antagonists
Famotidine Pepcid MSD
Complexes Sucralfate Antepsin Chugai
Prostaglandin analogues Misoprostol Cytotec Pharmacia
Pantoprazole Protium Altana
Rabeprazole Pariet Janssen-Cilag, Eisai
Esomeprazole Nexium AstraZeneca
Lansoprazole Zoton Wyeth
PPI
Omeprazole Losec MUPS AstraZeneca
Anti-emetics Prochlorperazine Buccastem Reckitt Benckiser
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Table 6.7: Lactose free alternatives for the drugs used in the management of IBD
Group Name Generic name Brand Name & Dosage Manufacturer
Pentasa 500mg tablets Ferring
Ipocol 400mg Sandoz
Mesalazine
Salofalk 250mg tablets Dr Falk
Balsalazide Colazide 750 mg Shire
Olsalazine Dipentum 250/500mg Celltech
Sulfasalazine Salazopyrin-EN 500mg Pharmacia
Aminosalicylates
Budesonide Entocort CR 3mg AstraZeneca
Immunosuppressant’s Ciclosporin Neoral 100mg Novartis
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Table 6.8: Lactose free drugs that may be used in the treatment of other GI disorders.
Group Name Generic name Brand Name & Dosage Manufacturer
Docusate Sodium Dioctyl 100mg SchwarzLaxatives
Macrogols Movicol Norgine
Ursofalk 250mg Dr FalkUrsodeoxycholic acid Ursodeoxycholic acid
Ursogal Galen
Bile acid sequestrants Colestyramine Questran Bristol-Myers Squibb
Creon 10,000 & 25,000 Solvay
Pancreatin Pancreatin Pancrex V 125mg capsules Paines& Byrne
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Table 6.9: Other lactose free drugs that may be used in IBD and patients with GI disorders.
Group Name Generic name Brand Name & Dosage Manufacturer
Paracetamol 500mg TescoParacetamol
Paracetamol 500mg caplets Value Health
Co-Codamol 8/500 AlpharmCo-Codamol
Co-Codamol 30/500 CP
Analgesics
Co-Dydramol Co-Dydramol M&A Pharmaceuticals
Fluoxetine Fluoxetine 20mg TillomedSelective Serotonin
Re-uptake Inhibitors Paroxetine 20mg Sandoz
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6.5: DISCUSSION
These results clearly show that lactose is present in medications prescribed for
the treatment of IBD and also a wide range of GI disorders. This could lead to
symptoms of lactose intolerance in susceptible individuals. Doctors may not
know that the medicines they prescribe contain lactose as the details of the
excipients in medicines are not available in the BNF [the most trusted guide used
by doctors in the UK] (338). Although the European Commission guidelines of
2003 state that by law, manufacturers must list the excipient in the patient
leaflets; they are however not required to quantify the amount present. A
summary of the product characteristics of drugs are listed in the Medicines
Compendium; this is used by pharmacists to find information about excipients
but all the versions of the drug are not listed in MC or ECM [electronic version
of the compendium of medicine]. It should also be noted that neither the MC nor
the ECM are widely used by doctors and allied health professionals - and many
maybe not even aware of their existence. I feel that the presence and quantity of
lactose should be displayed in a prominent place to alert both the prescriber and
the patient e.g. in the BNF or the drug packet.
Clinicians may not feel that the amount of lactose present in drug
formulation is enough to contribute towards the symptoms of a patient. However
sensitivity to lactose and the severity of symptoms it causes, vary widely in
patients. Petrini et al. observed two lactase-deficient women with Graves’ disease
who experienced severe diarrhoea after ingestion of propylthiouracil [amount of
lactose not specified] and methimazole [about 60 mg of lactose] (339).
Brandstetter et al. described the case of a young woman with lactase deficiency
who complained of gastrointestinal symptoms after inhalation of a capsule of
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cromolyn sodium containing 20 mg of lactose (340). Lieb et al. described two
patients with lactose malabsorption in whom abdominal cramps and diarrhoea
developed after a medication with lithium carbonate and flurazepam
hydrochloride [unspecified dosages of lactose] was started (341).Several other
medications have also been implicated to cause lactose sensitivity in susceptible
individuals (339-344).
Due to variations in tolerance to lactose by individuals, a single threshold
for all lactose sensitive individuals cannot be determined. Despite this it has been
widely reported that most individuals can tolerate up to 11.8g of lactose per day
[250ml of milk] (192, 331 & 345). Studies have shown that symptoms can be
precipitated by consumption of 3 to 5g of lactose (345-347) but in highly
sensitive individuals it has been reported that the symptoms may occur after
ingestion of as little as 200mg of lactose (347). Also, different types of
medications have been shown to cause lactose sensitivity and this may affect
compliance (130, 339-344). The reported threshold in very susceptible
individuals could easily be crossed by taking a single 3mg tablet of budenofalk
[Dr Falk] which contains 600mg of lactose. Patients often take more than one
medication for their condition and so these may have a cumulative exposure. I
have identified that the ingestion of certain medications for GI medications,
either alone or in combination may result in a patient consuming of over 10
grams of lactose a day in addition to that taken in their normal diet. However,
none of the medications used primarily for IBD alone or in combination would
result in intake greater than 10g per day of lactose but it is worth re-iterating that
they may take lactose containing drugs for other GI or co-existent illnesses e.g.
hypertension.
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The drugs used for treatment of IBD like 5-ASA preparations and
budesonide are formulated to deliver the active ingredients topically to the distal
small bowel and colon after oral ingestion. This is achieved in by a pH dependent
release mechanism or through bacterial degradation. I have shown that some of
these preparations contain lactose and as they remain intact in the upper GI tract
they will also deliver undigested lactose to the colon where they could give the
symptoms of LI. Of the nine 5-ASA drug preparations used in the treatment of
IBD that were tested, two contained lactose and lactose was not identified in the
other seven. The preparations where lactose was detected, were asacol MR
[400mg] 75mg of lactose [equivalent to 1.6mls of milk] and mesren MR [400mg]
77mg of lactose [equivalent to 1.6mls of milk] in a single tablet The maximum
amount of lactose that patients may consume per day from the ingestion of 5
ASA drugs used in the treatment of IBD was 1200mg [equivalent to 26mls of
milk] with Asacol MR 4800 mg a day. The other 7 preparations without lactose
pentasa 500mg, ipocol 400mg, salofalk 250mg, colazide 750mg, dipentum 250 &
500mg and salazopyrin-EN 500mg. Since the completion of this study the
formulation of asacol MR 400 mg has been changed by the manufacturer and it
has now become lactose free.
Improved lactose handling occurs when oro-caecal transit time is
prolonged. Drugs which affect gastro-intestinal motility either directly or as a
side effect could therefore have an influence on the digestion and absorption of
lactose. In clinical practice it is very common to find lactose malabsorbers who
believe that the ingestion of a very small amount e.g. in white coffee can produce
gastrointestinal symptoms. Frequently encouraged by information on the internet
etc or advised by their family physicians, they start a restrictive lactose-free diet.
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Moreover, in some recent scientific publications, authors suggest caution with
these medications or, even, advise to avoid them completely (342, 348 & 349).
The onset of gastrointestinal symptoms after ingestion of a lactose containing
drug in lactose maldigesters has been described but only in a limited number of
case reports (339-341, 344), and there are no large population or randomised
control studies. Drugs that impair mucosal function or modifies its structure may
have an effect on lactase expression or on its activity. The broad spectrum
antibiotic neomycin has been shown to reduce lactase activity (350). Fixed food
eruptions have been caused by lactose identified after oral administration of four
unrelated drugs (130). Lactose was shown to induce bronchospasm in asthmatics
(351).
The primary form of therapy for lactose sensitivity after diagnosis is to
adjust the amount of lactose containing foods in the diet accordingly. The results
here show that patients on a restricted diet may inadvertently take medications
that contain lactose in amounts that could cause symptoms. The details of
excipients in medications are not readily accessible by doctors and other health
professionals. They may also be unaware that lactose free alternatives are
available. It should be noted that liquid preparations of most drugs are lactose
free and provide another alternative form of treatment in those with known
lactose sensitivity. The clinical management of LS may be confused by not
taking into account “hidden” lactose in foods and medications. Symptoms may
occur in individuals, which could be contributed by this “hidden” lactose, this is
often overlooked by healthcare professionals (348). But it should be recognised
that there is lack of evidence [clinical studies, trials or case reports] which
170
demonstrates lactose present in these medications at small doses either causes
symptoms or exacerbation of IBD.
6.6: CONCLUSION
Assessment of lactose derived from medications should be considered in addition
to dietary sources for both primary and secondary hypolactasic patients. In such
patients the use of alternative ‘lactose free’ medications may avoid exacerbating
symptoms in GI disorders such as IBD or IBS. I propose that lactose free
medications should be prescribed to patients with a high risk of LS due to
ethnicity, in those whose symptoms worsen with no objective evidence of disease
deterioration, and in those who develop new symptoms after commencing
medications. Ideally, in these groups of patients, tests to diagnose LS should be
carried out to aid both dietary advice and the prescription of medications (136).
The significance of the presence of lactose in the medications need to be further
ascertained in a randomised control trial but in the interim, observational data
should be collected from patients with lactose sensitivity and GI conditions to see
if they have symptomatic benefit from using lactose free alternatives.
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CHAPTER 7
CONCLUSIONS AND FUTURE DIRECTION
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The discussion which follows draws together the important findings presented in
this dissertation. An attempt is made not to repeat the detailed discussions which
accompany each chapter, but instead to identify salient points and assess their
overall significance with some suggestions about future work.
The results demonstrate that sensitivity to lactose occurs in a high proportion
[approximately 70%] of patients with IBD, both ulcerative colitis and Crohn’s
disease - this was demonstrated in cohorts who were in remission. The
hypothesis that lactose sensitivity in IBD is related to lactase non-persistence
status is not true, as in this study, only 7% of IBD patients had the CC genotype
[which correlates very closely with primary lactase non-persistence]. 35% and
58% were CT or TT which are associated with lactase persistence. These results
were similar to the control group. Although there was a high incidence of IBD in
patients who were TT, the current results do not support any obvious increased
risk of IBD in people who have the T allele, compared with the C allele, as has
been previously reported. All patients with the CC genotype were lactose
sensitive, this concurs with the findings in previous studies. No differences in
genotype results were seen based on which segment of bowel was affected in
either form of IBD.
A significantly greater prevalence of positive breath tests after a lactose
challenge was seen in Crohn’s disease, as well as ulcerative colitis when
compared to healthy controls. The breath test was significantly positive in CD
patients who had ileal disease when compared to those with ileo-colonic or pure
colonic disease but no such effect was seen based on the distribution of the
disease in ulcerative colitis. A significant number of patients with IBD were
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shown to produce methane with or without a rise in hydrogen after lactose
challenge – to my knowledge this is the first time that this has been reported.
The results also show that genetic polymorphism analysis alone is not
sufficient to identify all patients who are lactose sensitive. The reason for the
higher incidence of lactose sensitivity in IBD patients reported here is because of
the comprehensive tests used. The quality of the study is further improved by
avoiding patients who have previously been assessed or primarily referred for
tests to diagnose lactose sensitivity. Small bowel disease would be expected to
lead to carbohydrate malabsorption, but my study shows that large bowel
disorders can also lead to malabsorption of lactose, the mechanism of this is
unclear. It should also be remembered that all the study population were in
remission and that it is therefore possible that increased disease activity may
have an additional effect.
Patients with a positive breath test had a significantly greater number of
symptoms and higher intensity scores. This supports the need for recording
symptoms as a part of the protocol for breath testing after lactose challenge.
Several patients had persistent or new symptoms after the 4 hour monitoring
period. Patients who suffered from diarrhoea after the lactose challenge often
started experiencing this several hours, even a day, after the lactose would have
disappeared from the intestine. In fact, 50% of the patients with CD, and over
75% of those with UC, who had the diarrhoea after the lactose challenge, still
had this 48 h later. This supports the hypothesis, that the mechanism causing
diarrhoea involves cell signaling, analogous to the diarrhoea in severe gut
infections, and is not simply an osmotic effect of the lactose.
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A pilot study was undertaken in a small cohort of patients with Crohn’s
disease who were in remission and known lactose sensitivity. It showed that a
minimal lactose diet leads to an improvement in both symptoms and health
related quality of life scores. The improvements seen were within a limited
period of observation and it is now important to determine whether this is
sustained over a longer duration of time. The benefits of excluding lactose in
patients with active IBD also merits a carefully constructed clinical trial where
patients again are formally tested by genotyping, breath testing with symptom
analysis following a lactose challenge before they are included.
The results here have shown that lactose is present in numerous
medications prescribed for the treatment of IBD and a wide range of co-existent
GI disorders. The amount of lactose that is present in medications could lead to
lactose sensitivity in susceptible individuals either on its own or in combination
with food. Doctors may not know that the medicines they prescribe contain
lactose as the details of the excipients in medicines are not easily available. They
may also be unaware that lactose free alternatives are available. The presence
and quantity of lactose should be displayed in a prominent place to alert both the
prescriber e.g. in the BNF and the patients e.g. within the information leaflet
contained in the drug packet. An informed decision can then be made particularly
when there is known sensitivity to lactose.
The Real-Time PCR and Restrictive fragment length polymorphism
method yielded exactly the same results in the evaluation of the lactase genotype.
The former technique is rapid and robust as well as being considerably less
labour intensive technique and is suitable for the screening of large numbers of
samples. It is also easy to do and when compared with the RFLP, has less
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number of steps and therefore a lower chance of errors. Since my work, this has
become the laboratory standard technique for this genotyping.
The breath samples after lactose hydrogen breath test was assessed by
two different breath analysers. The results here show that the hand held Micro H2
analyser would have diagnosed 95% of those who produce significant quantities
of hydrogen after a lactose challenge. It would however, only diagnose 53.9% of
those who malabsorb lactose as it cannot detect methane, unlike the Quintron
MicroLyzer. Since the diagnosis of lactose malabsorption should require the
measurement of hydrogen and methane, this device cannot be recommended to
be used on its own. A handheld device should now be developed to measure
expired methane similar to hydrogen. The advantages associated with such a
device will allow us to the freedom to perform near patient testing.
The laboratory standard to diagnose lactose sensitivity in any patient
should be based on comprehensive tests which include genetic testing,
measurement of breath hydrogen and methane for 4 hours, and a full record of
symptoms for up to 48 hours. In those who have the CC genotype, advice should
initially be given to remove all lactose from their diet, including that hidden in
foods and drugs. Those who are CT or TT should undergo a lactose challenge
test, where both breath hydrogen and methane are measured, together with a
record of gut and systemic symptoms. Those diagnosed lactose sensitive should
go on a lactose free diet and then be reassessed.
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What are the future research needs for understanding and managing lactose
sensitivity and its role in inflammatory bowel disease? Future prevalence
studies should be derived from population-based samples that include adequate
distributions across ages and ethnic variation in order to assess the effects of
these factors. From my current work the question arises as to what active disease
will do to this sensitivity to lactose – this should ideally be assessed by
comparing paired observations from individual patients when in different phases
of illness i.e. remission and relapse. Large scale trials are also needed where
patients with proven lactose sensitivity and inflammatory bowel disease, whether
active or in remission, are recruited to assess the benefits of eliminating dietary
lactose.
It is also important to perform further work to ascertain the true
significance of the abdominal and systemic symptoms generated after a lactose
challenge. In particular it should be determined whether these symptoms, which
form part of the definition of lactose sensitivity, are due to subjective or placebo
effects. To do this, blinded challenges with and without lactose are needed.
All the current methods for diagnosing problems with lactose digestion
have limitations. The optimal test would be able to assess and quantify the true
functional lactase capacity in an individual in a non-invasive manner this may be
possible with new innovations such as positron emitting tomography.
Apart from further work to determine the significance of lactose
sensitivity in IBD, there is another novel finding from my work that definitely
merits further research. The discovery of high methane in the breath samples of
patients with IBD before and after the ingestion of lactose needs to be further
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explored. As this gas is only produced by Archae, the possibility that they may
play a pathogenetic role in IBD now needs to be investigated.
The further investigation of the interplay between inflammatory bowel
disease, lactose sensitivity and the so called ‘bacterial metabolic toxin’
hypothesis, may yet give very valuable insights into the pathogenesis of this
condition and open up new treatment options.
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APPENDIX 1
DIET PILOT FOOD DIARY
Name: Trial number:
Dates:
First week Second week:
Third week Fourth Week:
Instructions: Please read carefully.
Please write everything down: Keep your form with you all day, and write down everything you eat or drink. A piece of candy, a can of
pop, cup of tea, or a small doughnut may not seem like much but these all add up!. Don't depend on your memory at the end of the day.
Record what you’re eating as you go.
Be specific: Make sure you include "extras," such as gravy on your meat or cheese on your vegetables. Do not generalize. For example,
record chips as chips, not as potatoes. Estimate amounts: If you had a piece of cake, estimate the size [2" x 1" x 2"] or the weight [3
ounces]. If you had a vegetable, record how much you ate [1/4 cup]. When eating meat, remember that a 3-ounce cooked portion is
about the size of a deck of cards.
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Breakfast Morning
Snacks
Lunch Afternoon
Snacks
Dinner Evening
Snacks
Milk consumed
1 cup= 200mls
Monday
Tuesday
Wednesday
Thursday
Friday
Saturday
Sunday
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APPENDIX 2
DIET PILOT SYMPTOM DIARY
Well Being
0= very well, 1=slightly
below par, 2=poor, 3= very
poor, 4= terrible
Abdominal Pain
0= none, 1=mild,
2=moderate, 3=
severe
No of Liquid
stools
Others Symptoms
Examples: Rashes, Headache, Fatigue, Muscle
and joint pain, Palpitations, Itching, Flatulence,
Bloatedness, Nausea etc
Monday
Tuesday
Wednesday
Thursday
Friday
Saturday
Sunday
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APPENDIX 3
Short IBD Questionnaire** [SIBDQ]
This questionnaire is designed to find out how you have been feeling during the
last 2 weeks. You will be asked about symptoms you have been having as a result
of your IBD, the way you have been feeling in general, and how your mood has
been.
1. How often has the feeling of fatigue or of being tired or worn out been a
problem for you during the last 2 weeks? Please choose an option from
[Systemic]
a. All of the time
b. Most of the time
c. A good bit of time
d. Some of the time
e. A little of the time
f. Hardly any of the time
g. None of the time
2. How often during the last 2 weeks have you had to delay or cancel social
engagement because of your bowel problem? Please choose an option
from   (Social]
a. All of the time
b. Most of the time
c. A good bit of time
d. Some of the time
e. A little of the time
f. Hardly any of the time
g. None of the time
3. How much difficulty have you had, as a result of your bowel problems,
doing leisure or sports activities you would have liked to have done in the
last 2 weeks? Please choose an option from [Social]
a. A great deal of difficulty, activities made impossible
b. A lot of difficulty
c. A fair bit of difficulty
d. Some difficulty
e. A little difficulty
f. Hardly any difficulty
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g. No difficulty; the bowel problem did not limit sports or leisure
activities
4. How often during the last 2 weeks have you been troubled by pain in the
abdomen? Please choose an option from   (Bowel]
a. All of the time
b. Most of the time
c. A good bit of time
d. Some of the time
e. A little of the time
f. Hardly any of the time
g. None of the time
5. How often during the past 2 weeks have you felt depressed or
discouraged? Please choose an option from [Emotional]
a. All of the time
b. Most of the time
c. A good bit of time
d. Some of the time
e. A little of the time
f. Hardly any of the time
g. None of the time
6. Overall, in the last 2 weeks, how much of a problem have you had passing
large amounts of gas? Please choose an option from [Bowel]
a. A major problem
b. A big problem
c. A significant problem
d. Some trouble
e. A little trouble
f. Hardly any trouble
g. No trouble
7. Overall, in the last 2 weeks, how much of a problem have you had
maintaining or getting to the weight you would like to be? Please choose
an option from [Systemic]
a. A major problem
b. A big problem
c. A significant problem
d. Some trouble
e. A little trouble
f. Hardly any trouble
g. No trouble
184
8. How often during the last 2 weeks have felt relaxed and free of tension?
Please choose an option from [Emotional]
a. All of the time
b. Most of the time
c. A good bit of time
d. Some of the time
e. A little of the time
f. Hardly any of the time
g. None of the time
9. How often during the last 2 weeks have you been troubled by a feeling of
having to go to the bathroom even though your bowels were empty?
Please choose an option from [Bowel]
a. All of the time
b. Most of the time
c. A good bit of time
d. Some of the time
e. A little of the time
f. Hardly any of the time
g. None of the time
10. How much of the time during the last 2 weeks have you felt angry as a
result of your bowel problem? Please choose an option from [Emotional]
a. All of the time
b. Most of the time
c. A good bit of time
d. Some of the time
e. A little of the time
f. Hardly any of the time
g. None of the time
**The Inflammatory Bowel Disease Questionnaire [IBDQ] is the copyright of
McMaster University [Copyright ©1989, McMaster University Hamilton,
Ontario, Canada]. The license for its use in this academic study was obtained by
paying a license fee.
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APPENDIX 4
MINIMAL LACTOSE DIET SHEET
WHAT IS LACTOSE?
Lactose is a sugar found naturally in the milk of mammals. Lactose is also found
in foods prepared with mammal's milk. Lactase is an enzyme that plays a vital
role in breaking down lactose in order that your body can absorb it more
effectively.
HOW DO I CONTROL MY LACTOSE INTAKE?
Lactose intolerance is very individual and the amount tolerated by one person may
cause symptoms for another. Similarly, the type of lactose containing products
that individuals are able to tolerate varies. Dietary control of individual symptoms
largely depends on each person knowing, through trial and error, how much
lactose and in what form, their body can handle lactose-containing foods.
Sensitivity to lactose also changes over time and with changes in your general
health status. Finding out how much lactose you are able to tolerate can help you
to live with the condition and provides a greater variety in your diet.
RESTRICTING YOUR LACTOSE INTAKE
Initially you may wish to restrict your lactose strictly in order that you alleviate
uncomfortable symptoms. After a trial period under the supervision of your
consultant you may be able to gradually be reintroduced.
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After this time with guidance you may be able to gradually increase the
amount of lactose in your daily diet and trial different lactose containing foods. If
your original symptoms reappear you know that you have exceeded your tolerance
level and therefore you must stick to a level of intake slightly below that which
causes symptoms.
The minimal lactose diet for lactose intolerance and excludes foods most
likely to cause symptoms. This diet must be followed strictly for 3-4 weeks. If
your symptoms do not improve a review with the consultant is needed. Your
symptoms may not be caused by lactose intolerance and other possibilities will
need to be explored.
Following this further advice, if the low lactose diet is unsuccessful at
relieving symptoms, after the trial period it is essential that the dietary restrictions
do not continue unnecessarily. Unnecessary restrictions can lead to nutrition
shortcomings or even fail to detect other illness.
If your symptoms have improved the next step is to establish your
tolerance levels. Challenge your tolerance regularly to see if your tolerance has
improved. When testing your tolerance to your usual cow’s milk, drink less than
one cupful along with a meal or snack. If you experience symptoms, wait until
these resolve and then trial an even smaller amount.
Knowing your tolerance level should mean that you could include some
diary products in your diet. Remember these are important sources of calcium and
protein and therefore should not be limited unless it is essential to do so. After you
have established the range of foods and tolerance levels you can handle, please
contact your consultant to ensure that your new diet is nutritionally adequate.
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WHAT TO LOOK FOR ON FOOD LABELLING
The following ingredients, if listed, on a product label indicate that the food
contains lactose and therefore should be avoided. Ingredients include: -
Milk [cows, goats, sheep]
Milk Solids
Non-milk Solids
Skimmed Milk Powder
Cream
Artificial Cream
Cheese
Yoghurt Animal Fat
Margarine
Butter
Buttermilk
Butterfat
Lactose
Milk Powder
Curd & Whey
Remember to look for lactose containing foods as well e.g. butter, cream, and
cheese. It is important to realise that differing brands vary considerable with the
ingredients that are used in their products, therefore also read the food labels
carefully. If you are in any doubt about a product - avoid it and then contact your
consultant to see if it is suitable. Certain ingredients are not a source of lactose
despite their name e.g. lacto albumin, lactate, lactic acid, casein, non-diary
creamer, milk protein.
Your consultant can support you in making appropriate food choices,
identifying your tolerance levels, planning meals and in ensuring that your diet is
well balanced and nutritionally adequate. Vitamin and mineral supplements may
be necessary - if you are concerned in any way contact your consultant.
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WHAT ABOUT MEDICATIONS?
Lactose can be used in both prescription and over the counter medication. Ask
your consultant or local pharmacist if you are concerned about your medication.
Do not stop taking your medication without first consulting your doctor.
VARIETY
Reducing the lactose content of your diet causes some limitations in your dietary
variety. It is important to try and consume a varied diet using the foods that are
suitable for use. This will help to ensure that you are getting adequate amounts of
vitamins and minerals.
MILK ALTERNATIVES
Soya and rice milk is lactose free. Lactolite and Lactard are milk alternatives,
which have very low lactose content. With all of these products it is important to
try and use a calcium-fortified version. Many lactose-containing foods are
essential sources of calcium within the diet. It is important to include alternative
sources of calcium. Yoghurts, which contain active bacterial cultures for the
yoghurt making, contain lactase enzymes, which support the lactose digestion.
Therefore, yoghurt may be tolerated and provides a valuable source of calcium.
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MINIMAL LACTOSE DIET
FOODS ALLOWED FOODS EXCLUDED
Breads & Cereals Bread / cakes; biscuits. Breakfast
cereals [check ingredients]. Rice;
flour, semolina; sago
Milk breads, buns and cakes –
check ingredients. Prepared mixes
e.g. muffins, pancakes
Milk & Dairy
Products
Soya and rice milk.
Reduced lactose milks e.g.
“Lactolite” or “Lactcid”.
Hard cheeses. Live yoghurt.
Milk – fresh, dried, evaporated,
condensed, skimmed, sterilised.
Cottage cheese, cheese spreads.
Other creams. Fromage Frais.
Fats & Oils Butter [up to 30 g / day].
Tomor, Flora, Outline & other
margarine free from ingredients *
Salad oil, lard, cooking oil., olive
oil
Excess butter or margarine.
Margarine [check ingredients]
Desserts Soya desserts / soy ice-cream
[check label]. Homemade pies and
desserts.
Some commercial cakes & biscuits.
Packet jellies.
Puddings and sauces made with
milk.
Ice-cream, commercial cakes and
biscuits containing milk.
Meat, Fish,
Poultry, Eggs
Plain beef, chicken, fish, lamb, pork
etc.
Some sausages. Eggs.
Creamed or crumbed meats or fish.
Some sausages, meat pies.
“Ready” cooked meats.
Fruit All fruits – fresh, tinned or frozen None.
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Vegetables Potato and all vegetables cooked
without milk or butter.
Instant potato, white sauce for
vegetables unless made with soy
milk.
Soups Clear soups, bouillon, vegetable
soup, home-made soups using
known ingredients. Some packet
soups.
Cream soups unless made with soy
milk.
Packet soups with lactose.
Some stock powders and stock
cubes.
Drinks Tea, coffee, cocoa,
Fruit squashes, soft drinks.
Horlicks, Ovaltine, Bournvita,
Milo.
Non-dairy creamers containing
lactose, drinking chocolate.
Miscellaneous Sucrose, white sugar, brown sugar,
icing sugar, fructose, glucose.
Vegemite, Marmite
Peanut butter, jams,marmalade.
Salt, pepper, spices, seasonings.
Boiled sweets, fruit gums etc
Proper mayonnaise. Lactose free
chocolate
Artificial sweeteners with lactose.
Fudge, caramels, toffees, chocolate.
Salad dressings.
Most crunchy snack products e.g.
Wotsits, Cheese Puffs etc.
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SUGGESTED DAILY MEAL PLAN
Breakfast
Cereal and fruit juice or soya milk or reduced lactose milk and sugar.
Egg and bacon. Bread and butter and marmalade.
Black tea or coffee and sugar [herbal or lemon tea].
Mid Morning
Black tea or coffee and sugar. Biscuits – check ingredients.
Lunch
Meat, fish, egg, cheese. Salad or vegetables. Bread and butter or potatoes.
Fruit or soya dessert.
Mid Afternoon
Black tea or coffee and sugar. Cake – check ingredients.
Evening meal
Meat, fish, egg, cheese. Salad or vegetables. Bread and butter or potatoes.
Soya milk pudding, milk free sponge or pastry.
Bedtime
Black tea or coffee and sugar.
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APPENDIX 5
COMPARISON OF A PORTABLE BREATH
HYDROGEN ANALYZER [MICRO H2] WITH THE
QUINTRON MICROLYZER IN MEASURING
BREAKDOWN PRODUCTS OF LACTOSE
METABOLISM.
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5.1: AIM
The aim of this study was to compare the accuracy of a portable breath hydrogen
analyser [Micro H2] with that of a widely used stable laboratory model [Quintron
MicroLyzer Self-Correcting Model SC] in measuring the breakdown products of
lactose metabolism. This would simplify the detection of lactose sensitivity in
clinical practice [as described in the preceding chapters].
5.2: INTRODUCTION
The most commonly used methods to diagnose hypolactasia rely on the indirect
measurement of breakdown products following an oral dose of lactose. The breath
hydrogen test is based on the fact that bacteria in the colon ferment undigested
lactose, causing the release of hydrogen, which is then absorbed through the
intestine wall into the blood circulation. In some people, the hydrogen is
converted to methane by methanogenic bacteria in the colon. The hydrogen and
methane generated is absorbed by the cells in the colonic mucosa and then
transported by the blood to the lung and then exhaled. An increased concentration
of at least 20 parts per million (352) in exhaled hydrogen or an increase of 5 ppm
of exhaled methane following lactose ingestion, as compared with the pre-test
value is generally accepted as the threshold to reveal lactose maldigestion (126).
The combined measurements of the exhaled concentrations of hydrogen and
methane provide more reliable indicators (304) of the fermentation processes in
the large intestine than results based on measurements of breath hydrogen alone.
It is desirable to find an easy, cheap and reliable method of diagnosing
lactose maldigestion. A rapid breath hydrogen analyzer [Sensistor AB, Linkoping,
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Sweden] to detect lactose malabsorption was described first by Berg in 1985 who
used the hydrogen in expired air to give a voltage change that can be transformed
into a ‘ppm’ value from a calibration curve (353). Rumessen used an exhaled H2
monitor [Gas Measurement Instruments Ltd, Renfrew, Scotland] which detects the
gas using an electrochemical cell comprising of working, reference and counter
electrodes. The potential of the working electrode is held constant against the
reference electrode. H2 is oxidized at the working electrode generating a current
which is proportional to the amount of H2 diffusing; the signal is converted to give
a digital display (354).
Since then, different devices have been constructed to facilitate measuring
breath hydrogen levels in the clinical setting. These include hand held devices that
give an instant result and those based in laboratories where bags of exhaled breath
are taken to be analysed after completing the lactose challenge. Bedfont EC 60
Hydrogen monitor and the newer Bedfont Gastro+ [Bedfont Scientific Ltd,
Maidstone, UK] use an end tidal sampling system which allows diffusion of
expired air directly into the electrochemical sensor. The electric output from the
sensor is fed to a liquid crystal display which displays results in parts per million.
Another device which is commonly used in the measurement of expired hydrogen
is the Micro H2 [Micro Medical Limited, Kent UK] which also provides an instant
value for breath hydrogen using a sensor drift detection technique. A study
comparing the portable breath hydrogen analyser Micro H2 with a Quintron
MicroLyzer, Model DP [Quintron Instrument Company, Milwaukee USA] which
uses gas chromatography technique where expired gas is collected in a bag and
taken to this machine in a lab and analysed was carried out by Peuhkuri et al
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(273). It showed a 100% concurrence between the two methods for the diagnosis
of lactose maldigestion using breath hydrogen analysis in 44 cases. They
concluded that the Micro H2 appeared as reliable for measuring breath hydrogen
concentrations as the Quintron MicroLyzer in order to diagnose hypolactasia
(273).
5.3: METHODS
5.3.1: SUBJECTS
The study population consisted of 134 subjects, 55 patients with Ulcerative
Colitis, 49 with Crohn’s disease & 30 Healthy volunteers. The study populations
were all of Caucasian origin. All IBD patients were in clinical remission at the
time of the study as determined by a Harvey-Bradshaw index (260) score of 4 or
less in those with CD and by the simple clinical colitis activity index (261) score
of 3 or less in those with UC. The study was approved by the South East Wales
Research Ethics Committee.
5.3.2: BREATH HYDROGEN ANALYSERS
As a reference analyser for detecting the breakdown products of lactose
metabolism in exhaled air, the Quintron MicroLyzer Self-Correcting Model SC
[Quintron Instrument Co. Inc., Milwaukee, WI, USA] was chosen as this was the
analyser which is used as the standard in the laboratory currently where I was
based as described in chapter 2.
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The Micro H2 [Micro Medical Limited, Kent, UK] a portable, hand-held,
hydrogen monitor which is designed to give instant results was used for
comparison, again as described in chapter 2. The technical data for both the
analyzers is summarised in Table 5.1. The calibration of both analyzers was
carried out with Microcan-Disposable Calibration Gas [MicroGas UK Batch
3335/1006] which contains 100 ppm of Hydrogen, 50ppm of Methane and 6%
Carbon Dioxide and balance Air [UN1956] 20 litres at 20°C and 300 psig for the
Quintron MicroLyzer. The Micro H2 was calibrated using Microcan gas [MCG
100] which contains 50ppm of Hydrogen [UK batch 3330/0075].
Table 5.1: Technical data of the Micro H2 monitor, and the Quintron MicroLyzer
SC, according to the manufacturer’s manual.
Micro H2 Hydrogen
Monitor
Quintron MicroLyzer SC
Range 0-500ppm 0-500ppm
Sensitivity 1ppm ±2ppm
Dimensions 17X6X2.6cms 45X28X31cms
Weight 0.16 kg 7.2 kg
Power Supply Single 9 V PP3 220 V
Calibration Gas H2 50 ppm H2100 ppm,
CH4 50 ppm & CO2 6%
Sample size Single breath 20mls of breath
[minimum]
Results Display Liquid Crystal Display Liquid Crystal Display
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5.3.3: EXPERIMENTAL DESIGN
Participants were told not to eat or drink anything other than water from midnight
the night before the test which commenced at 9am. They were also told not to
smoke for at least 4 hours before the test. In addition, they were advised to choose
lactose-free food and avoid those foods that they recognise will produce
gastrointestinal symptoms in the preceding 3 days. They had not received any
antibiotic treatment or had bowel preparation for gastro-intestinal investigations
during the 4 weeks before the study. The subjects were given 50grams of lactose
[Lactose powder BP: BN: M07001589 MS/13880/1 North Staffordshire Hospital
Trust Pharmacological Services] dissolved in 300mls of water. Breath samples
were obtained before the ingestion of the lactose and then at 30 min intervals for 3
hours and then an hour later. On each occasion, the subject exhaled into the Micro
H2 and then straight afterwards they breathed into a polyethylene bag via a one
way valve. Once the bag had fully inflated, the collected sample was stored to be
later analysed by the Quintron MicroLyzer which measured both breath hydrogen
and methane values. The test was defined as positive if the rise in hydrogen or
methane or both is 20 ppm and 5 ppm above the baseline/nadir, respectively.
5.3.4: STATISTICS
Sensitivity, specificity and positive and negative predictive values were calculated
in order to evaluate the Micro H2 method compared with the breath hydrogen
results from the Quintron MicroLyzer. Sensitivity [%] = true positives / [true
positives + false negatives] X 100, Specificity [%] = true negatives / [true
negatives + false positives] X 100, Positive predictive value [%] = true positives /
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[true positives + false positives] X 100 & Negative predictive value [%] = true
negatives / [true negatives + false negatives] X 100. The Bland-Altman plot, or
difference plot, was used to compare the two measurement techniques (355). In
this method, the differences between the two techniques are plotted against the
averages of the two techniques. Horizontal lines are drawn at the mean difference,
and at the limits of agreement, which are defined as the mean difference ± 1.96
times the standard deviation of the differences. The data was entered and analysed
by statistical software SPSS version 12 [Chicago, USA].
5.4: RESULTS
Out of the total 134 participants, there were 68 females and 66 males in the study.
The age range was 19-86 years and their mean age was 44.98years. The mean age
for male patients was very similar to female participants 44.9 versus 45 years and
the age range was 20-86 years for male and 19-81 years for female participants.
The results obtained with Quintron MicroLyzer which was taken to be the
standard, showed 39 [29.1 %] participants had a positive test and therefore 95
[70.9%] had a negative result. The test was positive in 18/66 [27.3%] male and
20/68 [30.9%] females participants. Of the 39 who had a positive test as
determined by the results from the Quintron MicroLyzer, 19 [48.7%] were
positive for Hydrogen [H2] production, 17 [43.6%] were positive for methane
[CH4] and 3 [7.7%] were positive for both H2 & CH4.
The results obtained with Micro H2 analyser, which is only able to detect
hydrogen, showed that 21 [15.7%] participants had a positive test and 113
[84.3%] had a negative test. The test was positive in 8/66 [12.1%] men and 13/68
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[19.1%] females participants. The Micro H2 picked up 21/22 [95.5%] cases that
the Quintron MicroLyzer had detected significant rises in breath hydrogen.
However, it missed one person i.e. 1/22 [4.5%] of cases. This was a 26 year old
female with ulcerative colitis for 9 years. The rise in Hydrogen from nadir was 10
ppm with Micro H2 but was 28 ppm with Quintron MicroLyzer.
If the results of lactose metabolism were just based on hydrogen detection
alone then the Micro H2 had a sensitivity of 95.5%, a specificity of 100%, and a
positive predictive value of 100% and a negative predictive value of 99.1%.
However, the gases produced by metabolism of lactose are both hydrogen
and methane. TheMicro H2 does not measure methane levels and so it would have
missed 17 other cases where there was a significant rise in the levels of this gas
after lactose ingestion. This means that in the subjects studied, 17 [43.6%] cases
with results from the Quintron MicroLyzer suggestive of hypolactasia, were due
to methane production and would not have been picked up if only this handheld
device was used. The Micro H2 therefore has an overall sensitivity of 53.9%, a
specificity of 100%, a positive predictive value of 100% and a negative predictive
value of 83.2%. The results are summarized in table 5.2.
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Tables 5.2: Comparison of Micro H2 results with Quintron MicroLyzer in
measuring the breakdown products of lactose metabolism- the number of patients
[not percentage] is given for each of these tests.
Quintron MicroLyzerMicro H2
Positive Negative Total
Positive 21 0 21
Negative 18 [17 CH4 & 1 H2] 95 113
Total 39 95 134
The amount of H2 detected by the Micro H2 ranged from 0 ppm to 78 ppm
when compared to 0 ppm to 227 ppm with the Quintron MicroLyzer. The highest
increase in the breath hydrogen concentration over the baseline after ingestion of
lactose was extremely variable and ranged from 4 to 78 ppm measured with the
Micro H2, or from 8 to 217 ppm measured with the Quintron MicroLyzer. The
increase in hydrogen from the basal values to the highest recorded ones during the
test is also shown in figure 5.1. The amount of methane detected was 0 ppm to
157 ppm with Quintron MicroLyzer with the highest rise in methane ranged from
0 ppm to 157 ppm.
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Figure 5.1: Basal and Maximum Hydrogen rise between Micro H2 and Quintron
MicroLyzer.
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The maximum rise in hydrogen from the base line or nadir detected by Micro H2
was 74 ppm [range 21-74] for a positive test and 13 ppm for a negative test [range
0-13]. The mean peak rise in hydrogen detected by the Micro H2 for a positive test
from base line or nadir detected was 34.5±13.99. The maximum rise in hydrogen
from the base line or nadir detected by the Quintron MicroLyzer was 212 ppm
[range 20-212] for a positive test and 17 ppm for a negative test [range 0-17]. The
mean peak rise in hydrogen and methane detected by the Quintron MicroLyzer for
a positive test from base line or nadir detected was 42.1±54.3 ppm and 36.8 ± 40.6
ppm. The results are shown in table 5.3.
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Table 5.3: Summary of Hydrogen range and mean rise in participants with a
positive and negative test with the Quintron MicroLyzer compared to the
handheld Micro H2. [SD Standard deviation, ppm Parts per million, NA not
applicable]
Quintron
MicroLyzer
Micro H2
Positive test 0-227 ppm 0-78 ppm
Hydrogen Range
Negative test 0-17 ppm 0-13 ppm
Positive test 71.6 ± 56.9 ppm 33.5±13.7 ppm
Mean peak rise in
Hydrogen ± SD Negative test 4.4 ± 4.6 ppm 2.98±2.9 ppm
Positive test 5-157 ppm NA
Methane range
Negative test 0-4 ppm NA
Positive test 42.3 ± 46.3 ppm NA
Mean peak rise in
Methane ± SD Negative Test 0.35 ± 0.9 ppm NA
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For all the participants, the Quintron MicroLyzer gave higher levels of hydrogen
than the Micro H2 15.4 ± 33.95 ppm Vs 7.5 ± 12.5 ppm respectively, and the
mean difference between the results of the Quintron MicroLyzer and the Micro H2
was 7.87 ± 24.2 ppm. The rise in hydrogen in the 2 tests matches each other
though the magnitude of rise as expected from the results above is smaller with
Micro H2. These are shown in the figure 7.2. The rises in both positive and
negative cases are similar between the two analysers. The intra-individual
correlation between the Micro H2 and the Quintron is shown in the figure 5.3.
Figure 5.2: Mean rise in hydrogen during positive and negative test detected by
Micro H2 compared with Quintron MicroLyzer after a challenge with 50 grams of
lactose
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Figure 5.3: Comparison of the Micro H2 and the Quintron MicroLyzer hydrogen
monitors in measuring the maximum increase of breath hydrogen concentration
[ppm] in 134 volunteers after lactose challenge. The ‘line of linearity’ is plotted
on the figure.
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The Bland Altman’s plot [figure 5.4] shows the two methods [Micro H2 &
Quintron MicroLyzer] are interchangeable in the diagnosis of lactose
malabsorption if the test is based on hydrogen production alone (355) The
absolute values of the difference between the Micro H2 and Quintron MicroLyzer
were significantly related to the average level, with a Spearman’s rank correlation
r=-0.587and significance level p<0.0001.
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Figure 5.4: Bland Altman’s Plot showing Micro H2 with Quintron MicroLyzer are
interchangeable in the diagnosis of lactose malabsorption if was based only on the
detection of hydrogen in the expired breath sample.
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5.5: DISCUSSION
The results from these two systems were very similar for the detection of a
significant rise in breath hydrogen after a standard lactose challenge. The
handheld Micro H2 analyser would have only missed one case where the hydrogen
levels were found to have increased by a significant level when recorded on the
Quintron MicroLyzer. The results did however; show a difference in the
magnitude of the increase in hydrogen levels after a lactose load in the same
subject when the two systems were compared with much higher values obtained
from the Quintron MicroLyzer.
The Micro H2 analyser that was used has the ability to measure only
exhaled hydrogen rather than both hydrogen and methane which is possible with
the Quintron MicroLyzer. As a result the handheld system, although easier to use
with an instant result, gives restricted information on the fermentation processes
in the large intestine. CH4 is produced in the human intestine chiefly by H2-
utilising flora and so the adequate assessment of gut bacterial carbohydrate
fermentation requires parallel measurement of both breath H2 and CH4. The use of
hydrogen excretion as the only means to quantifying carbohydrate malabsorption
is not correct and flawed because methane-producing patients are likely to have a
higher 'false negative' results after an oral load of lactose (356). It has been shown
that as many as 40-50% of people can be identified as methane producers (304,
305). In some subjects, at least part of the hydrogen is used to produce methane,
but in most hydrogen-producing subjects, part of the hydrogen is dissolved into
the blood stream and exhaled through the lungs (304, 306). H2 and CH4 are only
produced by bacteria, and carbohydrates are the primary substrate for their
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production, the presence of either gas in breath will signal the breakdown of
carbohydrates in intestinal tract. Methanogenic bacteria are able to convert H2 to
CH4 within the colon (292, 299, 300). There is a complex interaction between H2
and CH4 production which was discussed in chapter 4.
In the study by Peuhkuri there were 44 volunteers [34 female and 10 male]
with no gastro-intestinal disease. Our study is a larger study with 134 participants,
with nearly equal sex distribution [66 males and 68 females] and also involving
healthy volunteers and disease groups although they were all in remission.
Peuhkuri et al showed that the diagnoses were the same in 100% of the cases with
the two breath hydrogen analysers, the Micro H2 and the Quintron MicroLyzer
(273). In contrast, my study shows that the Micro H2 would diagnose 95% of
those with hydrogen production but would only diagnose 53.9% of the total
number of cases that would be diagnosed using Quintron MicroLyzer this is due
to the inability of the Micro H2 to measure breath methane concentrations.
The Micro H2 gave higher peak levels of hydrogen than the Quintron
MicroLyzer 51.8 ppm [SD 86.0 ppm] and 32.3 ppm [SD 49.2 ppm] respectively in
Peuhkuri’s study, and the mean difference between the results of the Micro H2 and
the Quintron MicroLyzer was 19.5 ppm [SD 42.6 ppm] (273). In my work the
Micro H2 gave lower peak levels of hydrogen than the Quintron MicroLyzer 33.5
ppm [SD 13.7 ppm] and 71.6 ppm [SD 56.9 ppm] respectively, and the mean
difference between the results of the Quintron MicroLyzer and Micro H2 was 41.2
ppm [SD 46.7 ppm]. The results from the Quintron MicroLyzer were clearly
higher than Micro H2 meter. There are several potential reasons why this may
have differed from the Peukhuri paper. Firstly, I used the Quintron MicroLyzer
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Self-Correcting Model SC which in addition measures CO2 and corrects the
results for expired CO2 when compared to Quintron MicroLyzer DP model used
in the study by Peukhuri. This reduces a source of error in trace-gas analyses
which is contamination of the alveolar sample with dead space air during its
collection. This is based on the concept that CO2 is present in alveolar air at a
constant concentration, while it is absent in room air. If alveolar air is erroneously
mixed with room air, the concentration of CO2 will be reduced so will be the trace
gases present. By knowing the degree to which CO2 was diluted, a correction is
applied to calculate true alveolar concentration of the gas.
The higher values may also result from the different concentration of gases
used to calibrate the analyzers: 100ppm of H2 with Quintron MicroLyzer and
50ppm of H2 with Micro H2. Also, the sampling techniques differ between the
analysers and this may have an effect on the hydrogen concentrations measured.
The Micro H2 measures the hydrogen concentration of total breath and shows the
highest peak value after the end of the breath. Even though the subjects were
allowed to exhale slowly through the mouthpiece of the Micro H2 analyser,
methods of blowing may be varied. With the Quintron MicroLyzer, the gases are
collected in a bag and then hydrogen is measured from the collected breath and
the whole breath sample is used in the analysis. However it should be noted that
my comparison was conducted in a standardised fashion using a uniform protocol
to exclude any known sources of error. A set lactose load was used with a
predetermined sampling schedule. All participants were nil by mouth except water
for at least 9 hours before the test. They were also not allowed any medications,
told not to smoke for at least 4 hours before the test and smoking was not allowed
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during the test. All those with IBD had their disease in remission as determined by
standard criteria. During the lactose breath test the participants were in the
hospital under direct supervision and they were not allowed to leave the room.
This ensured that no one smoked during the test process. The CO2 concentration
in the alveolar air is at a constant concentration and it would have changed if the
participant has smoked. The detection of CO2 concentration by the Quintron
MicroLyzer is an advantage and this will help in picking up participants if they
have smoked during the test, if they had smoked prior to coming to the test their
CO2 concentration at baseline will be elevated and would fall to much lower levels
during the test and therefore have not been compliant with the instructions.
The Micro H2 is simple to use, transportable, can be taken to the patient
and gives results instantaneously. It is also cheaper to buy and has lower
maintenance costs. The Quintron MicroLyzer needs to be calibrated before it is
used each time. Every sample takes at least 2 minutes to analyse and it takes about
30 minutes for the analysis of all the samples taken from one person which leads
to higher labour costs. On the other hand, a potential advantage of the Quintron
MicroLyzer is that the patients could be sent home and they can collect their
samples unsupervised. This could free up time for both the physicians and
technicians where they could see more patients, in addition the samples collected
can be analysed at later date.
The Micro H2 did correctly pick up the rise in hydrogen in 95.5% of cases
compared to Quintron MicroLyzer. In clinical practice you could argue that the
breath samples to detect lactose malabsorption should be analysed first by a hand
held device and if the results are suggestive of malabsorption i.e. a raised
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hydrogen, then no further analysis is needed. Those samples that are negative
could then have separate, stored samples assessed later by the Quintron
MicroLyzer for both hydrogen and methane. This way the two analysers could be
used complementary to each other which have benefits like ease of use and
reduced laboratory time and cost in diagnosis of lactose malabsorption.
Measurement of breath hydrogen and methane, together with lactase
genotype, should now form the current best practice for investigation of lactose
sensitivity (136). A handheld device should be developed to measure expired
methane similar to hydrogen, with the advantages associated with a hand held
device; this would be of great help when formally assessing a patient for lactose
sensitivity.
5.6: CONCLUSION
The results show that the Micro H2 was not accurate in diagnosing lactose
malabsorption because of its inability to measure methane levels. It was, however,
reliable in measuring breath hydrogen concentrations alone after an oral dose of
lactose. The fact that it cannot measure breath methane concentrations is a serious
weakness, because this inability leads to an under diagnosis of lactose sensitivity.
I would therefore advocate, where possible, using the Quintron MicroLyzer with
analysis of both hydrogen and methane levels to determine hypolactasia in clinical
practice. The two analysers could be used complementary to each other i.e. if the
samples are analysed first by a hand held device and the results are not suggestive
of malabsorption, then they should be then assessed by the Quintron MicroLyzer
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for confirmation. This strategy has the benefits like ease of use and reduced
laboratory time and cost in diagnosis of lactose malabsorption.
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APPENDIX 6
CORRELATION BETWEEN THE RESULTS OF
LACTOSE BREATH TESTS AND GASTRO-
INTESTINAL SYMPTOMS
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6.1: AIMS
The aim of this study was to evaluate the sensitivity and specificity of gastro-
intestinal symptoms when compared with a positive breath test after an oral
lactose challenge. If there is a good correlation then lactose sensitivity could
perhaps be diagnosed by just assessing symptoms after the ingestion of lactose
and negate the need to obtain breath samples.
6.2: INTRODUCTION
Lactase-deficient individuals are unable to cleave lactose into glucose and
galactose, as a result, lactose reaches the large intestine where it is metabolized by
the colonic flora. The high osmotic load caused by lactose in the small intestine
and the bacterial metabolites that are produced appear to be the cause of the
symptoms associated with lactose malabsorption. In clinical practice breath tests
are often used to diagnose lactase deficiency. The specificity of the breath test
varies between 89-100% whilst its sensitivity ranges from 69-100% (126).
Although the breath tests are the most frequently used investigation to diagnose LI
there is very limited information available on the sensitivity and specificity of
symptoms which develop after a lactose challenge. Indeed, there are only a couple
of studies evaluating the relationship between the symptoms and the result of the
breath test. A study by Hermans (179) evaluated the severity of 4 symptoms
[bloating, flatulence, abdominal distension and diarrhoea] in 309 consecutive
patients with suspected lactose malabsorption. Blood glucose and H2
concentrations in breath samples were measured after a 50g lactose challenge.
During the 4 hours of the test, patients were asked to score their symptoms semi-
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quantitatively as 0 [no complaint], 1 [moderate complaint] or 2 [severe
complaint]. The sum total of the scores for each of these four symptoms was used
to calculate the total symptom score [TSS]. A positive breath test was defined as a
rise in hydrogen after lactose challenge if the H2 concentration rose by 20 ppm
above baseline and was seen in 40% of patients. An increase in the TSS by one
point was associated with a significant increase [p<0.05] in the mean peak
hydrogen concentration. The mean TSS of patients with a positive breath test
[TSS=1.7] was significantly [P<0.001] higher than the mean score of patients with
a negative breath test [TSS=0.96]. In addition, the authors noted that the peak
hydrogen concentration was higher in patients with higher a TSS when compared
with those with a low TSS. Another study suggested a strong association between
the number of GI symptoms and a positive H2 breath test. In this study by
Beyerlein(180), the intensity of five GI symptoms [nausea, abdominal pain,
borborygmi, bloating and diarrhoea] was recorded every 15 min up to 3 h after a
challenge with 50g of lactose. 1127 patients [72% females] participated and the
test was considered positive if the rise in hydrogen was by ≥20 ppm above
baseline. A positive test occurred in 376 [33%] patients - 21% of patients with one
symptom, 40% of patients with two symptoms, 44% of patients with three
symptoms, 67% of patients with four symptoms and 82% of patients with five
symptoms. Intensity of the symptoms was significantly higher for each symptom
in the positive group. They concluded that evaluating symptoms that developed
after the ingestion of a 50 g lactose load can be used as a simple screening test to
select patients who need to be referred for lactose intolerance testing.
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6.3: METHODS
Lactose breath test was carried out and the samples were analysed using Quintron
MicroLyzer as described in chapter 2. Samples were collected at baseline and then
for the next 4 hour period after a 50g lactose challenge as described in chapter 2.
At the time of sampling, patients were asked to rate five symptoms [abdominal
pain, nausea, bloating, borborygmi and diarrhoea] using a 10-point scale [0 – no
symptoms to 10 – severe] on a symptoms chart [Chapter 2]. For each patient, the
maximal intensity of each of the five symptoms was defined as the highest
symptom intensity value recorded during the duration of the breath test. The test
was considered positive if the hydrogen concentration in the exhaled air exceeded
20 ppm or methane exceeded 5ppm above baseline or nadir during the test period.
A symptom was considered positive if the patient reported an increase above
baseline in the severity of the symptom during the four hour monitoring period.
6.3.1: STATISTICAL ANALYSIS
Quantitative variables are given as mean ± standard deviation and categorical
variables are given as total numbers and percentages. The chi-squared test was
utilized to analyse differences between proportions. Differences in the mean age
of patients with positive and negative breath test were compared by using the
unpaired Student’s t-test. Correlations between variables were quantified by
calculating the Spearman rank correlation coefficients. P values less than 0.05
were considered to be significant. All sensitivity, specificity, predictive values and
likelihood ratios (13) were calculated by using the absence of the specific
symptom or the absence of any symptom as reference [=test negative]. The chi-
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squared test for trend was use to evaluate if the increase in the number of
symptoms is associated with increased positivity of breath test. The data was
entered into Statistical program SPSS version 12 [Chicago, USA].
6.4: RESULTS
The results from 140 participants which includes 110 patients with IBD
[59 UC & 51 CD patients], and the 30 healthy volunteers were available for
analysis. 41 participants [29.3%] had a positive breath test indicative of lactase
deficiency and 99 [70.7%] had a negative breath test. The mean age of patients
with a positive test was 49.6 ± 19.1 years and for those with a negative test was
43.1 ± 15.3 years which did not differ signiﬁcantly [p=0.31]. Similarly, no
statistically signiﬁcant association was found between gender and the result of the
breath test [p=0.65]. None of the HV had a positive breath test, 16 [27.2%] of UC
and 25 [49%] of CD had a positive breath test. The full details of the participants
and the implications of this are discussed in chapter 4, section 4.5.3 and page 95.
6.4.1: SENSITIVITY AND SPECIFICITY OF INDIVIDUAL SYMPTOMS
After the lactose challenge, 49 [35%] patients reported nausea, 61 [44%] bloating,
56 [40%] diarrhoea, 51 [36%] borborygmi and 59 [42%] abdominal pain.
Diarrhoea was reported by 25 [61%] with a positive breath test and 31 [31.3%]
with a negative breath test. Nausea was reported by 19 [46%] with a positive
breath test and 30 [30.3%] with negative breath test. Borborygmi was reported by
23 [56%] with a positive breath test and 28 [28%] with negative breath test.
Abdominal pain was reported by 25 [61%] with a positive breath test and 34
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[34.3%] with negative breath test. Bloatedness was reported by 25 [61%] with a
positive breath test and 36 [37%] with negative breath test. Diarrhoea &
borborygmi [45%] were the most sensitive symptoms and the most specific was
diarrhoea [81%]. Borborygmi had the highest negative predictive value at 72%
and diarrhoea had highest positive predictive value of 61.4%. The table 6.1 shows
the sensitivity, speciﬁcity, likelihood ratios and predictive values of each
symptom.
Table 6.1: Sensitivity, Speciﬁcity, Positive Predictive Value [PPV] and Negative
Predictive Value [NPV], Likelihood Ratio [LR] positive and negative for each
individual symptoms following lactose challenge.
Symptom Sensitivity
[%]
Specificity
[%]
PPV
[%]
NPV
[%]
Positive
LR
Negative
LR
Abdominal
pain
42 80 61 66 2.2 0.7
Diarrhoea 45 81 61 69 2.3 0.7
Bloatedness 41 80 61 64 2.0 0.7
Nausea &
Vomiting
39 76 46 70 1.6 0.8
Borborgymi 45 80 56 72 2.2 0.7
218
6.4.2: SENSITIVITY AND SPECIFICITY OF COMBINATIONS OF
SYMPTOMS
Thirty nine patients [27.9%] patients did not develop any symptoms during the
test. In this group of patients, 95.9% had a negative breath test. The proportion of
patients with a positive breath test increased with the number of symptoms
developed after the ingestion of lactose from 18.4 % in those developing only one
symptom to 73% in those developing all five symptoms as shown in table 6.2 and
shown as a scatter plot of proportion of positive breath test based on the number
of symptoms in figure 6.1. This trend of increased positivity of the breath test with
number of symptoms was statistically significant [χ2 for trend=31.74 & p<0.0001].
Table 6.2: Patients with positive and negative breath tests based on the number of
symptoms developed after lactose challenge and showing proportion of positive
breath test.
No of
symptoms
Positive
Breath Test
Negative
Breath Test
Totals Proportion
Positive Breath
Test
0 2 37 39 0.051
1 7 31 38 0.184
2 9 14 23 0.391
3 8 8 17 0.471
4 7 5 12 0.583
5 8 3 11 0.727
Totals 41 99 140 0.293
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Figure 6.1: Scatter plot of proportion of positive breath test based on the number of
symptoms developed after lactose challenge in all patients. Proportions are shown on Y
axis and number of symptoms on X axis with a regression line.
There was a strong positive correlation between the number of symptoms and
percentage of patients with a positive lactose breath test [r = 0.468; P < 0.01]. There was
no difference when the results were assessed by the disease state [i.e. UC Vs CD].
Sensitivity, speciﬁcity, PPV, NPV, positive and negative likelihood ratio’s of one, two,
three, four and ﬁve symptoms to identify a positive breath test are shown in Table 6.3.
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0 1 2 3 4 5 6
No of Symptoms
▲ Proportions with Regression Line
Proportion
positive
breath test
220
Table 6.2: Sensitivity, Speciﬁcity, Positive Predictive Value [PPV] and Negative Predictive Value [NPV], Positive and Negative
Likelihood Ratio [LR] of one, two, three, four and five symptoms following lactose challenge.
No of Symptoms Sensitivity [%] Specificity [%] PPV [%] NPV [%] Positive LR Negative LR
One [n=38] 78 54 18 95 1.7 0.4
Two [n=23] 82 73 39 95 3 0.3
Three [n=17] 81 82 53 95 4.6 0.2
Four [n=12] 77 88 58 95 6.5 0.3
Five [n= 10] 78 92 70 95 10.3 0.2
Patients developing zero [no] symptoms [n=39] were used as reference [2 with a positive breath test and 37 with negative breath
tests]
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6.4.3: INTENSITY OF SYMPTOMS BASED ON BREATH TEST
RESULTS
Patients with a positive breath test reported a higher intensity of symptoms when
compared with patients with a negative breath test. The differences in symptom
intensity [Figure 6.2 below] were statistically significant [p<0.05] for all five
symptoms: abdominal pain [3.8 vs.2.1], nausea [2.5 vs. 1.5], bloatedness [4.3 vs.
1.9], diarrhoea [4.2 Vs 2.2] and borborygmi [4.8 vs. 1.9]. These were significant
for both forms of IBD. Such relationship could not be established in healthy
volunteers as none of them had a positive test. The sum of subjective symptom
scores was higher in the 41 lactose intolerant subjects when compared to the 99
lactose tolerant subjects. The median score was 14 [7-17] in the former and 4 [1-
13] in the latter. This was statistically significant with a p value of < 0.032.
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Figure 6.2: Mean maximal symptom intensity score in those with a positive and
negative breath test following lactose challenge. Symptoms are given on the X
axis and mean maximal intensity score is shown on Y axis.
When the breath test was positive after a lactose challenge, the rise in hydrogen
from baseline or nadir ranged from 22 ppm to 227 ppm and for methane this
ranged from 7 ppm to 157 ppm. The test was positive in 41 cases where the mean
maximal rise in hydrogen and methane was 41 ppm and 22 ppm respectively. The
test was negative in 99 cases with a mean maximal rise in hydrogen and methane
was 12 and 2 ppm respectively and these are shown in figure 6.3.
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Figure 6.3: Mean maximal rise in hydrogen or methane recorded from base line
or nadir with a positive and negative breath test in individuals following lactose
challenge.
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6.5. DISCUSSION
The results show that the symptom of diarrhoea had the best sensitivity,
specificity and positive predictive value whilst borborygmi had the best negative
predictive value [72%] for a positive breath test after a standard lactose load.
Lactose malabsorption based on a breath test after the ingestion of lactose in the
participants was found to be 18.4% if they developed one symptom and 70% if all
the five symptoms were reported. This trend of increased positivity of the breath
test with the number of symptoms was statistically significant [p<0.0001].
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This study reports the sensitivity and specificity of abdominal pain,
nausea, bloating, borborygmi and diarrhoea in response to a lactose challenge
when compared to a positive breath test. This information is important as
symptoms of lactose intolerance overlap with features of irritable bowel syndrome
and, thus, discrimination between these two disease entities may be difficult
(224). The results here show some similarities but some differences to the study
by Beyerlein (180) who found that bloating had the best sensitivity [71%] and
NPV [82%], while they found that diarrhoea had the best specificity [90%] and
PPV [66%] to identify patients with a positive breath test. Beyerlein (180) found
that LM was present in 21% of subjects who developed one symptom and 80%
who had all five symptoms. Symptom intensity was significantly higher for each
symptom in the positive group. In another study by Peuhkuri (273) the sum of a
subjective symptom score was higher in the lactose maldigesters [18 subjects]
than in the lactose digesters [26 subjects]. These data indicate that evaluation of
symptoms developed in response to the ingestion of lactose could be used as a
simple screening test for lactose intolerance.
Although I have suggested earlier on in the thesis that the standard
investigation for lactose sensitivity should initially be genotyping, it is not widely
available and so most centres rely on breath testing. Studies comparing symptom
evaluation and genetic testing against lactose breath are warranted. From this
analysis, a pragmatic approach could be to consider other diagnoses in subjects
who do not develop any symptoms after a 50g lactose challenge as my work
suggests the likelihood of a positive test is only 5%. Breath testing may not be
necessary in patients who develop all five symptoms as the likelihood of them
having a positive test is high [73%]. Recommending these patients to strictly
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adhere to a lactose-free diet and re-evaluating their symptom pattern after 4–6
weeks could be tried first. Those patients with persisting symptoms on a
confirmed lactose-free diet should be further evaluated. In patients improving on a
lactose-free diet, formal documentation of low lactase activity may be appropriate
given the major lifestyle and diet changes implied by a life-long diagnosis of
lactose intolerance. Lactose breath testing should be recommended for patients
who develop one to four symptoms after the ingestion of 50 g lactose. Although
patients developing one symptom are more likely to be negative and patients
developing four symptoms are more likely to be positive, testing should be
performed given the implications on lifestyle and diet.
This study has several limitations. The PPV and NPV for individual
symptoms and their combination depend on the prevalence of lactase deficiency in
the examined population – this was not present in any of the healthy volunteers
who were selected on the basis that they had no symptoms or condition. The
results here are restricted to a Caucasian population and they should be interpreted
with caution in subjects of other ethnicity. The proposed approach for patients
who developed symptoms after the ingestion of lactose should be further
evaluated in a clinical setting. The cohort of IBD patients were all in remission
and again it is unclear if these results could be extrapolated if they have active
disease. Finally, of crucial importance was the lack of a placebo component which
would have helped to see if the symptoms and results seen here are truly related to
lactose.
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6.6: CONCLUSION
This study shows a positive correlation between the number of GI symptoms and
a positive breath test. Evaluating symptoms developed after ingestion of 50 g
lactose can be used as a simple screening test to select patients who need to be
referred for lactose intolerance testing but this needs to be confirmed in a clinical
setting.
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